Walgreens Boots Alliance (WBA) 10-Q 9 Apr 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Feb. 28, 2015	Mar. 31, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Walgreens Boots Alliance, Inc.
Entity Central Index Key	1618921
Current Fiscal Year End Date	-23
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,090,756,509
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	28-Feb-15

CONSOLIDATED_CONDENSED_BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (USD $)	Feb. 28, 2015		Aug. 31, 2014
In Millions, unless otherwise specified
Current Assets:
Cash and cash equivalents	$3,005		$2,646
Accounts receivable, net	7,017		3,218
Inventories	9,379		6,076
Other current assets	1,314		302
Total Current Assets	20,715		12,242
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization	15,646		12,257
Equity investment in Alliance Boots	0		7,336
Goodwill	17,044		2,359
Intangible assets	12,225		1,180
Other non-current assets	5,727		1,896
Total Non-Current Assets	50,642		25,028
Total Assets	71,357		37,270
Current Liabilities:
Short-term borrowings	1,061		774
Trade accounts payable	10,293		4,315
Accrued expenses and other liabilities	5,140		3,701
Income taxes	196		105
Total Current Liabilities	16,690		8,895
Non-Current Liabilities:
Long-term debt	16,001	[1]	3,736	[1]
Deferred income taxes	3,689		1,080
Other non-current liabilities	3,951		2,942
Total Non-Current Liabilities	23,641		7,758
Commitments and Contingencies (see Note 12)
Equity:
Preferred stock $.01 par value ($.0625 at August 31, 2014); authorized 32 million shares, none issued	0		0
Common stock $.01 par value ($.078125 at August 31, 2014); authorized 3.2 billion shares; issued 1,172,513,618 at February 28, 2015 and 1,028,180,150 at August 31, 2014	12		80
Paid-in capital	9,838		1,172
Employee stock loan receivable	-3		-5
Retained earnings	24,526		22,327
Accumulated other comprehensive (loss) income	-68		136
Treasury stock, at cost; 79,751,513 shares at February 28, 2015 and 77,793,261 at August 31, 2014	-3,491		-3,197
Total Walgreens Boots Alliance, Inc. Shareholders' Equity	30,814		20,513
Noncontrolling interests	212		104
Total Equity	31,026		20,617
Total Liabilities and Equity	$71,357		$37,270
[1]	All notes are presented net of unamortized discount, where applicable.

CONSOLIDATED_CONDENSED_BALANCE1

CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $)	Feb. 28, 2015	Aug. 31, 2014
Equity:
Preferred stock, par value (in dollars per share)	$0.01	$0.06
Preferred stock, authorized (in shares)	32,000,000	32,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.08
Common stock, authorized shares (in shares)	3,200,000,000	3,200,000,000
Common stock, issued (in shares)	1,172,513,618	1,028,180,150
Treasury stock, at cost (in shares)	79,751,513	77,793,261

CONSOLIDATED_CONDENSED_STATEME

CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (USD $)	Common Stock [Member]	Treasury Stock Amount [Member]	Paid-In Capital [Member]	Employee Stock Loan Receivable [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]	Noncontrolling Interests [Member]	Total
In Millions, except Share data
Beginning Balance at Aug. 31, 2014	$80	($3,197)	$1,172	($5)	$136	$22,327	$104	$20,617
Beginning Balance (in shares) at Aug. 31, 2014	950,386,889
Net earnings	0	0	0	0	0	2,892	45	2,937
Other comprehensive income, net of tax	0	0	0	0	-204	0	-5	-209
Dividends declared ($.675 per share)	0	0	0	0	0	-693	0	-693
Exchange of Walgreen Co. shares for Walgreens Boots Alliance, Inc. shares	-69	0	69	0	0	0	0	0
Issuance of shares for Alliance Boots acquisition	1	0	10,976	0	0	0	0	10,977
Issuance of shares for Alliance Boots acquisition (in shares)	144,333,468
Treasury stock purchases	0	-594	0	0	0	0	0	-594
Treasury stock purchases (in shares)	-9,216,429
Employee stock purchase and option plans	0	300	-5	0	0	0	0	295
Employee stock purchase and option plans (in shares)	7,258,177
Stock-based compensation	0	0	65	0	0	0	0	65
Acquisition of noncontrolling interest	0	0	-2,439	0	0	0	-130	-2,569
Employee stock loan receivable	0	0	0	2	0	0	0	2
Noncontrolling interests in businesses acquired	0	0	0	0	0	0	198	198
Ending Balance at Feb. 28, 2015	$12	($3,491)	$9,838	($3)	($68)	$24,526	$212	$31,026
Ending Balance (in shares) at Feb. 28, 2015	1,092,762,105

CONSOLIDATED_CONDENSED_STATEME1

CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
CONSOLIDATED CONDENSED STATEMENT OF EQUITY (UNAUDITED) [Abstract]
Cash dividends declared (in dollars per share)	$0.34	$0.32	$0.68	$0.63

CONSOLIDATED_CONDENSED_STATEME2

CONSOLIDATED CONDENSED STATEMENT OF EARNINGS (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
CONSOLIDATED CONDENSED STATEMENT OF EARNINGS (UNAUDITED) [Abstract]
Net sales	$26,573	$19,605	$46,127	$37,934
Cost of sales	19,691	13,955	33,949	27,132
Gross Profit	6,882	5,650	12,178	10,802
Selling, general and administrative expenses	5,606	4,569	10,062	8,948
Equity earnings in Alliance Boots	101	136	315	330
Operating Income (loss)	1,377	1,217	2,431	2,184
Gain on previously held equity interest	706	0	706	0
Other income (expense)	504	-59	703	166
Earnings (loss) before Interest and Tax Provision	2,587	1,158	3,840	2,350
Interest expense, net	144	37	199	78
Earnings (loss) Before Income Tax Provision	2,443	1,121	3,641	2,272
Income tax provision	391	391	712	810
Post tax earnings from equity method investments	8	0	8	0
Net Earnings (loss)	2,060	730	2,937	1,462
Net earnings attributable to noncontrolling interests	18	14	45	23
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.	$2,042	$716	$2,892	$1,439
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share)	$1.96	$0.75	$2.91	$1.51
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share)	$1.93	$0.74	$2.88	$1.49
Dividends declared, per share (in dollars per share)	$0.34	$0.32	$0.68	$0.63
Average shares outstanding (in shares)	1,043.60	951.9	994.7	950.6
Dilutive effect of stock options (in shares)	11.1	11.8	10.6	12
Average diluted shares (in shares)	1,054.70	963.7	1,005.30	962.6

CONSOLIDATED_CONDENSED_STATEME3

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) [Abstract]
Net Earnings	$2,060	$730	$2,937	$1,462
Other comprehensive income (loss), net of tax:
Postretirement liability	-8	-2	-9	6
Unrealized (loss) on cash flow hedges	0	0	-12	0
Changes in unrecognized gain (loss) on available-for-sale investments	90	-49	189	35
Share of other comprehensive income (loss) of Alliance Boots	92	-19	113	-56
Currency translation adjustments	-301	116	-490	281
Total Other Comprehensive Income (loss)	-127	46	-209	266
Total Comprehensive Income (loss)	1,933	776	2,728	1,728
Comprehensive income attributable to noncontrolling interests	13	14	40	23
Comprehensive income attributable to Walgreens Boots Alliance, Inc.	$1,920	$762	$2,688	$1,705

CONSOLIDATED_CONDENSED_STATEME4

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014
Cash Flows from Operating Activities:
Net earnings	$2,937	$1,462
Adjustments to reconcile net earnings to net cash provided by operating activities -
Depreciation and amortization	826	663
Change in fair value of warrants and related amortization	-859	-166
Gain on previously held equity interest	-706	0
Deferred income taxes	181	29
Stock compensation expense	65	52
Unrealized gain from fair value adjustments	-68	0
Equity earnings in Alliance Boots	-315	-330
Other	390	48
Changes in operating assets and liabilities -
Accounts receivable, net	-391	-117
Inventories	106	-288
Other current assets	21	13
Trade accounts payable	363	-171
Accrued expenses and other liabilities	-20	-25
Income taxes	-99	47
Other non-current assets and liabilities	-94	20
Net cash provided by operating activities	2,337	1,237
Cash Flows from Investing Activities:
Additions to property, plant and equipment	-643	-591
Proceeds from sale of assets	579	209
Return of restricted cash	74	0
Alliance Boots acquisition, net of cash received	-4,461	0
Other business and intangible asset acquisitions, net of cash received	-92	-297
Purchases of short-term investments held to maturity	-29	-34
Proceeds from short-term investments held to maturity	29	34
Investment in AmerisourceBergen	0	-430
Other	-165	-59
Net cash used for investing activities	-4,708	-1,168
Cash Flows from Financing Activities:
Payments of short-term borrowings	-330	0
Proceeds from issuance of long-term debt	12,279	0
Payments of long-term debt	-7,817	0
Stock purchases	-594	-205
Proceeds related to employee stock plans	293	416
Cash dividends paid	-642	-597
Other	-360	-12
Net cash (used for) provided by financing activities	2,829	-398
Effect of exchange rate changes on cash and cash equivalents	-99	0
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents	359	-329
Cash and cash equivalents at beginning of period	2,646	2,106
Cash and cash equivalents at end of period	$3,005	$1,777

Organization

Organization	6 Months Ended
	Feb. 28, 2015
Organization [Abstract]
Organization	Note 1.  Organization
	Walgreens Boots Alliance, Inc. ("WBA" or "Walgreens Boots Alliance") and subsidiaries is a global pharmacy-led wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale).  See Note 19, Segment Reporting for additional discussion.
	On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. ("Walgreens") pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the "Reorganization"). Pursuant to the Reorganization, Walgreens became a wholly owned subsidiary of Walgreens Boots Alliance, a newly-formed Delaware corporation, and each issued and outstanding share of Walgreens common stock, par value $0.078125, converted on a one-to-one basis into Walgreens Boots Alliance common stock, par value $0.01.
	On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH ("Alliance Boots") that Walgreens did not previously own (the "Second Step Transaction") in exchange for £3.133 billion in cash and 144,333,468 shares of WBA common stock pursuant to the Purchase and Option Agreement dated June 18, 2012, as amended (the "Purchase and Option Agreement"). Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods after the closing of the Reorganization and the Second Step Transaction on December 31, 2014.
	References to the "Company" refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires.

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Feb. 28, 2015
Basis of Presentation [Abstract]
Basis of Presentation	Note 2.  Basis of Presentation
	The consolidated condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The Consolidated Condensed Balance Sheets as of February 28, 2015 and August 31, 2014, the Consolidated Condensed Statement of Equity for the six month period ended February 28, 2015, the Consolidated Condensed Statements of Earnings and the Consolidated Condensed Statements of Comprehensive Income for the three and six month periods ended February 28, 2015 and 2014, and the Consolidated Condensed Statements of Cash Flows for the six months ended February 28, 2015 and 2014, have been prepared without audit. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Annual Report on Form 10-K, as amended, for the fiscal year ended August 31, 2014.
	In the opinion of the Company, the consolidated condensed financial statements for the unaudited interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company's operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, the positive impact on gross profit margins and gross profit dollars typically have been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a "generic conversion." In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on the Company's Retail Pharmacy USA segment's sales, gross profit margins and gross profit dollars.
	As part of the Second Step Transaction, the Company acquired the remaining 27.5% noncontrolling interest in Walgreens Boots Alliance Development GmbH ("WBAD"), a 50/50 joint venture between the Company and Alliance Boots. The Company already owned a 50% direct ownership in WBAD and indirectly owned an additional ownership interest through its previous 45% investment in Alliance Boots, representing a direct and indirect economic interest of 72.5%. The Company's acquisition of the remaining 27.5% effective ownership in WBAD as part of the Second Step Transaction was accounted for as an equity transaction as it has historically been consolidated by the Company. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. ("AHID"), which is not a member of the Company's consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.
	Immediately prior to the completion of the Second Step Transaction, the Company held a 45% equity interest in Alliance Boots and recorded its proportionate share of equity income in Alliance Boots in the Company's consolidated financial statements on a three-month reporting lag. Following the Second Step Transaction, the Company eliminated the three-month reporting lag and applied this change retrospectively as a change in accounting principle in accordance with Accounting Standards Codification ("ASC") Topic 250, Accounting Changes and Error Corrections. See Note 3, Change in Accounting Policy for further information.
	The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and on various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company's significant accounting policies, please see the Walgreens Annual Report on Form 10-K, as amended, for the fiscal year ended August 31, 2014. The additional accounting policies outlined below are incremental and incorporate the inclusion of the Alliance Boots operations.
	Consolidation
	The consolidated condensed financial statements include all majority-owned subsidiaries. Investments in less than majority-owned companies in which the Company does not have a controlling interest but does have significant influence are accounted for as equity method investments. All intercompany transactions have been eliminated.
	Restricted Cash
	The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. As of February 28, 2015, the amount of such restricted cash was $206 million. There was no restricted cash as of August 31, 2014.
	Accounts Receivable
	Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily include amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies), clients and members, as well as vendors and manufacturers. Charges to bad debt are based on both historical write-offs and specifically identified receivables.
	Inventory
	The Company values inventories on a lower of cost or market basis. Inventory includes product costs, inbound freight, direct labor, warehousing costs, overhead costs relating to the manufacture and distribution of products and vendor allowances not classified as a reduction of advertising expense.
	The Company's Retail Pharmacy USA segment inventory is accounted for using the last-in-first-out ("LIFO") method. At February 28, 2015 and August 31, 2014, Retail Pharmacy USA segment inventories would have been greater by $2.4 billion and $2.3 billion, respectively, if they had been valued on a lower of first-in-first-out ("FIFO") cost or market basis. LIFO inventory costs can only be determined annually when inflation rates and inventory levels are finalized; therefore, LIFO inventory costs for interim financial statements are estimated.
	The Company's Retail Pharmacy International and Pharmaceutical Wholesale segments costs are determined using the FIFO method, except for retail inventory in the Retail Pharmacy International segment. The Company's Retail Pharmacy International segment's retail inventory is primarily determined using the retail inventory method. Under the retail inventory method, cost is determined by applying a calculated cost-to-retail ratio across groupings of similar items. The cost-to-retail ratio is applied to ending inventory at its current owned retail valuation to determine the cost of ending inventory across groupings of similar items. Current owned retail valuation represents the retail price for which merchandise is offered for sale on a regular basis reduced for any permanent or clearance markdowns. Inherent in the retail method calculation are certain management judgments and estimates including initial mark-up, markdowns and shrinkage, which can impact the owned retail valuation and, therefore, the ending inventory valuation at cost.
	Vendor Allowances and Supplier Rebates
	Vendor allowances are principally received as a result of purchases, sales or promotion of vendors' products. Allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. Those allowances received for promoting vendors' products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising costs incurred, with the excess treated as a reduction of inventory costs.
	Rebates or refunds received by the Company from its suppliers, mostly in cash, are considered as an adjustment of the prices of the supplier's products purchased by the Company.
	Revenue Recognition
	Revenue is recognized when: (a) persuasive evidence of an arrangement exists, (b) delivery has occurred or services have been rendered, (c) the seller's price to the buyer is fixed or determinable, and (d) collectability is reasonably assured. The following revenue recognition policies have been established for the Company's reportable segments:
	Retail Pharmacy USA and Retail Pharmacy International
	The Company recognizes revenue at the time the customer takes possession of the merchandise, after making appropriate adjustments for estimated returns, which are immaterial. Revenue does not include sales related taxes. In certain international locations, the Company initially estimates revenue based on expected reimbursements from governmental agencies for dispensing prescription drugs and providing optical services. The estimates are based on historical experience and updated to actual reimbursement amounts.
	Pharmaceutical Wholesale
	Wholesale revenue is recognized upon shipment of goods, which is generally also the day of delivery. When the Company acts in the capacity of an agent or a logistics service provider, revenue is the fee received for the service and is recognized when the services have been performed. The Company has determined it is the agent when providing logistics services, which is based on its assessment of the following criteria: (a) whether it is the primary obligor in the arrangement, (b) whether it has latitude in establishing the price, changing the product or performing part of the service, (c) whether it has discretion in supplier selection, (d) whether it is involved in the determination of service specifications, and (e) whether it is exposed to credit risk.
	Financial Instruments
	The Company uses derivative instruments to hedge its exposure to interest rate and currency risks arising from operating and financing activities. In accordance with its risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes.
	Derivatives are recognized on the Consolidated Condensed Balance Sheets at their fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, it formally documents the hedge relationship and the risk management objective for undertaking the hedge which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The accounting for changes in fair value of a derivative instrument depends on whether the Company had designated it in a qualifying hedging relationship and further, on the type of hedging relationship. The Company applies the following accounting policies:
		·	Changes in the fair value of a derivative designated as a fair value hedge, along with the gain or loss on the hedged asset or liability attributable to the hedged risk, are recorded in the Consolidated Condensed Statements of Earnings.
		·	The effective portion of changes in the fair value of a derivative designated as a cash flow hedge is recorded in accumulated other comprehensive income (loss) in the Consolidated Condensed Statements of Comprehensive Income and reclassified into earnings in the period or periods during which the hedged item affects earnings.
		·	The effective portion of changes in the fair value of a derivative designated as a hedge of a net investment in a foreign operation is recorded in cumulative translation adjustments within accumulated other comprehensive income (loss) in the Consolidated Condensed Statements of Comprehensive Income. Recognition in earnings of amounts previously recorded in cumulative translation adjustments is limited to circumstances such as complete or substantially complete liquidation of the net investment in the hedged investments in foreign operations.
		·	Changes in the fair value of a derivative not designated in a hedging relationship are recognized in the Consolidated Condensed Statements of Earnings along with the ineffective portions of changes in the fair value of derivatives designated in hedging relationships.
	Cash receipts or payments on a settlement of derivative contract are reported in the Consolidated Condensed Statements of Cash Flows consistent with the nature of the underlying hedged item.
	For derivative instruments designated as hedges, the Company assesses, both at the hedge's inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. Highly effective means that cumulative changes in the fair value of the derivative are between 80% and 125% of the cumulative changes in the fair value of the hedged item. In addition, when the Company determines that a derivative is not highly effective as a hedge, hedge accounting is discontinued. When it is probable that a hedged forecasted transaction will not occur, the Company discontinues hedge accounting for the affected portion of the forecasted transaction, and reclassifies any gains or losses in accumulated other comprehensive income (loss) to earnings in the Consolidated Condensed Statements of Earnings. When a derivative in a hedge relationship is terminated or the hedged item is sold, extinguished or terminated, hedge accounting is discontinued prospectively.
	Pension and Postretirement Benefits
	The Company has various defined benefit pension plans that cover some of its foreign employees. The Company also has postretirement healthcare plans that cover qualifying domestic employees. Eligibility and the level of benefits for these plans varies depending participants' status, date of hire and or length of service. Pension and postretirement expenses and valuations are dependent on assumptions used by third party actuaries in calculating those amounts. These assumptions include discount rates, healthcare cost trends, long-term return on plan assets, retirement rates, mortality rates and other factors.
	The Company funds its pension plans in accordance with applicable regulations. Postretirement plans are not funded.
	Income Taxes
	In determining the provision for income taxes, the Company uses an annual effective income tax rate based on full-year forecast income, permanent differences between book and tax income, the relative proportion of foreign and domestic income, statutory income tax rates, projections of income subject to Subpart F rules and unrecognized tax benefits related to current year results. Discrete events such as the assessment of the ultimate outcome of tax audits, audit settlements, recognizing previously unrecognized tax benefits due to lapsing of the applicable statute of limitations, recognizing or de-recognizing benefits of deferred tax assets due to future year financial statement projections and changes in tax laws are recognized in the period in which they occur.
	The Company is subject to routine income tax audits that occur periodically in the normal course of business. U.S. federal, state, local and foreign tax authorities raise questions regarding the Company's tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. In evaluating the tax benefits associated with the various tax filing positions, the Company records a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more likely than not to be realized. Adjustments are made to the liability for unrecognized tax benefits in the period in which the Company determines the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available. As of February 28, 2015, approximately $115 million of unrecognized tax benefits were reported as current liabilities, with the balance being classified as long-term liabilities on the Consolidated Condensed Balance Sheets. Based on current knowledge, it is reasonably possible the amount of unrecognized tax benefits will decrease in the next 12 months by up to $115 million, primarily due to expected tax audit settlements in multiple tax jurisdictions. The Company does not expect the settlements to materially impact the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Balance Sheets or the Company's liquidity.
	Business Combinations
	Business combinations are accounted for under ASC Topic 805, Business Combinations, using the acquisition method of accounting. The cost of an acquired company is assigned to the tangible and intangible assets purchased and the liabilities assumed on the basis of their fair values at the date of acquisition. The determination of fair values of assets and liabilities acquired requires estimates and the use of valuation techniques when a market value is not readily available. Any excess of purchase price over the fair value of net tangible and intangible assets acquired is allocated to goodwill. The final determination of the fair value of certain assets and liabilities is completed within the one year measurement period as allowed under ASC Topic 805, Business Combinations. Transaction costs associated with business combinations are expensed as they are incurred.
	Noncontrolling Interests
	The Company accounts for its less than 100% interest in consolidated subsidiaries in accordance with ASC Topic 810, Consolidation, and accordingly, the Company presents noncontrolling interests as a component of equity on its Consolidated Condensed Balance Sheets and reports the noncontrolling interest net earnings or loss as Net earnings attributable to noncontrolling interests in the Consolidated Condensed Statements of Earnings.
	Currency
	Assets and liabilities of non-U.S. dollar functional currency operations are translated into U.S. dollars at end-of-period exchange rates while revenues, expenses and cash flows are translated at average monthly exchange rates over the period. Equity is translated at historical exchange rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss) in the Consolidated Condensed Balance Sheets.
	For U.S. dollar functional currency operations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Revenues and expenses are remeasured at average monthly exchange rates over the period, except for those expenses related to nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Gains or losses from foreign currency remeasurement and transactions are included in selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. For all periods presented, there were no material operational gains or losses from foreign currency transactions.
	Warrants
	Walgreens, Alliance Boots and AmerisourceBergen Corporation ("AmerisourceBergen") entered into a Framework Agreement dated as of March 18, 2013, pursuant to which (1) Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock (approximately 7 percent of the then fully diluted equity of AmerisourceBergen, assuming the exercise in full of the warrants described below) in open market transactions; (2) Walgreens and Alliance Boots collectively were issued (a) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016, and (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017. The parties and affiliated entities also entered into certain related agreements governing relations between and among the parties thereto, including the Shareholders Agreement, the Transaction Rights Agreement and the Limited Liability Company Agreement of WAB Holdings LLC, a limited liability company formed for the purpose of acquiring and holding AmerisourceBergen common stock, each of which (including the Framework Agreement) is summarized in, and copies of which were filed as exhibits to, Walgreens Current Report on Form 8-K filed with the SEC on March 20, 2013.
	Pursuant to the Reorganization and Second Step Transaction discussed in Note 1, Organization, and Note 2, Basis of Presentation, Walgreens and Alliance Boots became wholly owned subsidiaries of WBA effective December 31, 2014. The Company holds all AmerisourceBergen warrants issued to Walgreens and Alliance Boots in its consolidated subsidiaries.
	The warrants are valued at the date of issuance and the end of the period using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen's employee stock options and the exercise price; and the details specific to the warrants. The Company reports its warrants at fair value within other non-current assets in the Consolidated Condensed Balance Sheets. A deferred credit from the day-one valuation attributable to the warrants granted to Walgreens is being amortized over the life of the warrants. Gains and losses due to changes in the fair value on warrants are recognized in other income (expense) in the Consolidated Condensed Statement of Earnings. See Note 10, Financial Instruments, for additional disclosure regarding the Company's warrants.

Change_in_Accounting_Policy

Change in Accounting Policy	6 Months Ended
	Feb. 28, 2015
Change in Accounting Policy [Abstract]
Change in Accounting Policy	3. Change in Accounting Policy
	Walgreens historically accounted for its investment and proportionate share of earnings in Alliance Boots utilizing a three-month reporting lag. Concurrent with the completion of the Second Step Transaction, the Company eliminated the three-month reporting lag. The Company determined that the elimination of the three-month reporting lag was preferable because having Alliance Boots and its subsidiaries have the same period-end reporting date improves overall financial reporting as business performance is reflected in the Company's consolidated financial statements on a more timely basis.
	In accordance with ASC Topic 810, Consolidation, a change to eliminate a previously existing reporting lag is considered a change in accounting principle in accordance with ASC Topic 250, Accounting Changes and Error Corrections. Changes in accounting principles are to be reported through retrospective application of the new principle to all prior financial statement periods presented. Accordingly, the consolidated condensed financial statements have been recast to reflect the period specific effects of eliminating the three-month reporting lag. The acquisition of the initial 45% interest was reflected in the Company's August 31, 2012 balance sheet. The Company's equity earnings and income statement for the year ended August 31, 2012, were not recasted as the impact was not material.
	The elimination of the three-month reporting lag for the equity investment in Alliance Boots resulted in the adjustments as of and for the periods indicated below (in millions, except per share amounts). The impact of the change in accounting policy on the current period financial statements is not material.
		Three Months Ended February 28, 2014									Six Months Ended February 28, 2014
		As			Adjustments			After			As Reported			Adjustments			After
		Reported						Change in									Change in
								Accounting									Accounting
								Principle									Principle
	Consolidated Condensed Statements of Earnings
	Equity earnings in Alliance Boots	$	194		$	(58	)	$	136		$	345		$	(15	)	$	330
	Operating Income		1,275			(58	)		1,217			2,199			(15	)		2,184
	Earnings Before Income Tax Provision		1,179			(58	)		1,121			2,287			(15	)		2,272
	Income tax provision		411			(20	)		391			815			(5	)		810
	Net Earnings		768			(38	)		730			1,472			(10	)		1,462
	Net Earnings Attributable to Walgreens Boots Alliance, Inc.		754			(38	)		716			1,449			(10	)		1,439
	Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – basic		0.79			(0.04	)		0.75			1.52			(0.01	)		1.51
	Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted		0.78			(0.04	)		0.74			1.51			(0.02	)		1.49
	Consolidated Condensed Statements of Comprehensive  Income
	Net Earnings		768			(38	)		730			1,472			(10	)		1,462
	Share of other comprehensive loss of Alliance Boots		(36	)		17			(19	)		(70	)		14			(56	)
	Cumulative translation adjustments		191			(75	)		116			253			28			281
	Total Other Comprehensive Income		104			(58	)		46			224			42			266
	Total Comprehensive Income		872			(96	)		776			1,696			32			1,728
	Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.	$	858		$	(96	)	$	762		$	1,673		$	32		$	1,705
		As of August 31, 2014
		As Reported			Adjustments			After
								Change in
								Accounting
								Principle
	Consolidated Condensed Balance Sheet
	Non-Current Assets:
	Equity investment in Alliance Boots	$	7,248		$	88		$	7,336
	Total Non-Current Assets		24,940			88			25,028
	Total Assets		37,182			88			37,270
	Non-Current Liabilities:
	Deferred income taxes		1,048			32			1,080
	Total Non-Current Liabilities		7,726			32			7,758
	Equity:
	Retained earnings		22,229			98			22,327
	Accumulated other comprehensive income		178			(42	)		136
	Total Walgreens Boots Alliance, Inc. Shareholders' Equity		20,457			56			20,513
	Total Equity		20,561			56			20,617
	Total Liabilities and Equity	$	37,182		$	88		$	37,270
		Six Months Ended February 28, 2014
		As Reported			Adjustments			After
								Change in
								Accounting
								Principle
	Consolidated Condensed Statement of Cash Flows
	Cash Flows from Operating Activities:
	Net earnings	$	1,472		$	(10	)	$	1,462
	Deferred income taxes		34			(5	)		29
	Equity earnings in Alliance Boots		(345	)		15			(330	)
	The cumulative effect of eliminating the three-month reporting lag was recorded as an after-tax increase to retained earnings of $98 million as of September 1, 2013, the first day of the Company's 2014 fiscal year.

Leases_and_Store_Closures

Leases and Store Closures	6 Months Ended
	Feb. 28, 2015
Leases and Store Closures [Abstract]
Leases and Store Closures	4. Leases and Store Closures
	Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may or may not include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.
	The Company continuously evaluates its real estate portfolio in conjunction with its capital needs. The Company has entered into several sale-lease-back transactions. In some of these transactions, the Company negotiated fixed rate renewal options which constitute a form of continuing involvement, resulting in the assets remaining on the balance sheet and a corresponding finance lease obligation.
	Annual minimum rental commitments under all leases having an initial or remaining non-cancelable term of more than one year are shown below (in millions):
		Financing			Capital			Operating
		Obligation			Lease			Lease
	2015	$	19		$	68		$	3,071
	2016		18			66			3,006
	2017		18			62			2,886
	2018		18			59			2,814
	2019		18			59			2,561
	Later		1,153			901			23,102
	Total Minimum Lease Payments	$	1,244		$	1,215		$	37,440
	The capital and finance lease amounts include $1.6 billion of imputed interest and executory costs. Total minimum lease payments have not been reduced by minimum sublease rentals of approximately $211 million on leases due in the future under non-cancelable subleases.
	In March 2014, the Company's Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources in a manner intended to increase shareholder value. The Company incurred no pre-tax charges related to this plan in the three month period ended February 28, 2015. For the six month period ended February 28, 2015, the Company incurred total pre-tax charges of $17 million primarily related to lease termination costs. The Company incurred no pre-tax charges for the three and six month periods ended February 28, 2014.
	The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and six month periods ended February 28, 2015, the Company recorded charges of zero and $26 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company's store optimization plan. This compares to $6 million and $33 million for the three and six month periods ended February 28, 2014, respectively. These charges are reported in selling, general and administrative expenses on the Consolidated Condensed Statements of Earnings.
	The changes in reserve for facility closings and related lease termination charges include the following (in millions):
		February 28,			August 31,
		2015			2014
	Balance – beginning of period	$	257		$	123
	Provision for present value of non-cancellable lease payments on closed facilities		11			171
	Assumptions about future sublease income, terminations and changes in interest rates		2			(8	)
	Interest accretion		13			14
	Liability assumed through acquisition of Alliance Boots		13			-
	Cash payments, net of sublease income		(36	)		(43	)
	Balance – end of period	$	260		$	257
	The Company remains secondarily liable on approximately 72 leases. The maximum potential undiscounted future payments are $360 million at February 28, 2015. Lease option dates vary, with some extending to 2041.
	Rental expense, which includes common area maintenance, insurance and taxes, was as follows (in millions):
		Three Months Ended						Six Months Ended
		February 28,						February 28,
		2015			2014			2015			2014
	Minimum rentals	$	809		$	673		$	1,486		$	1,333
	Contingent rentals		1			1			3			4
	Less: Sublease rental income		(6	)		(7	)		(11	)		(12	)
		$	804		$	667		$	1,478		$	1,325

Equity_Method_Investments

Equity Method Investments	6 Months Ended
	Feb. 28, 2015
Equity Method Investments [Abstract]
Equity Method Investments	5. Equity Method Investments
	Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method upon completion of the Second Step Transaction on December 31, 2014.  Equity method investments as of February 28, 2015 and August 31, 2014 were as follows (in millions, except percentages):
		28-Feb-15					31-Aug-14
		Carrying		Ownership			Carrying		Ownership
		Value		Percentage			Value		Percentage
	Alliance Boots	$	N/A		100	%	$	7,336		45	%
	Other		762		12% - 50	%		74		30% - 50	%
	Total	$	762				$	7,410
	N/A        Not applicable
	Alliance Boots
	On August 2, 2012, pursuant to the Purchase and Option Agreement the Company acquired 45% of the issued and outstanding share capital of Alliance Boots in exchange for $4.025 billion in cash and approximately 83.4 million shares of Walgreens common stock.  The Purchase and Option Agreement provided, subject to the satisfaction or waiver of specified conditions, a call option that gave the Company the right, but not the obligation, to acquire the remaining 55% of Alliance Boots in exchange for an additional £3.1 billion in cash as well as an additional 144.3 million Company shares, subject to certain adjustments (the "call option").  On August 5, 2014, the Purchase and Option Agreement was amended to permit the exercise of the call option beginning on that date, and the Company, through an indirectly wholly-owned subsidiary to which the Company previously assigned its right to the call option, exercised the call option on August 5, 2014. The Company's equity earnings, initial investment and the call option excluded the Alliance Boots minority interest in Galenica Ltd. ("Galenica"). The Alliance Boots investment in Galenica was distributed to the Alliance Boots shareholders other than Walgreens in May 2013, which had no impact on the Company's financial results.
	Prior to the closing of the Second Step Transaction on December 31, 2014, the Company accounted for its 45% investment in Alliance Boots using the equity method of accounting. Because the underlying net assets in Alliance Boots were denominated in a foreign currency, translation gains or losses had an impact on the recorded value of the Company's investment. The Company utilized a three-month reporting lag in recording equity income in Alliance Boots, which was eliminated on December 31, 2014 (See Note 3, Change in Accounting Policy). The Company's share of Alliance Boots earnings was recorded as Equity earnings in Alliance Boots in the Consolidated Condensed Statements of Earnings. The Company's investment was recorded as Equity investment in Alliance Boots in the Consolidated Condensed Balance Sheets.
	The Company's initial investment in Alliance Boots exceeded its proportionate share of the net assets of Alliance Boots by $2.4 billion. This premium of $2.4 billion was recognized as part of the carrying value in the Company's equity investment in Alliance Boots. The difference was primarily related to the fair value of Alliance Boots indefinite-lived intangible assets and goodwill. The Company's equity method income from the investment in Alliance Boots was adjusted to reflect the amortization of fair value adjustments in certain definite lived assets of Alliance Boots. The Company's incremental amortization expense associated with the Alliance Boots investment was approximately $4 million and $14 million for the three and six month periods ended February 28, 2015, respectively. The Company's incremental amortization expense associated with the Alliance Boots investment was approximately $10 million and $20 million for the three and six month periods ended February 28, 2014, respectively. The incremental amortization expense has been recorded as a reduction in equity earnings from Alliance Boots for all periods prior to closing of the Second Step Transaction on December 31, 2014.
	The Second Step Transaction closed on December 31, 2014. (See Note 1, Organization, and Note 2, Basis of Presentation.) In connection with this transaction as required by ASC Topic 805, Business Combinations, the Company recorded a non-cash gain of $706 million resulting from the remeasurement of the previously held equity interest in Alliance Boots at its acquisition date fair value. The non-cash gain includes $80 million of foreign currency translation gains and losses reclassified from accumulated other comprehensive income. This gain is preliminary and may be subject to change as the Company finalizes purchase accounting.
	Other Equity Method Investments
	Other equity method investments primarily relate to equity method investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company's pharmaceutical wholesale investments in China. Also included are additional investments in pharmaceutical wholesaling and distribution, retail pharmacy and our hearing care operator, an equity method investment received through the sale of the Take Care Employer business in fiscal 2014 and joint ventures associated with the Company's infusion and respiratory businesses. The Second Step Transaction resulted in the Company acquiring stakes in various equity method investments held by Alliance Boots. These newly acquired investments are included with the equity investments of the Company within other noncurrent assets on the Consolidated Condensed Balance Sheets. The Company reported $8 million of equity earnings in equity method investments for the three and six month periods ended February 28, 2015, respectively. Equity earnings from the historical Walgreens equity method investments for the three and six month periods ended February 28, 2014, respectively were immaterial. The Company's share of equity income is reported as post tax earnings from equity method investments, in the Consolidated Condensed Statements of Earnings.
	Summarized Financial Information
	Summarized financial information for the Company's equity method investees is as follows:
	Balance Sheet (in millions)
		February 28, 2015(1)		August 31, 2014(1)
	Current assets	$	4,674	$	9,074
	Noncurrent assets		625		22,363
	Current liabilities		4,067		9,372
	Noncurrent liabilities		253		10,608
	Shareholders' equity (2)		979		11,457
	Income Statement (in millions)
		Three Months Ended					Six Months Ended
		February 28,					February 28,
		2015(3)		2014(3)			2015(3)		2014(3)
	Net sales	$	5,317	$	9,688		$	14,978	$	19,100
	Gross Profit		979		2,083			3,168		4,055
	Net Income		246		324			743		771
	Share of income from equity method investments(3)		109		136			323		330
	(1) Net assets in foreign equity method investments are translated at their respective February 28, 2015 and August 31, 2014 spot rates.
	(2) Shareholders' equity at February 28, 2015 and August 31, 2014 includes $151 million and $283 million respectively, related to noncontrolling interests.
	(3) Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method upon completion of the Second Step Transaction on December 31, 2014. Earnings for the three and six month periods ended February 28, 2015 reflect incremental acquisition-related amortization expense of $4 million ($3 million net of tax) and $14 million ($8 million net of tax), respectively.  Incremental acquisition-related amortization expense for the three and six month periods ended February 28, 2014 were $10 million ($8 million net of tax) and $20 million ($16 million net of tax), respectively. Earnings in foreign equity method investments are translated at their respective average exchange rates.

AvailableforSale_Investments

Available-for-Sale Investments	6 Months Ended
	Feb. 28, 2015
Available-for-Sale Investments [Abstract]
Available-for-Sale Investments	6. Available-for-Sale Investments
	Walgreens, Alliance Boots and AmerisourceBergen entered into a Framework Agreement dated as of March 18, 2013, pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock (approximately 7 percent of the then fully diluted equity of AmerisourceBergen, assuming the exercise in full of the warrants described within Note 10, Financial Instruments) in open market transactions.
	In conjunction with its long-term relationship with AmerisourceBergen, Walgreens acquired shares of AmerisourceBergen through open market transactions totaling $140 million and $430 million, respectively, during the three and six months ended February 28, 2014. As of February 28, 2015, the Company held 11.5 million shares, approximately 5.2% of AmerisourceBergen's outstanding common stock at a total fair value of $1.2 billion. The Company's cumulative cost basis of common shares acquired was $717 million at February 28, 2015.
	Pursuant to ASC Topic 320, Investments – Debt and Equity Securities, the Company has deemed the investment in AmerisourceBergen shares an available-for-sale investment reported at fair value and included it within other non-current assets in the Consolidated Condensed Balance Sheets. As an available-for-sale investment, changes in the fair value are recorded through other comprehensive income. The value of the investment is recorded at the closing price of AmerisourceBergen common stock as of the balance sheet date.
	A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):
		28-Feb-15
		Cost		Unrealized gains		Foreign Exchange losses			Unrealized losses		Fair value
	AmerisourceBergen common stock	$	717	$	461	$	-		$	-	$	1,178
	Other investments		75		6		(4	)		-		77
	Total available-for-sale investments	$	792	$	467	$	(4	)	$	-	$	1,255
		31-Aug-14
		Cost		Unrealized gains		Foreign Exchange losses			Unrealized losses		Fair value
	AmerisourceBergen common stock	$	717	$	170	$	-		$	-	$	887
	Total available-for-sale investments	$	717	$	170	$	-		$	-	$	887
	For the three and six month periods ended February 28, 2015 and 2014, there were no sales of available-for-sale investments.
	The Company has $77 million of other available-for-sale investments classified within other current assets in the Consolidated Condensed Balance Sheets at February 28, 2015.

Acquisitions

Acquisitions	6 Months Ended
	Feb. 28, 2015
Acquisitions [Abstract]
Acquisitions	7. Acquisitions
	Alliance Boots
	The Second Step Transaction closed on December 31, 2014, resulting in the acquisition by the Company of 55% of the issued and outstanding share capital of Alliance Boots, increasing its interest to 100%. (See Note 1, Organization, and Note 2, Basis of Presentation.) The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. As a result of the Second Step Transaction, the Company significantly expanded its operations to include pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution businesses in major international markets.
	As a result of the closing of the Second Step Transaction, the Company increased its interest in WBAD, a 50/50 joint venture between Walgreens and Alliance Boots, to 100%. Because Walgreens held, prior to the Second Step Transaction, a 50% direct interest and an additional indirect interest in WBAD through its 45% ownership of Alliance Boots, the financial results of WBAD were fully consolidated into the Walgreens consolidated financial statements with the remaining 27.5% effective interest being recorded as a noncontrolling interest. The acquisition of the 27.5% noncontrolling interest has been accounted for as an equity transaction with no gain or loss recorded in the statement of earnings under ASC Topic 805, Business Combinations. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. ("AHID"), which is not a member of the Company's consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.
	The total purchase price of the Second Step Transaction of $15.9 billion included £3.133 billion in cash (approximately $4.9 billion at the December 31, 2014 spot rate of $1.56 to £1.00) and 144.3 million of the Company's common shares at a fair value of $11.0 billion (based on the December 30, 2014 closing market price of $76.05). Of the total purchase price, $13.3 billion was preliminarily allocated to acquire the 55% ownership interest in Alliance Boots and $2.6 billion was preliminarily allocated to acquire the noncontrolling interest in WBAD. The purchase price attributed to the acquisition of the noncontrolling interest in WBAD was determined based on the relative fair value of Alliance Boots and WBAD, respectively.
	The preliminary impact of the equity transaction is as follows (in millions):
		Amount
	Consideration attributable to WBAD	$	2,569
	Less:  Carrying value of the Company's pre-existing noncontrolling interest		130
	Impact to additional paid in capital	$	2,439
	As of February 28, 2015, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired and therefore the purchase price allocation for Alliance Boots and WBAD has not been completed. The preliminary purchase price allocation will be subject to further refinement and may result in material changes. These changes will primarily relate to the allocation of consideration and the fair value assigned to all tangible and intangible assets acquired and identified. The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).
	Consideration paid
	Cash	$	4,874
	Common stock		10,977
	Total consideration transferred		15,851
	Less: consideration attributed to WBAD		(2,569	)
			13,282
	Fair value of the investment in Alliance Boots held before the Second Step Transaction		8,290
	Total consideration	$	21,572
	Identifiable assets acquired and liabilities assumed including noncontrolling interests
	Cash and cash equivalents	$	413
	Accounts receivable		3,805
	Inventories		3,713
	Other current assets		902
	Property, plant and equipment		3,774
	Intangible assets		11,461
	Other non-current assets		1,760
	Trade accounts payable, accrued expenses and other liabilities		(7,722	)
	Borrowings		(8,999	)
	Deferred income taxes		(2,437	)
	Other non-current liabilities		(456	)
	Noncontrolling interests		(198	)
	Total identifiable net assets and noncontrolling interests		6,016
	Goodwill	$	15,556
	As a result of the Company acquiring the remaining 55% interest in Alliance Boots, the Company's previously held 45% interest was remeasured to fair value, resulting in a gain of $706 million. This gain has been recognized as Gain on previously held equity interest in the Consolidated Condensed Statements of Earnings. This gain is preliminary and may be subject to change as the Company finalizes purchase accounting.
	The fair value of the previously held equity interest of $8.3 billion in Alliance Boots was determined using the Income Approach methodology.  The fair value measurement of the previously held equity interest is based on significant inputs not observable in the market, and thus represents Level 3 measurements. The fair value estimates for the previously held equity interest are based on (a) projected discounted cash flows, (b) historical and projected financial information, and (c) synergies including cost savings, as relevant, that market participants would consider when estimating the fair value of the previously held equity interest in Alliance Boots. The fair value for trade names and trademarks was determined using the relief from royalty method of the income approach; pharmacy licenses and customer relationships used the excess earnings method of the income approach; and loyalty card holders used the incremental cash flow method which is a form of the income approach. Personal property fair values were determined primarily using the indirect cost approach. While real property fair values were determined using the income, market and/or cost approach.
	The preliminary identified definite and indefinite lived intangible assets were as follows:
	Definite-Lived Intangible Assets	Weighted-Average			Amount
		Useful Life			(in millions)
		(in years)
	Customer relationships		12		$	1,676
	Loyalty card holders		12			723
	Trade names and trademarks		15			544
	Favorable lease interests		3			55
	Total				$	2,998
	Indefinite-Lived Intangible Assets	Amount
		(in millions)
	Trade names and trademarks	$	6,192
	Pharmacy licenses		2,271
	Total	$	8,463
	The preliminary goodwill of $15.6 billion arising from the Second Step Transaction consists of expected purchasing synergies, operating efficiencies by benchmarking performance and applying best practices across the combined company, consolidation of operations, reductions in selling, general and administrative expenses and combining workforces. The Company determined that the preliminary goodwill should be allocated across all segments because each segment will benefit from synergies related to the acquisition that will increase each segment’s overall profitability. The Company determined that $4.7 billion of preliminary goodwill arising from synergies was directly attributable to the Retail Pharmacy USA segment. The Company also allocated $3.6 billion of preliminary goodwill from the acquisition to the Retail Pharmacy USA segment based on a with and without analysis whereby the difference between the fair value of a segment before the acquisition and its fair value after the acquisition represents the amount of goodwill assigned to that segment. Of the remaining preliminary goodwill, $3.8 billion was allocated to the Retail Pharmacy International segment and $3.5 billion was allocated to the Pharmaceutical Wholesale segment. The allocation of the goodwill to the individual reporting units within the respective segments has not been completed. Substantially all of the goodwill recognized is not expected to be deductible for income tax purposes.
	The Company incurred legal and other professional services costs related to the Second Step Transaction, which were included in selling, general and administrative expenses, of $59 million and $83 million for the three and six month periods ended February 28, 2015.
	The preliminary fair value of the assets acquired includes inventory having an estimated fair value of $3.7 billion. This fair value includes a $106 million "step-up" adjustment to capitalize the estimated profit in acquired finished goods inventory as of the date of the Second Step Transaction, all of which was expensed to cost of sales during the three and six months ended February 28, 2015 over the first inventory turn.
	The following table presents supplemental unaudited condensed pro forma consolidated statements of earnings for 2015 and 2014 as if the Second Step Transaction had occurred on September 1, 2013, the first day of the Company's fiscal 2014. As described in Note 3, Change in Accounting Policy, the information has been presented without a lag. The unaudited condensed pro forma statements reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair valuation of assets acquired, the impact of acquisition financing, transaction costs and the related income tax effects. The unaudited condensed pro forma statements do not include any anticipated synergies which may be achievable subsequent to the date of the Second Step Transaction. The unaudited condensed pro forma statements also exclude certain non-recurring items such as the gain on Walgreens previously held 45% investment in Alliance Boots and other transaction related costs. Accordingly, the unaudited condensed pro forma results have been prepared for comparative purposes only and are not intended to be indicative of what the Company's results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.
		Pro forma					Pro forma
		Three months ended					Six months ended
		February 28,					February 28,
		2015			2014		2015		2014
	(in millions, except per share amounts)
	Net sales	$	30,202		$	29,276	$	59,173	$	56,999
	Net earnings		1,253			966		2,621		1,973
	Net earnings per common share:
	Basic	$	1.2		$	0.88	$	2.51	$	1.8
	Diluted		1.19			0.87		2.49		1.78
Actual results from Alliance Boots operations included in the Consolidated Condensed Statements of Earnings since December 31, 2014, the date of the Second Step Transaction, are as follows (in millions, except per share amounts):
	Three months ended			Six months ended
	February 28,			February 28,
	2015			2015
(in millions, except per share amounts)
Net sales	$	5,525		$	5,525
Net earnings		330			330
Net earnings per common share:
Basic	$	0.32		$	0.33
Diluted		0.31			0.33
Other Acquisitions
The aggregate purchase price of all businesses, excluding Alliance Boots, net of cash received was $92 million for the six month period ended February 28, 2015. These acquisitions added $23 million to goodwill and $64 million to intangible assets, primarily pharmacy files. The remaining fair value relates to immaterial amounts of tangible assets, less liabilities assumed. Operating results of the businesses acquired have been included in the Consolidated Condensed Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Feb. 28, 2015
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	8. Goodwill and Other Intangible Assets
	Historically, Walgreens operations were within one reportable segment. As a result of the Second Step Transaction effective December 31, 2014, the Company realigned its reportable segments into the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments (see Note 19, Segment Reporting). Goodwill added as a result of the Second Step Transaction has been preliminarily allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale reportable segments.
	Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):
			Retail Pharmacy			Retail Pharmacy			Pharmaceutical			Total
			USA			International			Wholesale
	31-Aug-14		$	2,359		$	-		$	-		$	2,359
	Acquisitions			8,311			3,747			3,521			15,579
	Sale of business(1)			(706	)		-			-			(706	)
	Other(2)			(3	)		-			-			(3	)
	Currency translation adjustments			-			(99	)		(86	)		(185	)
	28-Feb-15		$	9,961		$	3,648		$	3,435		$	17,044
	-1	Represents Walgreens Infusion and Respiratory Services goodwill that has been reclassified as an asset held for sale. See Note 22, Subsequent Events for further details.
	-2	Other primarily represents immaterial purchase accounting adjustments for the Company's acquisitions.
	As a result of the Second Step Transaction, the Company recorded $15.6 billion of goodwill and $11.5 billion of intangible assets in conjunction with the preliminary purchase accounting. See Note 7, Acquisitions for additional information regarding the transaction.
	The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):
			28-Feb-15			31-Aug-14
	Gross Amortizable Intangible Assets
	Purchased prescription files		$	925		$	1,079
	Favorable lease interests			427			382
	Purchasing and payer contracts			95			301
	Non-compete agreements			154			151
	Trade names and trademarks			735			191
	Customer relationships			1,724			-
	Loyalty card holders			716			-
	Other amortizable intangible assets			4			4
	Total gross amortizable intangible assets			4,780			2,108
	Accumulated amortization
	Purchased prescription files			471			474
	Favorable lease interests			187			174
	Purchasing and payer contracts			61			145
	Non-compete agreements			82			70
	Trade names and trademarks			84			69
	Customer relationships			46			-
	Loyalty card holders			10			-
	Other amortizable intangible assets			1			4
	Total accumulated amortization			942			936
	Total amortizable intangible assets, net		$	3,838		$	1,172
	Indefinite Lived Intangible Assets
	Trade names and trademarks		$	6,136		$	8
	Pharmacy licenses			2,251			-
	Total indefinite lived intangible assets		$	8,387		$	8
	Total intangible assets, net		$	12,225		$	1,180
	The carrying amount of amortizable intangible assets and accumulated amortization included currency translation adjustments of $(129) million and $46 million, respectively, as of February 28, 2015.
	The carrying amount of indefinite lived intangible assets included currency translation adjustments of $(76) million as of February 28, 2015.
	Amortization expense for intangible assets was $209 million and $276 million for the three and six months ended February 28, 2015, respectively and $73 million and $143 million for the three and six months ended February 28, 2014, respectively.
	Estimated annual amortization expense for intangible assets recorded at February 28, 2015 is as follows (in millions):
			2015			2016			2017			2018			2019
	Estimated annual amortization expense:		$	426		$	465		$	424		$	388		$	366

ShortTerm_Borrowings_and_LongT

Short-Term Borrowings and Long-Term Debt	6 Months Ended
	Feb. 28, 2015
Short-Term Borrowings and Long-Term Debt [Abstract]
Short-Term Borrowings and Long-Term Debt	9. Short-Term Borrowings and Long-Term Debt
	Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars. Debt issuances are denominated in U.S. dollars, unless otherwise noted):
			February 28,				August 31,
			2015				2014
	Short-Term Borrowings(1)
	Current portion of loans assumed through the purchase of land and buildings; various interest rates from 5.000% to 8.750%; various maturities from 2015 to 2035		$	2			$	8
	1.000% unsecured notes due 2015			750				750
	Other(2)			309				16
	Total short-term borrowings		$	1,061			$	774
	Long-Term Debt(1)
	Unsecured variable rate notes due 2016		$	750			$	-
	Unsecured Pound Sterling variable rate term loan due 2019			2,235				-
	1.800% unsecured notes due 2017			999				999
	1.750% unsecured notes due 2017			749				-
	5.250% unsecured notes due 2019(3)			1,016				1,010
	2.700% unsecured notes due 2019			1,248				-
	2.875% unsecured Pound Sterling notes due 2020(4)			615				-
	3.300% unsecured notes due 2021			1,247				-
	3.100% unsecured notes due 2022			1,199				1,199
	3.800% unsecured notes due 2024			1,995				-
	3.600% unsecured Pound Sterling notes due 2025(4)			462				-
	2.125% unsecured Euro notes due 2026(5)			837				-
	4.500% unsecured notes due 2034			497				-
	4.400% unsecured notes due 2042			496				496
	4.800% unsecured notes due 2044			1,500				-
	Loans assumed through the purchase of land and buildings; various interest rates from 5.000% to 8.750%; various maturities from 2015 to 2035			41				40
	Other(6)			117				-
				16,003				3,744
	Less: current maturities			2				8
	Total long-term debt		$	16,001			$	3,736
	-1	All notes are presented net of unamortized discount, where applicable.
	-2	Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including $29 million of U.S. dollar equivalent bank overdrafts.
	-3	Also includes interest rate swap fair market value adjustments, see Note 11, Fair Value Measurements for additional fair value disclosures.
	-4	Pound Sterling denominated notes are translated at the February 28, 2015 spot rate of $1.54 to one British Pound Sterling.
	-5	Euro denominated notes are translated at the February 28, 2015 spot rate of $1.12 to one Euro.
	-6	Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
	Extinguishment of Debt Assumed in Second Step Transaction
	As a result of the Second Step Transaction (see Note 7, Acquisitions), the Company assumed $9.0 billion of Alliance Boots existing debt. In January 2015, the Company repaid substantially all of the assumed debt with proceeds from the November 2014 debt issuances described below.
	$8.0 Billion Note Issuance
	On November 18, 2014, WBA received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $7.9 billion from a public offering of notes with varying maturities and interest rates, the majority of which are fixed rate. The notes are unsecured, unsubordinated debt obligations of WBA and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of WBA from time to time outstanding. The notes are fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens as described below. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $44 million. The fair value of the notes as of February 28, 2015 was $8.3 billion. Fair value for these notes was determined based upon quoted market prices.
	The following table summarizes each tranche of notes issued:
	Notes Issued
	(in millions)			Maturity Date	Interest Rate	Interest Payment Dates
	$	750		18-May-16	Variable; three-month U.S. dollar LIBOR, reset quarterly, plus 45 basis points	February 18, May 18, August 18, and November 18; commencing on February 18, 2015
		750		17-Nov-17	Fixed 1.750%	May 17 and November 17; commencing on May 17, 2015
		1,250		18-Nov-19	Fixed 2.700%	May 18 and November 18; commencing on May 18, 2015
		1,250		18-Nov-21	Fixed 3.300%	May 18 and November 18; commencing on May 18, 2015
		2,000		18-Nov-24	Fixed 3.800%	May 18 and November 18; commencing on May 18, 2015
		500		18-Nov-34	Fixed 4.500%	May 18 and November 18; commencing on May 18, 2015
		1,500		18-Nov-44	Fixed 4.800%	May 18 and November 18; commencing on May 18, 2015
	$	8,000
	Walgreens Guarantee
	The Walgreens guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens from time to time outstanding. The purpose of the guarantee is to protect the notes against structural subordination to certain indebtedness of Walgreens. The Walgreens guarantee will automatically terminate, and the obligations of Walgreens under the Walgreens guarantee will be unconditionally released and discharged, if and when (i) the aggregate outstanding principal amount of Capital Markets Indebtedness (as defined), including the Existing Notes (as defined), and Commercial Bank Indebtedness (as defined), in each case, of Walgreens is less than $2.0 billion and (ii) Walgreens does not guarantee any Capital Markets Indebtedness (other than the notes or the Euro/Sterling Notes (as defined)) or Commercial Bank Indebtedness, in each case, of WBA. In addition, the Walgreens guarantee will automatically terminate, and the obligations of Walgreens under the Walgreens guarantee will be unconditionally released and discharged, with respect to any series of outstanding notes, upon (i) repayment of such series of outstanding notes in full, (ii) the satisfaction and discharge of the indenture with respect to such series of outstanding notes or (iii) the defeasance or covenant defeasance of such series of outstanding notes in accordance with the terms of the indenture. Once released in accordance with its terms, the Walgreens guarantee will not subsequently be required to be reinstated.
	Redemption Option
	WBA may redeem (a) the notes due 2017, at any time in whole or from time to time in part, (b) the notes due 2019, at any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part, (c) the notes due 2021, at any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part, (d) the notes due 2024, at any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part, (e) the notes due 2034, at any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part, and (f) the notes due 2044, at any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part, in each case, at WBA's option for the sum of accrued and unpaid interest plus a redemption price equal to the greater of:
	(1) 100% of the principal amount of the fixed rate notes being redeemed; and
	(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044.
	In addition, at any time on or after October 18, 2019 with respect to the notes due 2019, September 18, 2021 with respect to the notes due 2021, August 18, 2024 with respect to the notes due 2024, May 18, 2034 with respect to the notes due 2034, or May 18, 2044 with respect to the notes due 2044, WBA may redeem some or all of the applicable series of fixed rate notes at its option, at a redemption price equal to 100% of the principal amount of the applicable fixed rate notes being redeemed, plus accrued and unpaid interest on the fixed rate notes being redeemed to, but excluding, the redemption date.
	Change in Control
	If WBA experiences a change of control triggering event, unless WBA has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, WBA will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.
	£700 Million and €750 Million Notes Issuance
	On November 20, 2014, WBA issued three series of debt securities denominated in Euros and Pound Sterling in a public offering, each with varying maturities and interest rates. Interest on all notes is payable annually on November 20, commencing on November 20, 2015. The notes are unsecured, unsubordinated debt obligations of WBA and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of WBA from time to time outstanding. The notes are fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens as described below.  Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $11 million. The fair value of the notes as of February 28, 2015 was $2.0 billion. Fair value for these notes was determined based upon quoted market prices.
	The following table details each tranche of Euro and Pound Sterling notes issued:
	Notes Issued (in millions)				Maturity Date	Interest Rate
Euro Notes:
	€	750		20-Nov-26	Fixed 2.125%
Pound Sterling Notes:
	£	400		20-Nov-20	Fixed 2.875%
		300		20-Nov-25	Fixed 3.600%
	£	700
Walgreens Guarantee
The Walgreens guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens from time to time outstanding. The purpose of the guarantee is to protect the notes against structural subordination to certain indebtedness of Walgreens. The Walgreens guarantee will automatically terminate, and the obligations of Walgreens under the Walgreens guarantee will be unconditionally released and discharged, if and when (i) the aggregate outstanding principal amount of Capital Markets Indebtedness (as defined), including the Existing Notes (as defined), and Commercial Bank Indebtedness (as defined), in each case, of Walgreens is less than $2.0 billion and (ii) Walgreens does not guarantee any Capital Markets Indebtedness (other than the notes or the U.S. Dollar Notes (as defined)) or Commercial Bank Indebtedness, in each case, of WBA. In addition, the Walgreens guarantee will automatically terminate, and the obligations of Walgreens under the Walgreens guarantee will be unconditionally released and discharged, with respect to any series of outstanding notes, upon (i) repayment of such series of outstanding notes in full, (ii) the satisfaction and discharge of the indenture with respect to such series of outstanding notes or (iii) the defeasance or covenant defeasance of such series of outstanding notes in accordance with the terms of the indenture. Once released in accordance with its terms, the Walgreens guarantee will not subsequently be required to be reinstated.
Redemption Option
WBA may redeem (a) the Euro notes, at any time prior to August 20, 2026 in whole or from time to time prior to August 20, 2026 in part, (b) the Pound Sterling notes due 2020, at any time prior to October 20, 2020 in whole or from time to time prior to October 20, 2020 in part, and (c) the Pound Sterling notes due 2025, at any time prior to August 20, 2025 in whole or from time to time prior to August 20, 2025 in part, in each case, at WBA's option for the sum of accrued and unpaid interest plus at a redemption price equal to the greater of:
(1) 100% of the principal amount of the notes to be redeemed; and
(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate, (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025.
In addition, at any time on or after August 20, 2026 with respect to the Euro notes, October 20, 2020 with respect to the Pound Sterling notes due 2020, or August 20, 2025 with respect to the Pound Sterling notes due 2025, WBA may redeem some or all of the applicable series of notes at its option, at a redemption price equal to 100% of the principal amount of the applicable notes to be redeemed, plus, in every case, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date.
Change in Control
If WBA experiences a change of control triggering event, unless WBA has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, WBA will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.
$4.0 Billion Note Issuance
On September 13, 2012, Walgreens obtained net proceeds from a public offering of $4.0 billion of notes with varying maturities and interest rates, the majority of which, at issuance, were fixed rate. The notes are unsecured senior debt obligations and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of WBA and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of WBA. Total issuance costs relating to the notes, including underwriting discounts and fees, were $26 million.
The Company repaid the $550 million variable rate notes on their March 13, 2014 maturity date. Additionally, the Company repaid the $750 million 1.000% fixed rate notes on their March 13, 2015 maturity date.
The following table details each tranche of outstanding notes as of February 28, 2015:
Notes Issued			Maturity Date	Interest Rate	Interest Payment Dates
(in millions)
$	750		13-Mar-15	Fixed 1.000%	March 13 and September 13; commencing on March 13, 2013
	1,000		15-Sep-17	Fixed 1.800%	March 15 and September 15; commencing on March 15, 2013
	1,200		15-Sep-22	Fixed 3.100%	March 15 and September 15; commencing on March 15, 2013
	500		15-Sep-42	Fixed 4.400%	March 15 and September 15; commencing on March 15, 2013
$	3,450
The fair value of the notes as of February 28, 2015 and August 31, 2014 was $3.5 billion and $3.4 billion, respectively. Fair value for these notes was determined based upon quoted market prices.
Redemption Option and Change in Control
Walgreens may redeem the fixed rate notes at its option, at any time in whole, or from time to time in part, at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 20 basis points for the notes due 2017, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042.  If a change of control triggering event occurs, Walgreens will be required, unless it has exercised its right to redeem the notes, to offer to purchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase.
$1.0 Billion Note Issuance
On January 13, 2009, Walgreens issued notes totaling $1.0 billion bearing an interest rate of 5.250% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of Walgreens. On December 31, 2014, WBA fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of WBA and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of WBA. The notes are not convertible or exchangeable. Total issuance costs relating to this offering including underwriting discounts and fees, were $8 million. The fair value of the notes as of February 28, 2015 and August 31, 2014 was $1.1 billion and $1.1 billion, respectively. Fair value for these notes was determined based upon quoted market prices.
Redemption Option and Change in Control
Walgreens may redeem the notes, at any time in whole or from time to time in part, at its option at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless Walgreens has exercised its option to redeem the notes, it will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption.
Other Borrowings
The Company periodically borrows under its commercial paper program and may continue to borrow under it in future periods. There were no commercial paper borrowings outstanding at February 28, 2015 or 2014. The Company had average daily short-term borrowings of $4 million of commercial paper outstanding at a weighted average interest rate of 0.02% for the six months ended February 28, 2015. For the six month period ended February 28, 2014, the Company had average daily short-term borrowings of $14 million of commercial paper outstanding at a weighted average interest rate of 0.23%.
On November 10, 2014, WBA and Walgreens entered into a term loan credit agreement (the "Term Loan Agreement") which provides the ability to borrow up to £1.45 billion on an unsecured basis. As of February 28, 2015, the Company has borrowed £1.45 billion ($2.2 billion at the February 28, 2015 spot rate of $1.54 to £1) under the Term Loan Agreement. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on the Company's credit ratings.
On November 10, 2014, WBA and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the "Revolving Credit Agreement"), replacing prior Walgreens agreements dated July 20, 2011 and July 23, 2012. The new unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit.  On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at WBA's option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on the Company's credit ratings. The Company's ability to access these facilities is subject to compliance with the terms and conditions of the credit facilities, including financial covenants. The covenants require the Company to maintain certain financial ratios related to the proportion of consolidated debt to total capitalization and priority debt, along with limitations on the sale of assets and purchases of investments. Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. The Company pays a facility fee to the financing banks to keep these lines of credit active. At February 28, 2015, there were no borrowings or letters of credit issued against the revolving credit facility.
On December 19, 2014, WBA and Walgreens entered into a Revolving Credit Agreement (the "364-Day Credit Agreement") with the lenders party thereto. The 364-Day Credit Agreement is a 364-day unsecured, multicurrency revolving facility. The aggregate commitment of all lenders under the 364-Day Credit Agreement is $750 million. At February 28, 2015, there were no borrowings against the 364-Day Credit Agreement.
Walgreens as co-obligor guarantees the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all obligations of Walgreens Boots Alliance under the Term Loan Agreement, the Revolving Credit Agreement, and the 364-Day Credit Agreement, which guarantee will remain in full force and effect until certain conditions are met.

Financial_Instruments

Financial Instruments	6 Months Ended
	Feb. 28, 2015
Financial Instruments [Abstract]
Financial Instruments	10. Financial Instruments
	The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks.  As a result of the Second Step Transaction, the Company acquired all the derivative instruments held by Alliance Boots at their acquisition date fair values.
	The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 28, 2015, excluding warrants which are presented separately in this footnote, were as follows (in millions):
			Notional(1)				Fair Value				Location in Consolidated
											Condensed Balance Sheets
	Derivatives designated as fair value hedges:
	Interest rate swaps		$	1,000			$	22			Other non-current assets
	Derivatives designated as cash flow hedges:
	Basis swap			71				6			Other current assets
	Derivatives not designated as hedges:
	Interest rate swaps			1,542				-			Other current assets
	Interest rate caps			3,879				-			Other current assets
	Foreign currency forwards			2,037				60			Other current assets
	Foreign currency forwards			104				7			Other current liabilities
		-1	Amounts in U.S. dollar equivalents, where appropriate.
	The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2014, excluding warrants which are presented separately in this footnote, are as follows (in millions):
			Notional				Fair Value				Location in Consolidated
											Condensed Balance Sheets
	Derivatives designated as fair value hedges:
	Interest rate swaps		$	1,000			$	16			Other non-current assets
	Derivatives designated as cash flow hedges:
	Forward interest rate swaps			1,500				44			Other non-current liabilities
	The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances and designates them as cash flow hedges.
	The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.
	Fair Value Hedges
	The Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six-month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges.
	The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):
			Location in Consolidated				Three Months Ended February 28,							Six Months Ended
			Condensed Statements of Earnings											February 28,
								2015				2014			2015			2014
	Interest rate swaps		Interest expense, net				$	4			$	(6	)	$	(6	)	$	(17	)
	Notes		Interest expense, net					(4	)			6			6			18
	The changes in fair value of the Company's debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Condensed Balance Sheets (see Note 9, Short-Term Borrowings and Long-Term Debt). At February 28, 2015 and August 31, 2014, the cumulative fair value adjustments resulted in an increase in long-term debt of $18 million and $12 million, respectively. No material gains or losses were recorded from ineffectiveness during the three and six month periods ended February 28, 2015 or during the three and six month periods ended February 28, 2014.
	Cash Flow Hedges
	In fiscal 2014, the Company entered into a series of forward starting interest rate swap transactions locking in the then current three-month LIBOR interest rate on $1.5 billion of the then anticipated issuance of debt, with expected maturity tenures of 10 and 30 years. The swap transactions were designated as cash flow hedges of the variability in the expected cash outflows of interest payments on the then forecasted debt due to changes in the benchmark interest rates. In November 2014, in conjunction with the issuance of the $2.0 billion notes maturing in fiscal 2024 and the $1.5 billion notes maturing in fiscal 2044, the Company terminated these forward starting interest rate swaps, locking in the effective yields on the related debt. Cash of $45 million was paid to settle the 10-year swap and cash of $18 million was paid to settle the 30-year swap in November 2014. The changes in fair value of the swaps until their termination were included in other comprehensive income, and any ineffectiveness was recorded directly to interest expense in the Consolidated Condensed Statements of Earnings. The cumulative changes included in other comprehensive income will be amortized into earnings in the same periods during which interest expense on the identified debt is recognized.
	As a result of the Second Step Transaction, the Company assumed $9.0 billion of Alliance Boots existing debt, a portion of which was hedged using interest rate swaps and interest rate caps. In January 2015, the Company repaid substantially all of the assumed debt and simultaneously terminated swaps converting £1.0 billion of outstanding debt from floating to fixed rates with no material gain or loss recognized. At February 28, 2015, £1.0 billion of floating to fixed rate swaps with no material fair value remain outstanding. The swaps mature in July 2015 and are not designated as hedging instruments. Interest rate caps with notional principal amounts of £1.5 billion and €2.0 billion to protect the Company from rising interest rates on the corresponding amounts of assumed Alliance Boots existing debt were in place on completion of the Second Step Transaction. In January 2015, interest rate caps with an aggregate notional principal of €600 million were terminated with no material gain or loss recognized. The remaining caps mature in July 2015, have no material fair value and are not designated as hedging instruments.
	There were no material gains and losses due to the change in fair value of derivatives designated as cash flow hedges recognized in other comprehensive income during the three and six month periods ended February 28, 2015 and 2014.
	In addition, the Company acquired a basis swap held by Alliance Boots which is designated as a hedge of future contracted interest payments on Unidades de Fomento ("UF") denominated bonds in Chile. The basis swap matures in May 2015.
	No portion of the derivatives designated as cash flow hedges was excluded from hedge assessment. No material gains or losses were recorded in earnings from ineffectiveness during the three and six month periods ended February 28, 2015 or during the three and six month periods ended February 28, 2014.
	Derivatives not Designated as Hedges
	The Company enters into derivative transactions that are not designated as accounting hedges.  These derivative instruments are economic hedges of interest rate and foreign currency risks. The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
		Location in Consolidated		Three Months				Six Months Ended February 28, 2015
		Condensed Statements of Earnings		Ended February 28, 2015
	Interest rate swaps	Interest expense, net		$	(1	)		$	(1	)
	Foreign currency forwards	Selling, general and administrative expense		$	(28	)		$	(28	)
	Second Step Transaction foreign currency forwards	Other income (expense)		$	(70	)		$	(166	)
	Warrants
	As discussed in Note 2, Basis of Presentation, the Company holds (a) a warrant to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016, and (b) a warrant to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017. The warrants issued to Alliance Boots were acquired by the Company as part of the Second Step Transaction.
	The Company reports its warrants at fair value. The fair value and balance sheet presentation of warrants was as follows (in millions):
		Location in Consolidated		February 28,				August 31,
		Condensed Balance Sheets		2015				2014
	Asset derivatives not designated as hedges:
	Warrants	Other non-current assets		$	2,231			$	553
	The gains and losses due to changes in fair value of the warrants recognized in earnings were as follows (in millions):
		Location in Consolidated		Three Months								Six Months Ended
		Condensed Statements of Earnings		Ended February 28,								February 28,
				2015				2014				2015			2014
	Warrants	Other income (expense)		$	559			$	(64	)		$	849		$	156
	Derivatives Credit Risk
	Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.
	Derivatives Offsetting
	The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Feb. 28, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	11. Fair Value Measurements
	The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:
	Level 1 -	Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2 -	Observable inputs other than quoted prices in active markets.
	Level 3 -	Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
			28-Feb-15		Level 1		Level 2		Level 3
	Assets:
	Restricted cash (1)		$	206	$	206	$	-	$	-
	Money market funds (2)			1,881		1,881		-		-
	Available-for-sale investments (3)			1,255		1,255		-		-
	Interest rate swaps (4)			22		-		22		-
	Basis swap			6		-		6		-
	Foreign currency forwards (5)			60		-		60		-
	Warrants (6)			2,231		-		2,231		-
	Liabilities:
	Foreign currency forwards (5)			7		-		7		-
			31-Aug-14		Level 1		Level 2		Level 3
	Assets:
	Money market funds (2)		$	1,879	$	1,879	$	-	$	-
	Available-for-sale investments (3)			887		887		-		-
	Interest rate swaps (4)			16		-		16		-
	Warrants (5)			553		-		553		-
	Liabilities:
	Forward interest rate swaps (7)			44		-		44		-
	-1	Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
	-2	Money market funds are valued at the closing price reported by the fund sponsor.
	-3	Fair values of quoted investments are based on current bid prices as of the balance sheet dates.  See Note 6, Available-for-Sale Investments for additional disclosures.
	-4	The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves.  See Note 10, Financial Instruments for additional disclosures.
	-5	The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
	-6	Warrants were valued using a Monte Carlo simulation.  Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.
	-7	Forward interest rate swaps were valued using three-month LIBOR rates. See Note 10, Financial Instruments for additional disclosures.
	There were no transfers between levels for the three and six months ended February 28, 2015 and February 28, 2014.
	The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company's debt in the footnotes to the consolidated financial statements.  Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Short-Term Borrowings and Long-Term Debt for further details. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Feb. 28, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies
	The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company's business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company's consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
	On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company's assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company's consolidated financial statements in a future fiscal period. Management's assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management's assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.
	On June 11, 2013, the Company entered into a Settlement and Memorandum of Agreement (the "Agreement") with the United States Department of Justice and the United States Drug Enforcement Administration ("DEA") that settled and resolved all administrative and civil matters arising out of DEA's previously-disclosed concerns relating to the Company's distribution and dispensing of controlled substances. Under the terms of the Agreement, the Company paid an $80 million settlement amount, surrendered its DEA registrations for six pharmacies in Florida until May 26, 2014, and for its Jupiter, Florida distribution center until September 13, 2014, and agreed to implement certain remedial actions. In addition, the Company dismissed with prejudice its petition with the United States Court of Appeals for the District of Columbia Circuit that challenged certain enforcement authority of the DEA. On July 31, 2013 and August 13, 2013, putative shareholders filed derivative actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors and Walgreen Co. as a nominal defendant (collectively, the "defendants"), arising out of the Company's June 2013 settlement with the DEA described above. The actions assert claims for breach of fiduciary duty on the grounds that the directors allegedly should have prevented the events that led to the settlement. The plaintiffs filed an amended consolidated complaint on October 4, 2013, pursuant to which they sought damages and other relief on behalf of the Company. The defendants filed their motion to dismiss on December 3, 2013.  Subsequent thereto, the plaintiffs filed an opposition brief on February 7, 2014 and the defendants filed their reply brief on March 10, 2014. In June 2014, the parties executed a settlement term sheet reflecting an agreement in principle to settle this matter, subject to, among other things, the execution of final settlement documentation and court approval. On September 11, 2014, the defendants, denying all wrongdoing and liability, entered into a Stipulation and Agreement of Settlement whereby the Company agreed to certain corporate governance measures and the payment of up to $3.5 million for plaintiffs' counsel fees and costs in exchange for a complete release of all claims against all defendants. The Court entered a final order approving the Stipulation and Agreement of Settlement on December 16, 2014. The settlement of this matter did not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.
	On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company's definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions assert claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement is subject to, among other things, court approval.
	On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. The defendants plan to file a motion to dismiss.

Stock_Compensation_Plans

Stock Compensation Plans	6 Months Ended
	Feb. 28, 2015
Stock Compensation Plans [Abstract]
Stock Compensation Plans	13. Stock Compensation Plans
	The Walgreen Co. Omnibus Incentive Plan (the "Omnibus Plan") which became effective in fiscal 2013, provides for incentive compensation to the Company's non-employee directors, officers and employees, and consolidates into a single plan several previously existing equity compensation plans. A total of 60.4 million shares became available for delivery under the Omnibus Plan.
	In connection with the Reorganization, the Omnibus Plan was assumed by the Company and each Walgreens stock option, restricted stock unit award, performance share award, deferred stock unit award, and common stock converted automatically into an award with respect to the number of shares of common stock of the Company on a one-for-one basis. The Company's awards continue to be subject to the same terms and conditions as those that were applicable to such award immediately prior to their conversion. The Company did not record any incremental compensation expense related to the conversion.
	The Company granted 15,458 and 4,117,968 stock options under the Omnibus Plan for the three and six month periods ended February 28, 2015, respectively, compared to 149,684 and 6,534,762 stock options granted under the Omnibus Plan in the same three and six month periods ended last year. Stock-based compensation expense, which includes stock option, restricted stock unit, and performance share grants, was $34 million for the three month and $65 million for the six month periods ended February 28, 2015, compared to $31 million and $52 million for the same periods last year. Compensation expense for any individual quarter may not be representative of compensation expense for the entire fiscal year. Stock options granted in the current fiscal year had a weighted-average grant-date fair value of $14.64 using weighted average volatility, dividend yield and expected option life assumptions of 25.51%, 1.79% and 6.68 years, respectively, using the Black Scholes option pricing model. In accordance with ASC Topic 718 Compensation – Stock Compensation, compensation expense is recognized on a straight-line basis over the employee's vesting period or to the employee's retirement eligible date, if earlier. The recognized retiree eligible income recorded in the three and six month periods ended February 28, 2015, was $3 million and $2 million respectively, compared to expense of $5 million and $8 million for the same periods in the prior year.
	The Company granted 227,220 and 1,132,171 restricted stock units under the Omnibus Plan for the three and six month periods ended February 28, 2015, respectively, compared to 30,122 and 641,009 restricted stock units granted under the Omnibus Plan in the same three and six month periods last year. Restricted stock units granted in the current fiscal year had a weighted average grant date stock price of $74.61. Dividends issued under the program, paid in the form of additional restricted stock units, totaled 16,886 units for the three months and 37,421 units for the six months ended February 28, 2015 versus 19,159 units and 40,457 units in the same periods last year. The Company also granted 3,688 and 484,011 performance shares under the Omnibus Plan for the three month and six month periods ended February 28, 2015 versus 5,807 and 702,939 performance shares in the same periods last year. Performance shares granted in the current fiscal year had a weighted average grant date stock price of $66.82. In accordance with ASC Topic 718, compensation expense is recognized on a straight line basis based on a three year cliff vesting schedule for restricted stock unit awards and on a straight line basis over a three year performance period, based on performance targets, for performance share awards. For the three and six month periods ended February 28, 2015, the Company recognized $28 million and $47 million, of expense related to these plans, respectively. In the same periods last year, the Company recognized $16 million and $26 million of expense, respectively.
	The intrinsic value for options exercised was $153 million for the three month and $226 million for the six month periods ended February 28, 2015, respectively. The total fair value of options vested were $1 million for the three month and $51 million for the six month periods ended February 28, 2015, respectively.
	Cash received from the exercise of options was $132 million for the three months and $226 million for the six months ended February 28, 2015, respectively. The related tax benefit realized was $58 million for the three months and $85 million for the six months ended February 28, 2015, respectively.

Retirement_Benefits

Retirement Benefits	6 Months Ended
	Feb. 28, 2015
Retirement Benefits [Abstract]
Retirement Benefits	14. Retirement Benefits
	The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. Pursuant to the Second Step Transaction, the Company assumed a number of retirement benefit plans in the UK and other countries. The Company valued the assumed pension assets and liabilities on the acquisition date and will use an August 31 measurement date for its pension plans.
	Defined Benefit Pension Plans (non-US plans)
	The principal defined benefit pension plan is the Boots Pension Plan covering certain employees in the United Kingdom (the "Boots Plan"). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010 with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. The Company also has two smaller defined benefit plans in the UK, both of which were closed to future accruals effective July 1, 2010. Other defined benefit pension plans include several smaller plans in Germany, France and Guernsey.
	The obligation related to the Company's pension plans was acquired as a result of the Second Step Transaction. The pension costs presented for 2015 represent the costs for the period from December 31, 2014 through February 28, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, pension costs were included for fiscal 2014 and fiscal 2015 prior to the date of the Second Step Transaction within Equity earnings in Alliance Boots.
	Components of net periodic pension cost for the defined benefit pension plans (in millions):
		Three and Six Months Ended February 28, 2015
		Boots Pension Plan			Other Pension Plans
	Service cost	$	-		$	1
	Interest cost		52			1
	Expected return on plan assets		(43	)		-
	Settlements		-			1
	Total net periodic pension cost	$	9		$	3
	The Company made cash contributions to its defined benefit pension plans of $85 million from the date of the Second Step Transaction to February 28, 2015 which primarily related to committed deficit funding payments triggered by the Second Step Transaction. The Company plans to contribute an additional $65 million to its defined benefit pension plans in fiscal 2015.
	Defined Contribution Plans
	The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company's contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Board of Directors. The profit-sharing provision was a benefit of $21 million for the three months and expense of $54 million for the six months ended February 28, 2015, respectively compared to expense of $85 million and $165 million in the same periods last year. The benefit in the current period was due to a change in the discretionary portion of the profit sharing calculation.
	The Company also assumed a contract based defined contribution arrangement known as the Alliance Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The cost recognized in the Consolidated Condensed Statements of Earnings from the date of the Second Step Transaction through February 28, 2015 was $22 million.
	Postretirement Healthcare Plan
	The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company's postretirement health benefit plan is not funded.
	Components of net periodic benefit cost for the postretirement health benefit plan (in millions):
		Postretirement Health Benefit Plan
		Three Months Ended February 28,						Six Months Ended February 28,
		2015			2014			2015			2014
	Service cost	$	2		$	2			5		$	4
	Interest cost		4			4			8			8
	Amortization of actuarial loss		5			3			10			6
	Amortization of prior service cost		(6	)		(6	)		(12	)		(11	)
	Total postretirement benefit cost	$	5		$	3			11		$	7

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Feb. 28, 2015
Earnings Per Share [Abstract]
Earnings Per Share	15. Earnings Per Share
	The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. Outstanding options to purchase common shares that were anti-dilutive and excluded from the second quarter earnings per share calculation totaled 3,437,516 and 6,347,469 at February 28, 2015 and 2014, respectively. Anti-dilutive shares excluded from the year to date earnings per share calculation were 4,957,390 and 4,343,079 in fiscal 2015 and 2014, respectively.

Depreciation_and_Amortization

Depreciation and Amortization	6 Months Ended
	Feb. 28, 2015
Depreciation and Amortization [Abstract]
Depreciation and Amortization	16. Depreciation and Amortization
	The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):
		Three Months Ended February 28,				Six Months Ended February 28,
		2015		2014		2015		2014
	Depreciation expense	$	311	$	258	$	567	$	520
	Intangible asset and other amortization		196		73		259		143
	Total depreciation and amortization expense	$	507	$	331	$	826	$	663
	As discussed in Note 7, Acquisitions, the Company completed the acquisition of remaining 55% interest in Alliance Boots on December 31, 2014, as a result of which the financial results of Alliance Boots were fully consolidated into the results of the Company. The Company previously accounted for its 45% interest in Alliance Boots as an equity method investment. The total depreciation and amortization expense of the Company for the three and six month periods ended February 28, 2015 include the depreciation and amortization expense relating to the preliminary acquisition date fair values of Alliance Boots assets effective as of the date of the Second Step Transaction including all $106 million of inventory step-up amortization.

Supplemental_Cash_Flow_Disclos

Supplemental Cash Flow Disclosures	6 Months Ended
	Feb. 28, 2015
Supplemental Cash Flow Disclosures [Abstract]
Supplemental Cash Flow Disclosures	17. Supplemental Cash Flow Disclosures
	As a result of the Second Step Transaction the Company had the following non-cash transactions in the six month period ended February 28, 2015: $9.0 billion for debt assumed; $11.0 billion for the Company’s common stock issued; $2.6 billion of consideration attributable to WBAD; $8.3 billion related to the fair value of the Company’s 45% investment in Alliance Boots; $25.8 billion in fair value of assets acquired; and $19.8 billion in fair value of liabilities and noncontrolling interests assumed. Significant non-cash transactions for the six month period ended February 28, 2014 included $282 million for additional capital lease obligations.
	Cash interest paid for the six month period ended February 28, 2015 was $90 million compared to $67 million in the same period in the prior year. Cash paid for income taxes was $553 million and $674 million in the six months ended February 28, 2015 and 2014, respectively.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	6 Months Ended
	Feb. 28, 2015
Accumulated Other Comprehensive Income (Loss) [Abstract]
Accumulated Other Comprehensive Income (Loss)	18. Accumulated Other Comprehensive Income (Loss)
	The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six month periods ended February 28, 2015 and 2014 (in millions):
		Post-			Unrecognized			Unrealized			Share of			Cumulative			Total
		retirement			Gains on			Loss on			Alliance			Translation
		Liability			Available-for-			Cash Flow			Boots			Adjustments
					Sale			Hedges			OCI
					Investments
	Balance at November 30, 2014	$	14		$	206		$	(39	)	$	(92	)	$	(35	)	$	54
	Other comprehensive income (loss) before reclassification adjustments		(8	)		140			2			(89	)		(358	)		(313	)
	Amounts reclassified from accumulated OCI		-			-			(1	)		230			80			309
	Tax benefit (provision)		-			(50	)		(1	)		(49	)		(18	)		(118	)
	Net other comprehensive income (loss)	$	(8	)	$	90		$	-		$	92		$	(296	)	$	(122	)
	Balance at February 28, 2015	$	6		$	296		$	(39	)	$	-		$	(331	)	$	(68	)
		Post-retirement			Unrecognized			Unrealized			Share of			Cumulative			Total
		Liability			Gains on			Loss on			Alliance			Translation
					Available-for-			Cash Flow Hedges			Boots			Adjustments
					Sale						OCI
					Investments
	Balance at August 31, 2014	$	15		$	107		$	(27	)	$	(113	)	$	154		$	136
	Other comprehensive income (loss) before reclassification adjustments		(10	)		297			(18	)		(57	)		(648	)		(436	)
	Amounts reclassified from accumulated OCI		-			-			(1	)		230			80			309
	Tax benefit (provision)		1			(108	)		7			(60	)		83			(77	)
	Net other comprehensive income (loss)	$	(9	)	$	189		$	(12	)	$	113		$	(485	)	$	(204	)
	Balance at February 28, 2015	$	6		$	296		$	(39	)	$	-		$	(331	)	$	(68	)
		Post-retirement			Unrecognized			Unrealized			Share of			Cumulative Translation Adjustments			Total
		Liability			Gains on			Loss on			Alliance
					Available-for-			Cash Flow Hedges			Boots
					Sale						OCI
					Investments
	Balance at November 30, 2013	$	71		$	85		$	-		$	(132	)	$	104		$	128
	Other comprehensive income (loss) before reclassification adjustments		(3	)		(27	)		-			(30	)		156			96
	Tax benefit (provision)		1			(22	)		-			11			(40	)		(50	)
	Net other comprehensive income (loss)	$	(2	)	$	(49	)	$	-		$	(19	)	$	116		$	46
	Balance at February 28, 2014	$	69		$	36		$	-		$	(151	)	$	220		$	174
		Post-retirement			Unrecognized			Unrealized			Share of			Cumulative			Total
		Liability			Gains on			Loss on			Alliance			Translation
					Available-for-			Cash Flow Hedges			Boots			Adjustments
					Sale						OCI
					Investments
	Balance at August 31, 2013	$	63		$	1		$	-		$	(95	)	$	(61	)	$	(92	)
	Other comprehensive income (loss) before reclassification adjustments		9			57			-			(86	)		407			387
	Tax benefit (provision)		(3	)		(22	)		-			30			(126	)		(121	)
	Net other comprehensive income (loss)	$	6		$	35		$	-		$	(56	)	$	281		$	266
	Balance at February 28, 2014	$	69		$	36		$	-		$	(151	)	$	220		$	174

Segment_Reporting

Segment Reporting	6 Months Ended
	Feb. 28, 2015
Segment Reporting [Abstract]
Segment Reporting	19. Segment Reporting
	Prior to December 31, 2014, the Company's operations were within one reportable segment. As a result of the closing of the Second Step Transaction on December 31, 2014, (see Note 1, Organization, and Note 2, Basis of Presentation), the Company has realigned its operations into three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The reportable segments have been identified based on the financial data utilized by the Company's Acting Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company's reportable segments. The chief operating decision maker uses operating income to assess segment profitability.
		·	The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics, in addition to providing specialty and infusion and respiratory pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.
		·	The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the UK, Mexico, Chile, Thailand, Norway, Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.
		·	The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses. Wholesale operations are located in France, UK, Germany, Turkey, Spain, Russia, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.
	The accounting policies of the segments are in accordance with Note 2, Basis of Presentation.
	The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The "Eliminations and Unallocated Items" column contains corporate-related items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources.
	The segment information for the three and six month periods ended February 28, 2015 reflects the operating results of the Company's new business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a "source of procurement benefit" basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit as compared to the combined company.
	The Company has determined that it is impracticable to restate segment information for the three and six month periods ended February 28, 2014 as well as to provide disclosures under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations historically have been recorded in the Retail Pharmacy USA segment and not restated as it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction have been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior periods as it is impracticable. Additionally, comparative information has not been restated to reflect the 45% equity interest in Alliance Boots.
	The following table reflects results of operations of the Company's reportable segments (in millions):
			Retail Pharmacy
			USA			International			Pharmaceutical			Eliminations			Consolidated
									Wholesale			and
												Unallocated
												Items
	Three Months Ended February 28, 2015
	Sales to external customers		$	21,048		$	2,017		$	3,508		$	-		$	26,573
	Intersegment sales			-			30			357			(387	)		-
	Total Sales			21,048			2,047			3,865			(387	)		26,573
	Cost of sales			15,302			1,294			3,478			(383	)		19,691
	Gross Profit			5,746			753			387			(4	)		6,882
	Selling, general and administrative expenses			4,555			745			306			-			5,606
	Equity earnings in Alliance Boots			101			-			-			-			101
	Operating Income		$	1,292		$	8		$	81		$	(4	)	$	1,377
	Three Months Ended February 28, 2014
	Sales to external customers		$	19,605		$	-		$	-		$	-		$	19,605
	Intersegment sales			-			-			-			-			-
	Total Sales			19,605			-			-			-			19,605
	Cost of sales			13,955			-			-			-			13,995
	Gross Profit			5,650			-			-			-			5,650
	Selling, general and administrative expenses			4,569			-			-			-			4,569
	Equity earnings in Alliance Boots			136			-			-			-			136
	Operating Income		$	1,217		$	-		$	-		$	-		$	1,217
			Retail Pharmacy
			USA			International			Pharmaceutical Wholesale			Eliminations			Consolidated
												and
												Unallocated
												Items
	Six Months Ended February 28, 2015
	Sales to external customers		$	40,602		$	2,017		$	3,508		$	-		$	46,127
	Intersegment sales			-			30			357			(387	)		-
	Total Sales			40,602			2,047			3,865			(387	)		46,127
	Cost of sales			29,560			1,294			3,478			(383	)		33,949
	Gross Profit			11,042			753			387			(4	)		12,178
	Selling, general and administrative expenses			9,011			745			306			-			10,062
	Equity earnings in Alliance Boots			315			-			-			-			315
	Operating Income		$	2,346		$	8		$	81		$	(4	)	$	2,431
	Six Months Ended February 28, 2014
	Sales to external customers		$	37,934		$	-		$	-		$	-		$	37,934
	Intersegment sales			-			-			-			-			-
	Total Sales			37,934			-			-			-			37,934
	Cost of sales			27,132			-			-			-			27,132
	Gross Profit			10,802			-			-			-			10,802
	Selling, general and administrative expenses			8,948			-			-			-			8,948
	Equity earnings in Alliance Boots			330			-			-			-			330
	Operating Income		$	2,184		$	-		$	-		$	-		$	2,184
	Total assets:
	28-Feb-15		$	77,466		$	22,131		$	13,706		$	(41,946	)	$	71,357
	31-Aug-14			44,275			-			-			(7,005	)		37,270
	The following table reconciles the operating income from each reportable segment to earnings before interest and income tax provision (in millions):
			For the Three Months Ended						For the Six Months Ended
			February 28,			February 28,			February 28,			February 28,
			2015			2014			2015			2014
	Operating income:
Retail Pharmacy USA		$	1,292		$	1,217		$	2,346		$	2,184
Retail Pharmacy International			8			-			8			-
Pharmaceutical Wholesale			81			-			81			-
Eliminations/Other			(4	)		-			(4	)		-
Gain on previously held equity interest			706			-			706			-
Other (expense) income			504			(59	)		703			166
Earnings Before Interest and Tax provision (EBIT)		$	2,587		$	1,158		$	3,840		$	2,350

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	6 Months Ended
	Feb. 28, 2015
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	20. Recent Accounting Pronouncements
	In November 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-17, Pushdown Accounting.  This ASU provides companies with the option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. The election to apply pushdown accounting can be made either in the period in which the change of control occurred, or in a subsequent period. This ASU is effective as of November 18, 2014. The adoption did not have a material impact on the Company's results of operations, cash flows or financial position.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, as a new Topic, ASC Topic 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is expected to be effective for annual periods beginning after December 15, 2017 (fiscal 2019) and shall be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company's results of operations, cash flows or financial position.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This ASU raises the threshold for a disposal to qualify as discontinued operations and requires new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. Under the new standard, companies report discontinued operations when they have a disposal that represents a strategic shift that has or will have a major impact on operations or financial results. This update will be applied prospectively and is effective for annual periods, and interim periods within those years, beginning after December 15, 2014 (fiscal 2016). Early adoption is permitted provided the disposal was not previously disclosed. This update will not have a material impact on the Company's reported results of operations and financial position. The impact is non-cash in nature and will not affect the Company's cash position.

Supplemental_Guarantor_Condens

Supplemental Guarantor Condensed Consolidating Financial Information	6 Months Ended
	Feb. 28, 2015
Supplemental Guarantor Condensed Consolidating Financial Information [Abstract]
Supplemental Guarantor Condensed Consolidating Financial Information	21. Supplemental Guarantor Condensed Consolidating Financial Information
	The notes listed below are unsecured, unsubordinated debt obligations of WBA ("Parent Company") and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of WBA from time to time outstanding. The notes are fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens, a 100% owned subsidiary ("Guarantor Subsidiary"). Additionally, on December 31, 2014, WBA fully and unconditionally guaranteed the outstanding notes issued by Walgreens on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of WBA and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of WBA.
	The Walgreens guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens from time to time outstanding. The purpose of the guarantee is to protect the notes against structural subordination to certain indebtedness of Walgreens. The Walgreens guarantee will automatically terminate, and the obligations of Walgreens under the Walgreens guarantee will be unconditionally released and discharged, if and when (i) the aggregate outstanding principal amount of Capital Markets Indebtedness (as defined), including the Existing Notes (as defined), and Commercial Bank Indebtedness (as defined), in each case, of Walgreens is less than $2.0 billion and (ii) Walgreens does not guarantee any Capital Markets Indebtedness (other than the notes or the Euro/Sterling Notes (as defined)) or Commercial Bank Indebtedness, in each case, of WBA. In addition, the Walgreens guarantee will automatically terminate, and the obligations of Walgreens under the Walgreens guarantee will be unconditionally released and discharged, with respect to any series of outstanding notes, upon (i) repayment of such series of outstanding notes in full, (ii) the satisfaction and discharge of the indenture with respect to such series of outstanding notes or (iii) the defeasance or covenant defeasance of such series of outstanding notes in accordance with the terms of the indenture. Once released in accordance with its terms, the Walgreens guarantee will not subsequently be required to be reinstated.
	Notes Issued			Maturity Date	Interest Rate
	(in millions)
	$	750		18-May-16	Variable; three-month U.S. dollar LIBOR, reset quarterly, plus 45 basis points
		750		17-Nov-17	Fixed 1.750%
		1,250		18-Nov-19	Fixed 2.700%
		1,250		18-Nov-21	Fixed 3.300%
		2,000		18-Nov-24	Fixed 3.800%
		500		18-Nov-34	Fixed 4.500%
		1,500		18-Nov-44	Fixed 4.800%
	$	8,000
	Notes Issued (in millions)			Maturity Date	Interest Rate
	Euro Notes:
	€	750		20-Nov-26	Fixed 2.125%
	Pound Sterling Notes:
	£	400		20-Nov-20	Fixed 2.875%
		300		20-Nov-25	Fixed 3.600%
	£	700
	The condensed consolidating financial information of the Guarantor Subsidiary is presented below.
	This condensed consolidating financial information presents intercompany investments using the equity method. Under this method, investments are recorded at cost and adjusted for the ownership share of a subsidiary's cumulative results of operations, capital contributions and distributions, and other equity changes. There are no significant restrictions on the ability of the Guarantor Subsidiary to make distributions to the Company. The condensed consolidating financial information of the Guarantor Subsidiary should be read in connection with the Company's consolidated financial statements and related notes of which this note is an integral part.
	STATEMENT OF EARNINGS
	(UNAUDITED)
	(In millions)
			Three Months Ended February 28, 2015
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Net sales		$	14,379		$	12,545		$	-		$	(351	)	$	26,573
	Cost of sales			9,949			10,033			-			(291	)		19,691
	Gross Profit			4,430			2,512			-			(60	)		6,882
	Selling, general and administrative expenses			4,596			1,117			(47	)		(60	)		5,606
	Equity earnings in Alliance Boots			-			101			-			-			101
	Operating Income (loss)			(166	)		1,496			47			-			1,377
	Gain on previously held equity interest			-			706			-			-			706
	Other income (expense)			(69	)		575			(2	)		-			504
	Earnings (loss) before Interest and Tax Provision			(235	)		2,777			45			-			2,587
	Interest expense, net			106			6			32			-			144
	Earnings (loss) Before Income Tax Provision			(341	)		2,771			13			-			2,443
	Income tax provision			(171	)		557			5			-			391
	Post tax earnings from equity method investments			-			8			-			-			8
	Equity in income of subsidiaries			2,222			-			2,052			(4,274	)		-
	Net Earnings (loss)			2,052			2,222			2,060			(4,274	)		2,060
	Net earnings attributable to noncontrolling interests			-			18			-			-			18
	Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	2,052		$	2,204		$	2,060		$	(4,274	)	$	2,042
	STATEMENT OF EARNINGS
	(UNAUDITED)
	(In millions)
			Three Months Ended February 28, 2014
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Net sales		$	13,364		$	6,363		$	-		$	(122	)	$	19,605
	Cost of sales			9,027			4,985			-			(57	)		13,955
	Gross Profit			4,337			1,378			-			(65	)		5,650
	Selling, general and administrative expenses			4,095			539			-			(65	)		4,569
	Equity earnings in Alliance Boots			-			136			-			-			136
	Operating Income			242			975			-			-			1,217
	Gain on previously held equity interest			-			-			-			-			-
	Other income (expense)			-			(59	)		-			-			(59	)
	Earnings Before Interest and Tax Provision			242			916			-			-			1,158
	Interest expense, net			45			(8	)		-			-			37
	Earnings Before Income Tax Provision			197			924			-			-			1,121
Income tax provision			69			322			-			-			391
Equity in income of subsidiaries			602			-			-			(602	)		-
Net Earnings (loss)			730			602			-			(602	)		730
Net earnings attributable to noncontrolling interests			-			14			-			-			14
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	730		$	588		$	-		$	(602	)	$	716
STATEMENT OF EARNINGS
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2015
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Net sales		$	27,702		$	19,168		$	-		$	(743	)	$	46,127
Cost of sales			19,160			15,416			-			(627	)		33,949
Gross Profit			8,542			3,752			-			(116	)		12,178
Selling, general and administrative expenses			8,608			1,617			(47	)		(116	)		10,062
Equity earnings in Alliance Boots			-			315			-			-			315
Operating Income (loss)			(66	)		2,450			47			-			2,431
Gain on previously held equity interest			-			706			-			-			706
Other income (expense)			(166	)		871			(2	)		-			703
Earnings (loss) Before Interest and Tax Provision			(232	)		4,027			45			-			3,840
Interest expense, net			153			-			46			-			199
Earnings (loss) Before Income Tax Provision			(385	)		4,027			(1	)		-			3,641
Income tax provision			(190	)		902			-			-			712
Post tax earnings from equity method investments			-			8			-			-			8
Equity in income of subsidiaries			3,133			-			2,938			(6,071	)		-
Net Earnings (loss)			2,938			3,133			2,937			(6,071	)		2,937
Net earnings attributable to noncontrolling interests			-			45			-			-			45
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	2,938		$	3,088		$	2,937		$	(6,071	)	$	2,892
STATEMENT OF EARNINGS
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2014
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Net sales		$	25,872		$	12,278		$	-		$	(216	)	$	37,934
Cost of sales			17,599			9,632			-			(99	)		27,132
Gross Profit			8,273			2,646			-			(117	)		10,802
Selling, general and administrative expenses			7,753			1,312			-			(117	)		8,948
Equity earnings in Alliance Boots			-			330			-			-			330
Operating Income (loss)			520			1,664			-			-			2,184
Gain on previously held equity interest			-			-			-			-			-
Other income (expense)			-			166			-			-			166
Earnings Before Interest and Tax Provision			520			1,830			-			-			2,350
Interest expense, net			90			(12	)		-			-			78
Earnings Before Income Tax Provision			430			1,842			-			-			2,272
Income tax provision			163			647			-			-			810
Equity in income of subsidiaries			1,195			-			-			(1,195	)		-
Net Earnings (loss)			1,462			1,195			-			(1,195	)		1,462
Net earnings attributable to noncontrolling interests			-			23			-			-			23
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	1,462		$	1,172		$	-		$	(1,195	)	$	1,439
STATEMENT OF COMPREHENSIVE INCOME
(UNAUDITED)
(In millions)
		Three Months Ended February 28, 2015
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Comprehensive Income
Net Earnings (loss)		$	2,052		$	2,222		$	2,060		$	(4,274	)	$	2,060
Other comprehensive income (loss), net of tax:
Postretirement liability			(1	)		(7	)		-			-			(8	)
Unrealized gain (loss) on cash flow hedges			-			(1	)		1			-			-
Changes in unrecognized gain (loss) on available-for-sale investments			-			90			-			-			90
Share of other comprehensive income (loss) of Alliance Boots			-			92			-			-			92
Currency translation adjustments			-			(301	)		-			-			(301	)
Other Comprehensive Income (loss) of subsidiaries			(127	)		-			(128	)		255			-
Total Other Comprehensive Income (loss)			(128	)		(127	)		(127	)		255			(127	)
Total Comprehensive Income (loss)			1,924			2,095			1,933			(4,019	)		1,933
Comprehensive income attributable to noncontrolling interests			-			13			-			-			13
Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	1,924		$	2,082		$	1,933		$	(4,019	)	$	1,920
STATEMENT OF COMPREHENSIVE INCOME
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2015
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Comprehensive Income
Net Earnings (loss)		$	2,938		$	3,133		$	2,937		$	(6,071	)	$	2,937
Other comprehensive income (loss), net of tax:
Postretirement liability			(2	)		(7	)		-			-			(9	)
Unrealized gain (loss) on cash flow hedges			27			(1	)		(38	)		-			(12	)
Changes in unrecognized gain (loss) on available-for-sale investments			-			189			-			-			189
Share of other comprehensive income (loss) of Alliance Boots			-			113			-			-			113
Currency translation adjustments			-			(490	)		-			-			(490	)
Other Comprehensive Income (loss) of subsidiaries			(196	)		-			(171	)		367			-
Total Other Comprehensive Income (Loss)			(171	)		(196	)		(209	)		367			(209	)
Total Comprehensive Income (loss)			2,767			2,937			2,728			(5,704	)		2,728
Comprehensive income attributable to noncontrolling interests			-			40			-			-			40
Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	2,767		$	2,897		$	2,728		$	(5,704	)	$	2,688
STATEMENT OF COMPREHENSIVE INCOME
(UNAUDITED)
(In millions)
		Three Months Ended February 28, 2014
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Comprehensive Income
Net Earnings (loss)		$	730		$	602		$	-		$	(602	)	$	730
Other comprehensive income (loss), net of tax:
Postretirement liability			(2	)		-			-			-			(2	)
Unrealized gain (loss) on cash flow hedges			-			-			-			-			-
Changes in unrecognized gain (loss) on available-for-sale investments			-			(49	)		-			-			(49	)
Share of other comprehensive income (loss) of Alliance Boots			-			(19	)		-			-			(19	)
Currency translation adjustments			-			116			-			-			116
Other Comprehensive Income (loss) of subsidiaries			48			-			-			(48	)		-
Total Other Comprehensive Income (loss)			46			48			-			(48	)		46
Total Comprehensive Income (loss)			776			650			-			(650	)		776
Comprehensive income attributable to noncontrolling interests			-			14			-			-			14
Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	776		$	636		$	-		$	(650	)	$	762
STATEMENT OF COMPREHENSIVE INCOME
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2014
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Comprehensive Income
Net Earnings (loss)		$	1,462		$	1,195		$	-		$	(1,195	)	$	1,462
Other comprehensive income (loss), net of tax:
Postretirement liability			6			-			-			-			6
Unrealized gain (loss) on cash flow hedges			-			-			-			-			-
Changes in unrecognized gain (loss) on available-for-sale investments			-			35			-			-			35
Share of other comprehensive income (loss) of Alliance Boots			-			(56	)		-			-			(56	)
Currency translation adjustments			-			281			-			-			281
Other Comprehensive Income (loss) of subsidiaries			260			-			-			(260	)		-
Total Other Comprehensive Income (loss)			266			260			-			(260	)		266
Total Comprehensive Income (loss)			1,728			1,455			-			(1,455	)		1,728
Comprehensive income attributable to noncontrolling interests			-			23			-			-			23
Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	1,728		$	1,432		$	-		$	(1,455	)	$	1,705
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
(In millions)
		28-Feb-15
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Assets
Current Assets:
Cash and cash equivalents		$	1,840		$	1,165		$	-		$	-		$	3,005
Accounts receivable, net			2,027			4,990			-			-			7,017
Inventories			4,396			4,983			-			-			9,379
Current intercompany loan receivable			12,930			26,428			20,720			(60,078	)		-
Other current assets			533			1,005			11			(235	)		1,314
Total Current Assets			21,726			38,571			20,731			(60,313	)		20,715
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization			6,500			9,146			-			-			15,646
Equity investment in Alliance Boots			-			-			-			-			-
Goodwill			8,382			8,662			-			-			17,044
Intangible assets			286			11,939			-			-			12,225
Other non-current assets			162			5,561			4			-			5,727
Non-current intercompany loan receivable			-			3,725			19,113			(22,838	)		-
Investment in subsidiaries			32,379			-			27,039			(59,418	)		-
Total Non-Current Assets			47,709			39,033			46,156			(82,256	)		50,642
Total Assets		$	69,435		$	77,604		$	66,887		$	(142,569	)	$	71,357
Liabilities & Equity
Current Liabilities:
Short-term borrowings		$	757		$	304		$	-		$	-		$	1,061
Trade accounts payable			4,355			5,938			-			-			10,293
Current intercompany loan payable			12,258			24,604			23,216			(60,078	)		-
Accrued expenses and other liabilities			2,508			2,153			479			-			5,140
Income taxes			-			225			206			(235	)		196
Total Current Liabilities			19,878			33,224			23,901			(60,313	)		16,690
Non-Current Liabilities:
Long-term debt			3,737			128			12,136			-			16,001
Deferred income taxes			283			3,406			-			-			3,689
Non-current intercompany loan payable			15,983			6,855			-			(22,838	)		-
Other non-current liabilities			2,515			1,400			36			-			3,951
Total Non-Current Liabilities			22,518			11,789			12,172			(22,838	)		23,641
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity			27,039			32,379			30,814			(59,418	)		30,814
Noncontrolling interests			-			212			-			-			212
Total Equity			27,039			32,591			30,814			(59,418	)		31,026
Total Liabilities & Equity		$	69,435		$	77,604		$	66,887		$	(142,569	)	$	71,357
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
(In millions)
		31-Aug-14
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Assets
Current Assets:
Cash and cash equivalents		$	2,224		$	422		$	-		$	-		$	2,646
Accounts receivable, net			1,860			1,358			-			-			3,218
Inventories			4,301			1,755			-			-			6,076
Current intercompany loan receivable			6,755			8,277			-			(15,032	)		-
Other current assets			176			141			-			(15	)		302
Total Current Assets			15,316			11,973			-			(15,047	)		12,242
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization			6,932			5,325			-			-			12,257
Equity investment in Alliance Boots			-			7,336			-			-			7,336
Goodwill			343			2,016			-			-			2,359
Intangible assets			417			763			-			-			1,180
Other non-current assets			252			1,644			-			-			1,896
Non-current intercompany loan receivable			-			3,560			-			(3,560	)		-
Investment in subsidiaries			23,250			-			-			(23,250	)		-
Total Non-Current Assets			31,194			20,644			-			(26,810	)		25,028
Total Assets		$	46,510		$	32,617		$	-		$	(41,857	)	$	37,270
Liabilities & Equity
Current Liabilities:
Short-term borrowings		$	766		$	8		$	-		$	-		$	774
Trade accounts payable			3,850			465			-			-			4,315
Current intercompany loan payable			8,277			6,755			-			(15,032	)		-
Accrued expenses and other liabilities			3,044			657			-			-			3,701
Income taxes			-			120			-			(15	)		105
Total Current Liabilities		$	15,937			8,005			-			(15,047	)		8,895
Non-Current Liabilities:
Long-term debt			3,726			10			-			-			3,736
Deferred income taxes			404			676			-			-			1,080
Non-current intercompany loan payable			3,560			-			-			(3,560	)		-
Other non-current liabilities			2,370			572			-			-			2,942
Total Non-Current Liabilities			10,060			1,258			-			(3,560	)		7,758
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity			20,513			23,250			-			(23,250	)		20,513
Noncontrolling interests			-			104			-			-			104
Total Equity			20,513			23,354			-			(23,250	)		20,617
Total Liabilities & Equity		$	46,510		$	32,617		$	-		$	(41,857	)	$	37,270
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2015
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Cash Flows from Operating Activities		$	1,011		$	1,254		$	72		$	-		$	2,337
Cash Flows from Investing Activities:
Additions to property, plant and equipment			(302	)		(341	)		-			-			(643	)
Proceeds from sale of assets			121			458			-			-			579
Return of restricted cash			-			74			-			-			74
Alliance Boots acquisition, net of cash received			-			-			(4,461	)		-			(4,461	)
Other business and intangible asset acquisitions, net of cash received			(27	)		(65	)		-			-			(92	)
Purchases of short-term investments held to maturity			-			(29	)		-			-			(29	)
Proceeds from short-term investments held to maturity			-			29			-			-			29
Investment in AmerisourceBergen			-			-			-			-			-
Other			(165	)		-			-			-			(165	)
Net cash used for investing activities			(373	)		126			(4,461	)		-			(4,708	)
Cash Flows from Financing Activities:
Payments of short-term borrowings			-			(324	)		(6	)		-			(330	)
Proceeds from issuance of long-term debt			-			-			12,279			-			12,279
Payments of long-term debt			-			(7,817	)		-			-			(7,817	)
Stock purchases			(500	)		-			(94	)		-			(594	)
Proceeds related to employee stock plans			154			-			139			-			293
Cash dividends paid			(642	)		-			-			-			(642	)
Intra-company financing activities, net			-36			7,817			(7,781	)		-			-
Other			2			(286	)		(76	)		-			(360	)
Net cash (used for) provided by financing activities			(1,022	)		(610	)		4,461			-			2,829
Effect of exchange rate changes on cash and cash equivalents			-			(27	)		(72	)		-			(99	)
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents			(384	)		743			-			-			359
Cash and cash equivalents at beginning of period			2,224			422			-			-			2,646
Cash and cash equivalents at end of period		$	1,840		$	1,165		$	-		$	-		$	3,005
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2014
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Cash Flows from Operating Activities		$	471		$	766		$	-		$	-		$	1,237
Cash Flows from Investing Activities:
Additions to property, plant and equipment			(342	)		(301	)		-			52			(591	)
Proceeds from sale of assets			201			60			-			(52	)		209
Proceeds from sale of business									-						-
Business and intangible asset acquisitions, net of cash received			(254	)		(43	)		-			-			(297	)
Purchases of short-term investments held to maturity			-			(34	)		-			-			(34	)
Proceeds from short-term investments held to maturity			-			34			-			-			34
Investment in AmerisourceBergen			-			(430	)		-			-			(430	)
Other			-			(59	)		-			-			(59	)
Net cash used for investing activities			(395	)		(773	)		-			-			(1,168	)
Cash Flows from Financing Activities:
Stock purchases			(205	)		-			-			-			(205	)
Proceeds related to employee stock plans			416			-			-			-			416
Cash dividends paid			(597	)		-			-			-			(597	)
Other			(12	)		-			-			-			(12	)
Net cash (used for) provided by financing activities			(398	)		-			-			-			(398	)
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents			(322	)		(7	)		-			-			(329	)
Cash and cash equivalents at beginning of period			1,771			335			-			-			2,106
Cash and cash equivalents at end of period		$	1,449		$	328		$	-		$	-		$	1,777

Subsequent_Events

Subsequent Events	6 Months Ended
	Feb. 28, 2015
Subsequent Events [Abstract]
Subsequent Events	22. Subsequent Events
	On January 20, 2015, Walgreen Co., announced that it had signed a definitive agreement with Madison Dearborn Partners ("MDP"), under which MDP would acquire a majority interest in Walgreens Infusion Services. The transaction closed on April 7, 2015. Walgreens Infusion Services became a new independent, privately-held company. MDP owns a majority interest in the new company. WBA owns a significant minority interest and has representatives on the company's board of directors. At February 28, 2015, the Company had approximately $300 million (primarily accounts receivable and inventory) classified as current assets held for sale, approximately $900 million (primarily goodwill and intangible assets) classified as long-term assets available for sale and approximately $100 million classified as current liabilities held for sale all related to Walgreens Infusion Services operations.
	On April 8, 2015, the Company's Board of Directors approved a plan to implement a new restructuring program (the "restructuring program") as part of an initiative to reduce costs and increase operating efficiencies. The restructuring program implements and builds on the planned three-year, $1.0 billion cost-reduction initiative previously announced by Walgreen Co. on August 6, 2014 and includes a number of elements designed to help the Company to achieve profitable growth through increased cost efficiencies. The Company has identified additional opportunities for cost savings that increase the total expected cost savings of the restructuring program by $500 million to a projected $1.5 billion by the end of fiscal 2017. Significant areas of focus include plans to close approximately 200 stores across the USA; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the restructuring program focus primarily on the Company's Retail Pharmacy USA division, and are expected to be substantially completed by the end of fiscal 2017.
	The Company currently estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of between $1.6 billion and $1.8 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. The Company expects to incur pre-tax charges of between $525 million and $600 million for real estate costs, including lease obligations (net of estimated sublease income), between $650 million and $725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs, and between $425 million and $475 million for employee severance and other business transition and exit costs. The Company estimates that approximately 60% of the cumulative pre-tax charges will result in future cash expenditures, primarily related to lease and other real estate payments and employee separation costs.
	As the program is implemented, the restructuring charges will be recognized as the costs are incurred over time in accordance with GAAP.
	The amounts and timing of all estimates are subject to change until finalized. The actual amounts and timing may vary materially based on various factors.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Feb. 28, 2015
Basis of Presentation [Abstract]
Consolidation	Consolidation
	The consolidated condensed financial statements include all majority-owned subsidiaries. Investments in less than majority-owned companies in which the Company does not have a controlling interest but does have significant influence are accounted for as equity method investments. All intercompany transactions have been eliminated.
Restricted Cash	Restricted Cash
	The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. As of February 28, 2015, the amount of such restricted cash was $206 million. There was no restricted cash as of August 31, 2014.
Accounts Receivable	Accounts Receivable
	Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily include amounts due from third party providers (e.g., pharmacy benefit managers, insurance companies and governmental agencies), clients and members, as well as vendors and manufacturers. Charges to bad debt are based on both historical write-offs and specifically identified receivables.
Inventory	Inventory
	The Company values inventories on a lower of cost or market basis. Inventory includes product costs, inbound freight, direct labor, warehousing costs, overhead costs relating to the manufacture and distribution of products and vendor allowances not classified as a reduction of advertising expense.
	The Company's Retail Pharmacy USA segment inventory is accounted for using the last-in-first-out ("LIFO") method. At February 28, 2015 and August 31, 2014, Retail Pharmacy USA segment inventories would have been greater by $2.4 billion and $2.3 billion, respectively, if they had been valued on a lower of first-in-first-out ("FIFO") cost or market basis. LIFO inventory costs can only be determined annually when inflation rates and inventory levels are finalized; therefore, LIFO inventory costs for interim financial statements are estimated.
	The Company's Retail Pharmacy International and Pharmaceutical Wholesale segments costs are determined using the FIFO method, except for retail inventory in the Retail Pharmacy International segment. The Company's Retail Pharmacy International segment's retail inventory is primarily determined using the retail inventory method. Under the retail inventory method, cost is determined by applying a calculated cost-to-retail ratio across groupings of similar items. The cost-to-retail ratio is applied to ending inventory at its current owned retail valuation to determine the cost of ending inventory across groupings of similar items. Current owned retail valuation represents the retail price for which merchandise is offered for sale on a regular basis reduced for any permanent or clearance markdowns. Inherent in the retail method calculation are certain management judgments and estimates including initial mark-up, markdowns and shrinkage, which can impact the owned retail valuation and, therefore, the ending inventory valuation at cost.
Vendor Allowances and Supplier Rebates	Vendor Allowances and Supplier Rebates
	Vendor allowances are principally received as a result of purchases, sales or promotion of vendors' products. Allowances are generally recorded as a reduction of inventory and are recognized as a reduction of cost of sales when the related merchandise is sold. Those allowances received for promoting vendors' products are offset against advertising expense and result in a reduction of selling, general and administrative expenses to the extent of advertising costs incurred, with the excess treated as a reduction of inventory costs.
	Rebates or refunds received by the Company from its suppliers, mostly in cash, are considered as an adjustment of the prices of the supplier's products purchased by the Company.
Revenue Recognition	Revenue Recognition
	Revenue is recognized when: (a) persuasive evidence of an arrangement exists, (b) delivery has occurred or services have been rendered, (c) the seller's price to the buyer is fixed or determinable, and (d) collectability is reasonably assured. The following revenue recognition policies have been established for the Company's reportable segments:
	Retail Pharmacy USA and Retail Pharmacy International
	The Company recognizes revenue at the time the customer takes possession of the merchandise, after making appropriate adjustments for estimated returns, which are immaterial. Revenue does not include sales related taxes. In certain international locations, the Company initially estimates revenue based on expected reimbursements from governmental agencies for dispensing prescription drugs and providing optical services. The estimates are based on historical experience and updated to actual reimbursement amounts.
	Pharmaceutical Wholesale
	Wholesale revenue is recognized upon shipment of goods, which is generally also the day of delivery. When the Company acts in the capacity of an agent or a logistics service provider, revenue is the fee received for the service and is recognized when the services have been performed. The Company has determined it is the agent when providing logistics services, which is based on its assessment of the following criteria: (a) whether it is the primary obligor in the arrangement, (b) whether it has latitude in establishing the price, changing the product or performing part of the service, (c) whether it has discretion in supplier selection, (d) whether it is involved in the determination of service specifications, and (e) whether it is exposed to credit risk.
Financial Instruments	Financial Instruments
	The Company uses derivative instruments to hedge its exposure to interest rate and currency risks arising from operating and financing activities. In accordance with its risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes.
	Derivatives are recognized on the Consolidated Condensed Balance Sheets at their fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, it formally documents the hedge relationship and the risk management objective for undertaking the hedge which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The accounting for changes in fair value of a derivative instrument depends on whether the Company had designated it in a qualifying hedging relationship and further, on the type of hedging relationship. The Company applies the following accounting policies:
		·	Changes in the fair value of a derivative designated as a fair value hedge, along with the gain or loss on the hedged asset or liability attributable to the hedged risk, are recorded in the Consolidated Condensed Statements of Earnings.
		·	The effective portion of changes in the fair value of a derivative designated as a cash flow hedge is recorded in accumulated other comprehensive income (loss) in the Consolidated Condensed Statements of Comprehensive Income and reclassified into earnings in the period or periods during which the hedged item affects earnings.
		·	The effective portion of changes in the fair value of a derivative designated as a hedge of a net investment in a foreign operation is recorded in cumulative translation adjustments within accumulated other comprehensive income (loss) in the Consolidated Condensed Statements of Comprehensive Income. Recognition in earnings of amounts previously recorded in cumulative translation adjustments is limited to circumstances such as complete or substantially complete liquidation of the net investment in the hedged investments in foreign operations.
		·	Changes in the fair value of a derivative not designated in a hedging relationship are recognized in the Consolidated Condensed Statements of Earnings along with the ineffective portions of changes in the fair value of derivatives designated in hedging relationships.
	Cash receipts or payments on a settlement of derivative contract are reported in the Consolidated Condensed Statements of Cash Flows consistent with the nature of the underlying hedged item.
	For derivative instruments designated as hedges, the Company assesses, both at the hedge's inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. Highly effective means that cumulative changes in the fair value of the derivative are between 80% and 125% of the cumulative changes in the fair value of the hedged item. In addition, when the Company determines that a derivative is not highly effective as a hedge, hedge accounting is discontinued. When it is probable that a hedged forecasted transaction will not occur, the Company discontinues hedge accounting for the affected portion of the forecasted transaction, and reclassifies any gains or losses in accumulated other comprehensive income (loss) to earnings in the Consolidated Condensed Statements of Earnings. When a derivative in a hedge relationship is terminated or the hedged item is sold, extinguished or terminated, hedge accounting is discontinued prospectively.
Pension and Postretirement Benefits	Pension and Postretirement Benefits
	The Company has various defined benefit pension plans that cover some of its foreign employees. The Company also has postretirement healthcare plans that cover qualifying domestic employees. Eligibility and the level of benefits for these plans varies depending participants' status, date of hire and or length of service. Pension and postretirement expenses and valuations are dependent on assumptions used by third party actuaries in calculating those amounts. These assumptions include discount rates, healthcare cost trends, long-term return on plan assets, retirement rates, mortality rates and other factors.
	The Company funds its pension plans in accordance with applicable regulations. Postretirement plans are not funded.
Income Taxes	Income Taxes
	In determining the provision for income taxes, the Company uses an annual effective income tax rate based on full-year forecast income, permanent differences between book and tax income, the relative proportion of foreign and domestic income, statutory income tax rates, projections of income subject to Subpart F rules and unrecognized tax benefits related to current year results. Discrete events such as the assessment of the ultimate outcome of tax audits, audit settlements, recognizing previously unrecognized tax benefits due to lapsing of the applicable statute of limitations, recognizing or de-recognizing benefits of deferred tax assets due to future year financial statement projections and changes in tax laws are recognized in the period in which they occur.
	The Company is subject to routine income tax audits that occur periodically in the normal course of business. U.S. federal, state, local and foreign tax authorities raise questions regarding the Company's tax filing positions, including the timing and amount of deductions and the allocation of income among various tax jurisdictions. In evaluating the tax benefits associated with the various tax filing positions, the Company records a tax benefit for uncertain tax positions using the highest cumulative tax benefit that is more likely than not to be realized. Adjustments are made to the liability for unrecognized tax benefits in the period in which the Company determines the issue is effectively settled with the tax authorities, the statute of limitations expires for the return containing the tax position or when more information becomes available. As of February 28, 2015, approximately $115 million of unrecognized tax benefits were reported as current liabilities, with the balance being classified as long-term liabilities on the Consolidated Condensed Balance Sheets. Based on current knowledge, it is reasonably possible the amount of unrecognized tax benefits will decrease in the next 12 months by up to $115 million, primarily due to expected tax audit settlements in multiple tax jurisdictions. The Company does not expect the settlements to materially impact the Consolidated Condensed Statements of Earnings, the Consolidated Condensed Balance Sheets or the Company's liquidity.
Business Combinations	Business Combinations
	Business combinations are accounted for under ASC Topic 805, Business Combinations, using the acquisition method of accounting. The cost of an acquired company is assigned to the tangible and intangible assets purchased and the liabilities assumed on the basis of their fair values at the date of acquisition. The determination of fair values of assets and liabilities acquired requires estimates and the use of valuation techniques when a market value is not readily available. Any excess of purchase price over the fair value of net tangible and intangible assets acquired is allocated to goodwill. The final determination of the fair value of certain assets and liabilities is completed within the one year measurement period as allowed under ASC Topic 805, Business Combinations. Transaction costs associated with business combinations are expensed as they are incurred.
Noncontrolling Interests	Noncontrolling Interests
	The Company accounts for its less than 100% interest in consolidated subsidiaries in accordance with ASC Topic 810, Consolidation, and accordingly, the Company presents noncontrolling interests as a component of equity on its Consolidated Condensed Balance Sheets and reports the noncontrolling interest net earnings or loss as Net earnings attributable to noncontrolling interests in the Consolidated Condensed Statements of Earnings.
Currency	Currency
	Assets and liabilities of non-U.S. dollar functional currency operations are translated into U.S. dollars at end-of-period exchange rates while revenues, expenses and cash flows are translated at average monthly exchange rates over the period. Equity is translated at historical exchange rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss) in the Consolidated Condensed Balance Sheets.
	For U.S. dollar functional currency operations, foreign currency assets and liabilities are remeasured into U.S. dollars at end-of-period exchange rates, except for nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Revenues and expenses are remeasured at average monthly exchange rates over the period, except for those expenses related to nonmonetary balance sheet amounts, which are remeasured from historical exchange rates. Gains or losses from foreign currency remeasurement and transactions are included in selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. For all periods presented, there were no material operational gains or losses from foreign currency transactions.
Warrants	Warrants
	Walgreens, Alliance Boots and AmerisourceBergen Corporation ("AmerisourceBergen") entered into a Framework Agreement dated as of March 18, 2013, pursuant to which (1) Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in AmerisourceBergen, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of AmerisourceBergen common stock (approximately 7 percent of the then fully diluted equity of AmerisourceBergen, assuming the exercise in full of the warrants described below) in open market transactions; (2) Walgreens and Alliance Boots collectively were issued (a) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share exercisable during a six-month period beginning in March 2016, and (b) warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share exercisable during a six-month period beginning in March 2017. The parties and affiliated entities also entered into certain related agreements governing relations between and among the parties thereto, including the Shareholders Agreement, the Transaction Rights Agreement and the Limited Liability Company Agreement of WAB Holdings LLC, a limited liability company formed for the purpose of acquiring and holding AmerisourceBergen common stock, each of which (including the Framework Agreement) is summarized in, and copies of which were filed as exhibits to, Walgreens Current Report on Form 8-K filed with the SEC on March 20, 2013.
	Pursuant to the Reorganization and Second Step Transaction discussed in Note 1, Organization, and Note 2, Basis of Presentation, Walgreens and Alliance Boots became wholly owned subsidiaries of WBA effective December 31, 2014. The Company holds all AmerisourceBergen warrants issued to Walgreens and Alliance Boots in its consolidated subsidiaries.
	The warrants are valued at the date of issuance and the end of the period using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen's employee stock options and the exercise price; and the details specific to the warrants. The Company reports its warrants at fair value within other non-current assets in the Consolidated Condensed Balance Sheets. A deferred credit from the day-one valuation attributable to the warrants granted to Walgreens is being amortized over the life of the warrants. Gains and losses due to changes in the fair value on warrants are recognized in other income (expense) in the Consolidated Condensed Statement of Earnings. See Note 10, Financial Instruments, for additional disclosure regarding the Company's warrants.

Change_in_Accounting_Policy_Ta

Change in Accounting Policy (Tables)	6 Months Ended
	Feb. 28, 2015
Change in Accounting Policy [Abstract]
Schedule of Adjustments in Three-Month Reporting Lag for the Equity Investment	The elimination of the three-month reporting lag for the equity investment in Alliance Boots resulted in the adjustments as of and for the periods indicated below (in millions, except per share amounts). The impact of the change in accounting policy on the current period financial statements is not material.
		Three Months Ended February 28, 2014									Six Months Ended February 28, 2014
		As			Adjustments			After			As Reported			Adjustments			After
		Reported						Change in									Change in
								Accounting									Accounting
								Principle									Principle
	Consolidated Condensed Statements of Earnings
	Equity earnings in Alliance Boots	$	194		$	(58	)	$	136		$	345		$	(15	)	$	330
	Operating Income		1,275			(58	)		1,217			2,199			(15	)		2,184
	Earnings Before Income Tax Provision		1,179			(58	)		1,121			2,287			(15	)		2,272
	Income tax provision		411			(20	)		391			815			(5	)		810
	Net Earnings		768			(38	)		730			1,472			(10	)		1,462
	Net Earnings Attributable to Walgreens Boots Alliance, Inc.		754			(38	)		716			1,449			(10	)		1,439
	Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – basic		0.79			(0.04	)		0.75			1.52			(0.01	)		1.51
	Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted		0.78			(0.04	)		0.74			1.51			(0.02	)		1.49
	Consolidated Condensed Statements of Comprehensive  Income
	Net Earnings		768			(38	)		730			1,472			(10	)		1,462
	Share of other comprehensive loss of Alliance Boots		(36	)		17			(19	)		(70	)		14			(56	)
	Cumulative translation adjustments		191			(75	)		116			253			28			281
	Total Other Comprehensive Income		104			(58	)		46			224			42			266
	Total Comprehensive Income		872			(96	)		776			1,696			32			1,728
	Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.	$	858		$	(96	)	$	762		$	1,673		$	32		$	1,705
		As of August 31, 2014
		As Reported			Adjustments			After
								Change in
								Accounting
								Principle
	Consolidated Condensed Balance Sheet
	Non-Current Assets:
	Equity investment in Alliance Boots	$	7,248		$	88		$	7,336
	Total Non-Current Assets		24,940			88			25,028
	Total Assets		37,182			88			37,270
	Non-Current Liabilities:
	Deferred income taxes		1,048			32			1,080
	Total Non-Current Liabilities		7,726			32			7,758
	Equity:
	Retained earnings		22,229			98			22,327
	Accumulated other comprehensive income		178			(42	)		136
	Total Walgreens Boots Alliance, Inc. Shareholders' Equity		20,457			56			20,513
	Total Equity		20,561			56			20,617
	Total Liabilities and Equity	$	37,182		$	88		$	37,270
		Six Months Ended February 28, 2014
		As Reported			Adjustments			After
								Change in
								Accounting
								Principle
	Consolidated Condensed Statement of Cash Flows
	Cash Flows from Operating Activities:
	Net earnings	$	1,472		$	(10	)	$	1,462
	Deferred income taxes		34			(5	)		29
	Equity earnings in Alliance Boots		(345	)		15			(330	)

Leases_and_Store_Closures_Tabl

Leases and Store Closures (Tables)	6 Months Ended
	Feb. 28, 2015
Leases and Store Closures [Abstract]
Schedule of Future Minimum Lease Payments for Capital Lease and Operating Lease	Annual minimum rental commitments under all leases having an initial or remaining non-cancelable term of more than one year are shown below (in millions):
		Financing			Capital			Operating
		Obligation			Lease			Lease
	2015	$	19		$	68		$	3,071
	2016		18			66			3,006
	2017		18			62			2,886
	2018		18			59			2,814
	2019		18			59			2,561
	Later		1,153			901			23,102
	Total Minimum Lease Payments	$	1,244		$	1,215		$	37,440
Reserve for Facility Closings and Related Lease Termination Charges	The changes in reserve for facility closings and related lease termination charges include the following (in millions):
		February 28,			August 31,
		2015			2014
	Balance – beginning of period	$	257		$	123
	Provision for present value of non-cancellable lease payments on closed facilities		11			171
	Assumptions about future sublease income, terminations and changes in interest rates		2			(8	)
	Interest accretion		13			14
	Liability assumed through acquisition of Alliance Boots		13			-
	Cash payments, net of sublease income		(36	)		(43	)
	Balance – end of period	$	260		$	257
Schedule of Rental Expense	Rental expense, which includes common area maintenance, insurance and taxes, was as follows (in millions):
		Three Months Ended						Six Months Ended
		February 28,						February 28,
		2015			2014			2015			2014
	Minimum rentals	$	809		$	673		$	1,486		$	1,333
	Contingent rentals		1			1			3			4
	Less: Sublease rental income		(6	)		(7	)		(11	)		(12	)
		$	804		$	667		$	1,478		$	1,325

Equity_Method_Investments_Tabl

Equity Method Investments (Tables)	6 Months Ended
	Feb. 28, 2015
Equity Method Investments [Abstract]
Equity method investments	Equity method investments as of February 28, 2015 and August 31, 2014 were as follows (in millions, except percentages):
		28-Feb-15					31-Aug-14
		Carrying		Ownership			Carrying		Ownership
		Value		Percentage			Value		Percentage
	Alliance Boots	$	N/A		100	%	$	7,336		45	%
	Other		762		12% - 50	%		74		30% - 50	%
	Total	$	762				$	7,410
	N/A        Not applicable
Summarized financial information of equity method investees	Summarized financial information for the Company's equity method investees is as follows:
	Balance Sheet (in millions)
		February 28, 2015(1)		August 31, 2014(1)
	Current assets	$	4,674	$	9,074
	Noncurrent assets		625		22,363
	Current liabilities		4,067		9,372
	Noncurrent liabilities		253		10,608
	Shareholders' equity (2)		979		11,457
	Income Statement (in millions)
		Three Months Ended					Six Months Ended
		February 28,					February 28,
		2015(3)		2014(3)			2015(3)		2014(3)
	Net sales	$	5,317	$	9,688		$	14,978	$	19,100
	Gross Profit		979		2,083			3,168		4,055
	Net Income		246		324			743		771
	Share of income from equity method investments(3)		109		136			323		330
	(1) Net assets in foreign equity method investments are translated at their respective February 28, 2015 and August 31, 2014 spot rates.
	(2) Shareholders' equity at February 28, 2015 and August 31, 2014 includes $151 million and $283 million respectively, related to noncontrolling interests.
	(3) Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method upon completion of the Second Step Transaction on December 31, 2014. Earnings for the three and six month periods ended February 28, 2015 reflect incremental acquisition-related amortization expense of $4 million ($3 million net of tax) and $14 million ($8 million net of tax), respectively.  Incremental acquisition-related amortization expense for the three and six month periods ended February 28, 2014 were $10 million ($8 million net of tax) and $20 million ($16 million net of tax), respectively. Earnings in foreign equity method investments are translated at their respective average exchange rates.

AvailableforSale_Investments_T

Available-for-Sale Investments (Tables)	6 Months Ended
	Feb. 28, 2015
Available-for-Sale Investments [Abstract]
Summary of cost and fair value of available-for-sale securities	A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):
		28-Feb-15
		Cost		Unrealized gains		Foreign Exchange losses			Unrealized losses		Fair value
	AmerisourceBergen common stock	$	717	$	461	$	-		$	-	$	1,178
	Other investments		75		6		(4	)		-		77
	Total available-for-sale investments	$	792	$	467	$	(4	)	$	-	$	1,255
		31-Aug-14
		Cost		Unrealized gains		Foreign Exchange losses			Unrealized losses		Fair value
	AmerisourceBergen common stock	$	717	$	170	$	-		$	-	$	887
	Total available-for-sale investments	$	717	$	170	$	-		$	-	$	887

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Feb. 28, 2015
Acquisitions [Abstract]
Schedule of impact of equity transaction	The preliminary impact of the equity transaction is as follows (in millions):
		Amount
	Consideration attributable to WBAD	$	2,569
	Less:  Carrying value of the Company's pre-existing noncontrolling interest		130
	Impact to additional paid in capital	$	2,439
Schedule of business acquisition total consideration paid	The following table summarizes the consideration paid to acquire the remaining 55% interest in Alliance Boots and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the Second Step Transaction (in millions).
	Consideration paid
	Cash	$	4,874
	Common stock		10,977
	Total consideration transferred		15,851
	Less: consideration attributed to WBAD		(2,569	)
			13,282
	Fair value of the investment in Alliance Boots held before the Second Step Transaction		8,290
	Total consideration	$	21,572
Schedule of identifiable assets acquired and liabilities assumed including noncontrolling interests	Identifiable assets acquired and liabilities assumed including noncontrolling interests
	Cash and cash equivalents	$	413
	Accounts receivable		3,805
	Inventories		3,713
	Other current assets		902
	Property, plant and equipment		3,774
	Intangible assets		11,461
	Other non-current assets		1,760
	Trade accounts payable, accrued expenses and other liabilities		(7,722	)
	Borrowings		(8,999	)
	Deferred income taxes		(2,437	)
	Other non-current liabilities		(456	)
	Noncontrolling interests		(198	)
	Total identifiable net assets and noncontrolling interests		6,016
	Goodwill	$	15,556
Schedule of preliminary identified definite and indefinite lived intangible assets	The preliminary identified definite and indefinite lived intangible assets were as follows:
	Definite-Lived Intangible Assets	Weighted-Average			Amount
		Useful Life			(in millions)
		(in years)
	Customer relationships		12		$	1,676
	Loyalty card holders		12			723
	Trade names and trademarks		15			544
	Favorable lease interests		3			55
	Total				$	2,998
	Indefinite-Lived Intangible Assets	Amount
		(in millions)
	Trade names and trademarks	$	6,192
	Pharmacy licenses		2,271
	Total	$	8,463
Schedule of Unaudited pro forma results prepared for comparative purposes	Accordingly, the unaudited condensed pro forma results have been prepared for comparative purposes only and are not intended to be indicative of what the Company's results would have been had the Second Step Transaction occurred at the beginning of the periods presented or the results which may occur in the future.
		Pro forma					Pro forma
		Three months ended					Six months ended
		February 28,					February 28,
		2015			2014		2015		2014
	(in millions, except per share amounts)
	Net sales	$	30,202		$	29,276	$	59,173	$	56,999
	Net earnings		1,253			966		2,621		1,973
	Net earnings per common share:
	Basic	$	1.2		$	0.88	$	2.51	$	1.8
	Diluted		1.19			0.87		2.49		1.78
Schedule of actual results from business operation	Actual results from Alliance Boots operations included in the Consolidated Condensed Statements of Earnings since December 31, 2014, the date of the Second Step Transaction, are as follows (in millions, except per share amounts):
		Three months ended			Six months ended
		February 28,			February 28,
		2015			2015
	(in millions, except per share amounts)
	Net sales	$	5,525		$	5,525
	Net earnings		330			330
	Net earnings per common share:
	Basic	$	0.32		$	0.33
	Diluted		0.31			0.33

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Feb. 28, 2015
Goodwill and Other Intangible Assets [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):
			Retail Pharmacy			Retail Pharmacy			Pharmaceutical			Total
			USA			International			Wholesale
	31-Aug-14		$	2,359		$	-		$	-		$	2,359
	Acquisitions			8,311			3,747			3,521			15,579
	Sale of business(1)			(706	)		-			-			(706	)
	Other(2)			(3	)		-			-			(3	)
	Currency translation adjustments			-			(99	)		(86	)		(185	)
	28-Feb-15		$	9,961		$	3,648		$	3,435		$	17,044
	-1	Represents Walgreens Infusion and Respiratory Services goodwill that has been reclassified as an asset held for sale. See Note 22, Subsequent Events for further details.
	-2	Other primarily represents immaterial purchase accounting adjustments for the Company's acquisitions.
Schedule of Finite-Lived Intangible Assets by Major Class	The carrying amount and accumulated amortization of intangible assets consist of the following (in millions):
			28-Feb-15			31-Aug-14
	Gross Amortizable Intangible Assets
	Purchased prescription files		$	925		$	1,079
	Favorable lease interests			427			382
	Purchasing and payer contracts			95			301
	Non-compete agreements			154			151
	Trade names and trademarks			735			191
	Customer relationships			1,724			-
	Loyalty card holders			716			-
	Other amortizable intangible assets			4			4
	Total gross amortizable intangible assets			4,780			2,108
	Accumulated amortization
	Purchased prescription files			471			474
	Favorable lease interests			187			174
	Purchasing and payer contracts			61			145
	Non-compete agreements			82			70
	Trade names and trademarks			84			69
	Customer relationships			46			-
	Loyalty card holders			10			-
	Other amortizable intangible assets			1			4
	Total accumulated amortization			942			936
	Total amortizable intangible assets, net		$	3,838		$	1,172
	Indefinite Lived Intangible Assets
	Trade names and trademarks		$	6,136		$	8
	Pharmacy licenses			2,251			-
	Total indefinite lived intangible assets		$	8,387		$	8
	Total intangible assets, net		$	12,225		$	1,180
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated annual amortization expense for intangible assets recorded at February 28, 2015 is as follows (in millions):
			2015			2016			2017			2018			2019
	Estimated annual amortization expense:		$	426		$	465		$	424		$	388		$	366

ShortTerm_Borrowings_and_LongT1

Short-Term Borrowings and Long-Term Debt (Tables)	6 Months Ended
	Feb. 28, 2015
Short-Term Borrowings and Long-Term Debt [Abstract]
Short-Term Borrowings	Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars. Debt issuances are denominated in U.S. dollars, unless otherwise noted):
			February 28,				August 31,
			2015				2014
	Short-Term Borrowings(1)
	Current portion of loans assumed through the purchase of land and buildings; various interest rates from 5.000% to 8.750%; various maturities from 2015 to 2035		$	2			$	8
	1.000% unsecured notes due 2015			750				750
	Other(2)			309				16
	Total short-term borrowings		$	1,061			$	774
	-1	All notes are presented net of unamortized discount, where applicable.
	-2	Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including $29 million of U.S. dollar equivalent bank overdrafts.
	-3	Also includes interest rate swap fair market value adjustments, see Note 11, Fair Value Measurements for additional fair value disclosures.
	-4	Pound Sterling denominated notes are translated at the February 28, 2015 spot rate of $1.54 to one British Pound Sterling.
	-5	Euro denominated notes are translated at the February 28, 2015 spot rate of $1.12 to one Euro.
	-6	Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
Long-Term Debt	Long-Term Debt(1)
	Unsecured variable rate notes due 2016		$	750			$	-
	Unsecured Pound Sterling variable rate term loan due 2019			2,235				-
	1.800% unsecured notes due 2017			999				999
	1.750% unsecured notes due 2017			749				-
	5.250% unsecured notes due 2019(3)			1,016				1,010
	2.700% unsecured notes due 2019			1,248				-
	2.875% unsecured Pound Sterling notes due 2020(4)			615				-
	3.300% unsecured notes due 2021			1,247				-
	3.100% unsecured notes due 2022			1,199				1,199
	3.800% unsecured notes due 2024			1,995				-
	3.600% unsecured Pound Sterling notes due 2025(4)			462				-
	2.125% unsecured Euro notes due 2026(5)			837				-
	4.500% unsecured notes due 2034			497				-
	4.400% unsecured notes due 2042			496				496
	4.800% unsecured notes due 2044			1,500				-
	Loans assumed through the purchase of land and buildings; various interest rates from 5.000% to 8.750%; various maturities from 2015 to 2035			41				40
	Other(6)			117				-
				16,003				3,744
	Less: current maturities			2				8
	Total long-term debt		$	16,001			$	3,736
	-1	All notes are presented net of unamortized discount, where applicable.
	-2	Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including $29 million of U.S. dollar equivalent bank overdrafts.
	-3	Also includes interest rate swap fair market value adjustments, see Note 11, Fair Value Measurements for additional fair value disclosures.
	-4	Pound Sterling denominated notes are translated at the February 28, 2015 spot rate of $1.54 to one British Pound Sterling.
	-5	Euro denominated notes are translated at the February 28, 2015 spot rate of $1.12 to one Euro.
	-6	Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
Total $8.0 billion debt issuance [Member]
Debt Instrument [Line Items]
Details of each tranche of notes issued	The following table summarizes each tranche of notes issued:
	Notes Issued
	(in millions)			Maturity Date	Interest Rate	Interest Payment Dates
	$	750		18-May-16	Variable; three-month U.S. dollar LIBOR, reset quarterly, plus 45 basis points	February 18, May 18, August 18, and November 18; commencing on February 18, 2015
		750		17-Nov-17	Fixed 1.750%	May 17 and November 17; commencing on May 17, 2015
		1,250		18-Nov-19	Fixed 2.700%	May 18 and November 18; commencing on May 18, 2015
		1,250		18-Nov-21	Fixed 3.300%	May 18 and November 18; commencing on May 18, 2015
		2,000		18-Nov-24	Fixed 3.800%	May 18 and November 18; commencing on May 18, 2015
		500		18-Nov-34	Fixed 4.500%	May 18 and November 18; commencing on May 18, 2015
		1,500		18-Nov-44	Fixed 4.800%	May 18 and November 18; commencing on May 18, 2015
	$	8,000
Euro and Pound Sterling Notes [Member]
Debt Instrument [Line Items]
Details of each tranche of notes issued	The following table details each tranche of Euro and Pound Sterling notes issued:
	Notes Issued (in millions)				Maturity Date	Interest Rate
	Euro Notes:
		€	750		20-Nov-26	Fixed 2.125%
	Pound Sterling Notes:
		£	400		20-Nov-20	Fixed 2.875%
			300		20-Nov-25	Fixed 3.600%
		£	700
Total $4.0 billion debt issuance [Member]
Debt Instrument [Line Items]
Details of each tranche of notes issued	The following table details each tranche of outstanding notes as of February 28, 2015:
	Notes Issued			Maturity Date	Interest Rate	Interest Payment Dates
	(in millions)
	$	750		13-Mar-15	Fixed 1.000%	March 13 and September 13; commencing on March 13, 2013
		1,000		15-Sep-17	Fixed 1.800%	March 15 and September 15; commencing on March 15, 2013
		1,200		15-Sep-22	Fixed 3.100%	March 15 and September 15; commencing on March 15, 2013
		500		15-Sep-42	Fixed 4.400%	March 15 and September 15; commencing on March 15, 2013
	$	3,450

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Feb. 28, 2015
Financial Instruments [Abstract]
Notional Amounts of Derivative Instruments Outstanding	The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of February 28, 2015, excluding warrants which are presented separately in this footnote, were as follows (in millions):
			Notional(1)				Fair Value				Location in Consolidated
											Condensed Balance Sheets
	Derivatives designated as fair value hedges:
	Interest rate swaps		$	1,000			$	22			Other non-current assets
	Derivatives designated as cash flow hedges:
	Basis swap			71				6			Other current assets
	Derivatives not designated as hedges:
	Interest rate swaps			1,542				-			Other current assets
	Interest rate caps			3,879				-			Other current assets
	Foreign currency forwards			2,037				60			Other current assets
	Foreign currency forwards			104				7			Other current liabilities
		-1	Amounts in U.S. dollar equivalents, where appropriate.
	The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2014, excluding warrants which are presented separately in this footnote, are as follows (in millions):
			Notional				Fair Value				Location in Consolidated
											Condensed Balance Sheets
	Derivatives designated as fair value hedges:
	Interest rate swaps		$	1,000			$	16			Other non-current assets
	Derivatives designated as cash flow hedges:
	Forward interest rate swaps			1,500				44			Other non-current liabilities
Schedule of Derivative Assets at Fair Value	The Company reports its warrants at fair value. The fair value and balance sheet presentation of warrants was as follows (in millions):
		Location in Consolidated		February 28,				August 31,
		Condensed Balance Sheets		2015				2014
	Asset derivatives not designated as hedges:
	Warrants	Other non-current assets		$	2,231			$	553
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gains and Losses due to Changes in Fair Value Recognized in Earnings	The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):
			Location in Consolidated				Three Months Ended February 28,							Six Months Ended
			Condensed Statements of Earnings											February 28,
								2015				2014			2015			2014
	Interest rate swaps		Interest expense, net				$	4			$	(6	)	$	(6	)	$	(17	)
	Notes		Interest expense, net					(4	)			6			6			18
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gains and Losses due to Changes in Fair Value Recognized in Earnings	The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):
		Location in Consolidated		Three Months				Six Months Ended February 28, 2015
		Condensed Statements of Earnings		Ended February 28, 2015
	Interest rate swaps	Interest expense, net		$	(1	)		$	(1	)
	Foreign currency forwards	Selling, general and administrative expense		$	(28	)		$	(28	)
	Second Step Transaction foreign currency forwards	Other income (expense)		$	(70	)		$	(166	)
Warrant [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Gains and Losses due to Changes in Fair Value Recognized in Earnings	The gains and losses due to changes in fair value of the warrants recognized in earnings were as follows (in millions):
		Location in Consolidated		Three Months								Six Months Ended
		Condensed Statements of Earnings		Ended February 28,								February 28,
				2015				2014				2015			2014
	Warrants	Other income (expense)		$	559			$	(64	)		$	849		$	156

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Feb. 28, 2015
Fair Value Measurements [Abstract]
Assets measured at fair value on a recurring basis	Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):
			28-Feb-15		Level 1		Level 2		Level 3
	Assets:
	Restricted cash (1)		$	206	$	206	$	-	$	-
	Money market funds (2)			1,881		1,881		-		-
	Available-for-sale investments (3)			1,255		1,255		-		-
	Interest rate swaps (4)			22		-		22		-
	Basis swap			6		-		6		-
	Foreign currency forwards (5)			60		-		60		-
	Warrants (6)			2,231		-		2,231		-
	Liabilities:
	Foreign currency forwards (5)			7		-		7		-
			31-Aug-14		Level 1		Level 2		Level 3
	Assets:
	Money market funds (2)		$	1,879	$	1,879	$	-	$	-
	Available-for-sale investments (3)			887		887		-		-
	Interest rate swaps (4)			16		-		16		-
	Warrants (5)			553		-		553		-
	Liabilities:
	Forward interest rate swaps (7)			44		-		44		-
	-1	Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
	-2	Money market funds are valued at the closing price reported by the fund sponsor.
	-3	Fair values of quoted investments are based on current bid prices as of the balance sheet dates.  See Note 6, Available-for-Sale Investments for additional disclosures.
	-4	The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves.  See Note 10, Financial Instruments for additional disclosures.
	-5	The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
	-6	Warrants were valued using a Monte Carlo simulation.  Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.
	-7	Forward interest rate swaps were valued using three-month LIBOR rates. See Note 10, Financial Instruments for additional disclosures.

Retirement_Benefits_Tables

Retirement Benefits (Tables)	6 Months Ended
	Feb. 28, 2015
Boots Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Components of net periodic benefit cost	Components of net periodic pension cost for the defined benefit pension plans (in millions):
		Three and Six Months Ended February 28, 2015
		Boots Pension Plan			Other Pension Plans
	Service cost	$	-		$	1
	Interest cost		52			1
	Expected return on plan assets		(43	)		-
	Settlements		-			1
	Total net periodic pension cost	$	9		$	3
Defined Benefit Postretirement Health Benefit Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Components of net periodic benefit cost	Components of net periodic benefit cost for the postretirement health benefit plan (in millions):
		Postretirement Health Benefit Plan
		Three Months Ended February 28,						Six Months Ended February 28,
		2015			2014			2015			2014
	Service cost	$	2		$	2			5		$	4
	Interest cost		4			4			8			8
	Amortization of actuarial loss		5			3			10			6
	Amortization of prior service cost		(6	)		(6	)		(12	)		(11	)
	Total postretirement benefit cost	$	5		$	3			11		$	7

Depreciation_and_Amortization_

Depreciation and Amortization (Tables)	6 Months Ended
	Feb. 28, 2015
Depreciation and Amortization [Abstract]
Depreciation and Amortization by Major Category	The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):
		Three Months Ended February 28,				Six Months Ended February 28,
		2015		2014		2015		2014
	Depreciation expense	$	311	$	258	$	567	$	520
	Intangible asset and other amortization		196		73		259		143
	Total depreciation and amortization expense	$	507	$	331	$	826	$	663

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	6 Months Ended
	Feb. 28, 2015
Accumulated Other Comprehensive Income (Loss) [Abstract]
Components of Accumulated Other Comprehensive Income (Loss)	The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and six month periods ended February 28, 2015 and 2014 (in millions):
		Post-			Unrecognized			Unrealized			Share of			Cumulative			Total
		retirement			Gains on			Loss on			Alliance			Translation
		Liability			Available-for-			Cash Flow			Boots			Adjustments
					Sale			Hedges			OCI
					Investments
	Balance at November 30, 2014	$	14		$	206		$	(39	)	$	(92	)	$	(35	)	$	54
	Other comprehensive income (loss) before reclassification adjustments		(8	)		140			2			(89	)		(358	)		(313	)
	Amounts reclassified from accumulated OCI		-			-			(1	)		230			80			309
	Tax benefit (provision)		-			(50	)		(1	)		(49	)		(18	)		(118	)
	Net other comprehensive income (loss)	$	(8	)	$	90		$	-		$	92		$	(296	)	$	(122	)
	Balance at February 28, 2015	$	6		$	296		$	(39	)	$	-		$	(331	)	$	(68	)
		Post-retirement			Unrecognized			Unrealized			Share of			Cumulative			Total
		Liability			Gains on			Loss on			Alliance			Translation
					Available-for-			Cash Flow Hedges			Boots			Adjustments
					Sale						OCI
					Investments
	Balance at August 31, 2014	$	15		$	107		$	(27	)	$	(113	)	$	154		$	136
	Other comprehensive income (loss) before reclassification adjustments		(10	)		297			(18	)		(57	)		(648	)		(436	)
	Amounts reclassified from accumulated OCI		-			-			(1	)		230			80			309
	Tax benefit (provision)		1			(108	)		7			(60	)		83			(77	)
	Net other comprehensive income (loss)	$	(9	)	$	189		$	(12	)	$	113		$	(485	)	$	(204	)
	Balance at February 28, 2015	$	6		$	296		$	(39	)	$	-		$	(331	)	$	(68	)
		Post-retirement			Unrecognized			Unrealized			Share of			Cumulative Translation Adjustments			Total
		Liability			Gains on			Loss on			Alliance
					Available-for-			Cash Flow Hedges			Boots
					Sale						OCI
					Investments
	Balance at November 30, 2013	$	71		$	85		$	-		$	(132	)	$	104		$	128
	Other comprehensive income (loss) before reclassification adjustments		(3	)		(27	)		-			(30	)		156			96
	Tax benefit (provision)		1			(22	)		-			11			(40	)		(50	)
	Net other comprehensive income (loss)	$	(2	)	$	(49	)	$	-		$	(19	)	$	116		$	46
	Balance at February 28, 2014	$	69		$	36		$	-		$	(151	)	$	220		$	174
		Post-retirement			Unrecognized			Unrealized			Share of			Cumulative			Total
		Liability			Gains on			Loss on			Alliance			Translation
					Available-for-			Cash Flow Hedges			Boots			Adjustments
					Sale						OCI
					Investments
	Balance at August 31, 2013	$	63		$	1		$	-		$	(95	)	$	(61	)	$	(92	)
	Other comprehensive income (loss) before reclassification adjustments		9			57			-			(86	)		407			387
	Tax benefit (provision)		(3	)		(22	)		-			30			(126	)		(121	)
	Net other comprehensive income (loss)	$	6		$	35		$	-		$	(56	)	$	281		$	266
	Balance at February 28, 2014	$	69		$	36		$	-		$	(151	)	$	220		$	174

Segment_Reporting_Tables

Segment Reporting (Tables)	6 Months Ended
	Feb. 28, 2015
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table reflects results of operations of the Company's reportable segments (in millions):
		Retail Pharmacy
		USA			International			Pharmaceutical			Eliminations			Consolidated
								Wholesale			and
											Unallocated
											Items
	Three Months Ended February 28, 2015
	Sales to external customers	$	21,048		$	2,017		$	3,508		$	-		$	26,573
	Intersegment sales		-			30			357			(387	)		-
	Total Sales		21,048			2,047			3,865			(387	)		26,573
	Cost of sales		15,302			1,294			3,478			(383	)		19,691
	Gross Profit		5,746			753			387			(4	)		6,882
	Selling, general and administrative expenses		4,555			745			306			-			5,606
	Equity earnings in Alliance Boots		101			-			-			-			101
	Operating Income	$	1,292		$	8		$	81		$	(4	)	$	1,377
	Three Months Ended February 28, 2014
	Sales to external customers	$	19,605		$	-		$	-		$	-		$	19,605
	Intersegment sales		-			-			-			-			-
	Total Sales		19,605			-			-			-			19,605
	Cost of sales		13,955			-			-			-			13,995
	Gross Profit		5,650			-			-			-			5,650
	Selling, general and administrative expenses		4,569			-			-			-			4,569
	Equity earnings in Alliance Boots		136			-			-			-			136
	Operating Income	$	1,217		$	-		$	-		$	-		$	1,217
		Retail Pharmacy
		USA			International			Pharmaceutical Wholesale			Eliminations			Consolidated
											and
											Unallocated
											Items
	Six Months Ended February 28, 2015
	Sales to external customers	$	40,602		$	2,017		$	3,508		$	-		$	46,127
	Intersegment sales		-			30			357			(387	)		-
	Total Sales		40,602			2,047			3,865			(387	)		46,127
	Cost of sales		29,560			1,294			3,478			(383	)		33,949
	Gross Profit		11,042			753			387			(4	)		12,178
	Selling, general and administrative expenses		9,011			745			306			-			10,062
	Equity earnings in Alliance Boots		315			-			-			-			315
	Operating Income	$	2,346		$	8		$	81		$	(4	)	$	2,431
	Six Months Ended February 28, 2014
	Sales to external customers	$	37,934		$	-		$	-		$	-		$	37,934
	Intersegment sales		-			-			-			-			-
	Total Sales		37,934			-			-			-			37,934
	Cost of sales		27,132			-			-			-			27,132
	Gross Profit		10,802			-			-			-			10,802
	Selling, general and administrative expenses		8,948			-			-			-			8,948
	Equity earnings in Alliance Boots		330			-			-			-			330
	Operating Income	$	2,184		$	-		$	-		$	-		$	2,184
	Total assets:
	28-Feb-15	$	77,466		$	22,131		$	13,706		$	(41,946	)	$	71,357
	31-Aug-14		44,275			-			-			(7,005	)		37,270
Schedule of Earnings Before Interest and Income Tax Provision	The following table reconciles the operating income from each reportable segment to earnings before interest and income tax provision (in millions):
		For the Three Months Ended						For the Six Months Ended
		February 28,			February 28,			February 28,			February 28,
		2015			2014			2015			2014
	Operating income:
	Retail Pharmacy USA	$	1,292		$	1,217		$	2,346		$	2,184
	Retail Pharmacy International		8			-			8			-
	Pharmaceutical Wholesale		81			-			81			-
	Eliminations/Other		(4	)		-			(4	)		-
	Gain on previously held equity interest		706			-			706			-
	Other (expense) income		504			(59	)		703			166
	Earnings Before Interest and Tax provision (EBIT)	$	2,587		$	1,158		$	3,840		$	2,350

Supplemental_Guarantor_Condens1

Supplemental Guarantor Condensed Consolidating Financial Information (Tables)	6 Months Ended
	Feb. 28, 2015
Supplemental Guarantor Condensed Consolidating Financial Information [Abstract]
Long-Term Debt	Once released in accordance with its terms, the Walgreens guarantee will not subsequently be required to be reinstated.
	Notes Issued			Maturity Date	Interest Rate
	(in millions)
	$	750		18-May-16	Variable; three-month U.S. dollar LIBOR, reset quarterly, plus 45 basis points
		750		17-Nov-17	Fixed 1.750%
		1,250		18-Nov-19	Fixed 2.700%
		1,250		18-Nov-21	Fixed 3.300%
		2,000		18-Nov-24	Fixed 3.800%
		500		18-Nov-34	Fixed 4.500%
		1,500		18-Nov-44	Fixed 4.800%
	$	8,000
	Notes Issued (in millions)			Maturity Date	Interest Rate
	Euro Notes:
	€	750		20-Nov-26	Fixed 2.125%
	Pound Sterling Notes:
	£	400		20-Nov-20	Fixed 2.875%
		300		20-Nov-25	Fixed 3.600%
	£	700
Statement of Earnings	STATEMENT OF EARNINGS
	(UNAUDITED)
	(In millions)
			Three Months Ended February 28, 2015
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Net sales		$	14,379		$	12,545		$	-		$	(351	)	$	26,573
	Cost of sales			9,949			10,033			-			(291	)		19,691
	Gross Profit			4,430			2,512			-			(60	)		6,882
	Selling, general and administrative expenses			4,596			1,117			(47	)		(60	)		5,606
	Equity earnings in Alliance Boots			-			101			-			-			101
	Operating Income (loss)			(166	)		1,496			47			-			1,377
	Gain on previously held equity interest			-			706			-			-			706
	Other income (expense)			(69	)		575			(2	)		-			504
	Earnings (loss) before Interest and Tax Provision			(235	)		2,777			45			-			2,587
	Interest expense, net			106			6			32			-			144
	Earnings (loss) Before Income Tax Provision			(341	)		2,771			13			-			2,443
	Income tax provision			(171	)		557			5			-			391
	Post tax earnings from equity method investments			-			8			-			-			8
	Equity in income of subsidiaries			2,222			-			2,052			(4,274	)		-
	Net Earnings (loss)			2,052			2,222			2,060			(4,274	)		2,060
	Net earnings attributable to noncontrolling interests			-			18			-			-			18
	Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	2,052		$	2,204		$	2,060		$	(4,274	)	$	2,042
	STATEMENT OF EARNINGS
	(UNAUDITED)
	(In millions)
			Three Months Ended February 28, 2014
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Net sales		$	13,364		$	6,363		$	-		$	(122	)	$	19,605
	Cost of sales			9,027			4,985			-			(57	)		13,955
	Gross Profit			4,337			1,378			-			(65	)		5,650
	Selling, general and administrative expenses			4,095			539			-			(65	)		4,569
	Equity earnings in Alliance Boots			-			136			-			-			136
	Operating Income			242			975			-			-			1,217
	Gain on previously held equity interest			-			-			-			-			-
	Other income (expense)			-			(59	)		-			-			(59	)
	Earnings Before Interest and Tax Provision			242			916			-			-			1,158
	Interest expense, net			45			(8	)		-			-			37
	Earnings Before Income Tax Provision			197			924			-			-			1,121
	Income tax provision			69			322			-			-			391
	Equity in income of subsidiaries			602			-			-			(602	)		-
	Net Earnings (loss)			730			602			-			(602	)		730
	Net earnings attributable to noncontrolling interests			-			14			-			-			14
	Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	730		$	588		$	-		$	(602	)	$	716
	STATEMENT OF EARNINGS
	(UNAUDITED)
	(In millions)
			Six Months Ended February 28, 2015
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Net sales		$	27,702		$	19,168		$	-		$	(743	)	$	46,127
	Cost of sales			19,160			15,416			-			(627	)		33,949
	Gross Profit			8,542			3,752			-			(116	)		12,178
	Selling, general and administrative expenses			8,608			1,617			(47	)		(116	)		10,062
	Equity earnings in Alliance Boots			-			315			-			-			315
	Operating Income (loss)			(66	)		2,450			47			-			2,431
	Gain on previously held equity interest			-			706			-			-			706
	Other income (expense)			(166	)		871			(2	)		-			703
	Earnings (loss) Before Interest and Tax Provision			(232	)		4,027			45			-			3,840
	Interest expense, net			153			-			46			-			199
Earnings (loss) Before Income Tax Provision			(385	)		4,027			(1	)		-			3,641
Income tax provision			(190	)		902			-			-			712
Post tax earnings from equity method investments			-			8			-			-			8
Equity in income of subsidiaries			3,133			-			2,938			(6,071	)		-
Net Earnings (loss)			2,938			3,133			2,937			(6,071	)		2,937
Net earnings attributable to noncontrolling interests			-			45			-			-			45
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	2,938		$	3,088		$	2,937		$	(6,071	)	$	2,892
STATEMENT OF EARNINGS
(UNAUDITED)
(In millions)
		Six Months Ended February 28, 2014
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Net sales		$	25,872		$	12,278		$	-		$	(216	)	$	37,934
Cost of sales			17,599			9,632			-			(99	)		27,132
Gross Profit			8,273			2,646			-			(117	)		10,802
Selling, general and administrative expenses			7,753			1,312			-			(117	)		8,948
Equity earnings in Alliance Boots			-			330			-			-			330
Operating Income (loss)			520			1,664			-			-			2,184
Gain on previously held equity interest			-			-			-			-			-
Other income (expense)			-			166			-			-			166
Earnings Before Interest and Tax Provision			520			1,830			-			-			2,350
Interest expense, net			90			(12	)		-			-			78
Earnings Before Income Tax Provision			430			1,842			-			-			2,272
Income tax provision			163			647			-			-			810
Equity in income of subsidiaries			1,195			-			-			(1,195	)		-
Net Earnings (loss)			1,462			1,195			-			(1,195	)		1,462
Net earnings attributable to noncontrolling interests			-			23			-			-			23
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		$	1,462		$	1,172		$	-		$	(1,195	)	$	1,439
Statement of Comprehensive Income	STATEMENT OF COMPREHENSIVE INCOME
	(UNAUDITED)
	(In millions)
			Three Months Ended February 28, 2015
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Comprehensive Income
	Net Earnings (loss)		$	2,052		$	2,222		$	2,060		$	(4,274	)	$	2,060
	Other comprehensive income (loss), net of tax:
	Postretirement liability			(1	)		(7	)		-			-			(8	)
	Unrealized gain (loss) on cash flow hedges			-			(1	)		1			-			-
	Changes in unrecognized gain (loss) on available-for-sale investments			-			90			-			-			90
	Share of other comprehensive income (loss) of Alliance Boots			-			92			-			-			92
	Currency translation adjustments			-			(301	)		-			-			(301	)
	Other Comprehensive Income (loss) of subsidiaries			(127	)		-			(128	)		255			-
	Total Other Comprehensive Income (loss)			(128	)		(127	)		(127	)		255			(127	)
	Total Comprehensive Income (loss)			1,924			2,095			1,933			(4,019	)		1,933
	Comprehensive income attributable to noncontrolling interests			-			13			-			-			13
	Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	1,924		$	2,082		$	1,933		$	(4,019	)	$	1,920
	STATEMENT OF COMPREHENSIVE INCOME
	(UNAUDITED)
	(In millions)
			Six Months Ended February 28, 2015
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Comprehensive Income
	Net Earnings (loss)		$	2,938		$	3,133		$	2,937		$	(6,071	)	$	2,937
	Other comprehensive income (loss), net of tax:
	Postretirement liability			(2	)		(7	)		-			-			(9	)
	Unrealized gain (loss) on cash flow hedges			27			(1	)		(38	)		-			(12	)
	Changes in unrecognized gain (loss) on available-for-sale investments			-			189			-			-			189
	Share of other comprehensive income (loss) of Alliance Boots			-			113			-			-			113
	Currency translation adjustments			-			(490	)		-			-			(490	)
	Other Comprehensive Income (loss) of subsidiaries			(196	)		-			(171	)		367			-
	Total Other Comprehensive Income (Loss)			(171	)		(196	)		(209	)		367			(209	)
	Total Comprehensive Income (loss)			2,767			2,937			2,728			(5,704	)		2,728
	Comprehensive income attributable to noncontrolling interests			-			40			-			-			40
	Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	2,767		$	2,897		$	2,728		$	(5,704	)	$	2,688
	STATEMENT OF COMPREHENSIVE INCOME
	(UNAUDITED)
	(In millions)
			Three Months Ended February 28, 2014
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Comprehensive Income
	Net Earnings (loss)		$	730		$	602		$	-		$	(602	)	$	730
	Other comprehensive income (loss), net of tax:
	Postretirement liability			(2	)		-			-			-			(2	)
	Unrealized gain (loss) on cash flow hedges			-			-			-			-			-
	Changes in unrecognized gain (loss) on available-for-sale investments			-			(49	)		-			-			(49	)
	Share of other comprehensive income (loss) of Alliance Boots			-			(19	)		-			-			(19	)
	Currency translation adjustments			-			116			-			-			116
	Other Comprehensive Income (loss) of subsidiaries			48			-			-			(48	)		-
	Total Other Comprehensive Income (loss)			46			48			-			(48	)		46
	Total Comprehensive Income (loss)			776			650			-			(650	)		776
	Comprehensive income attributable to noncontrolling interests			-			14			-			-			14
	Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	776		$	636		$	-		$	(650	)	$	762
	STATEMENT OF COMPREHENSIVE INCOME
	(UNAUDITED)
	(In millions)
			Six Months Ended February 28, 2014
		Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
		Issuer			Subsidiaries			Company			Adjustments
		Subsidiary
Comprehensive Income
Net Earnings (loss)		$	1,462		$	1,195		$	-		$	(1,195	)	$	1,462
Other comprehensive income (loss), net of tax:
Postretirement liability			6			-			-			-			6
Unrealized gain (loss) on cash flow hedges			-			-			-			-			-
Changes in unrecognized gain (loss) on available-for-sale investments			-			35			-			-			35
Share of other comprehensive income (loss) of Alliance Boots			-			(56	)		-			-			(56	)
Currency translation adjustments			-			281			-			-			281
Other Comprehensive Income (loss) of subsidiaries			260			-			-			(260	)		-
Total Other Comprehensive Income (loss)			266			260			-			(260	)		266
Total Comprehensive Income (loss)			1,728			1,455			-			(1,455	)		1,728
Comprehensive income attributable to noncontrolling interests			-			23			-			-			23
Comprehensive income attributable to Walgreens Boots Alliance, Inc.		$	1,728		$	1,432		$	-		$	(1,455	)	$	1,705
Consolidated Condensed Balance Sheets	CONSOLIDATED CONDENSED BALANCE SHEETS
	(UNAUDITED)
	(In millions)
			28-Feb-15
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Assets
	Current Assets:
	Cash and cash equivalents		$	1,840		$	1,165		$	-		$	-		$	3,005
	Accounts receivable, net			2,027			4,990			-			-			7,017
	Inventories			4,396			4,983			-			-			9,379
	Current intercompany loan receivable			12,930			26,428			20,720			(60,078	)		-
	Other current assets			533			1,005			11			(235	)		1,314
	Total Current Assets			21,726			38,571			20,731			(60,313	)		20,715
	Non-Current Assets:
	Property, plant and equipment, at cost, less accumulated depreciation and amortization			6,500			9,146			-			-			15,646
	Equity investment in Alliance Boots			-			-			-			-			-
	Goodwill			8,382			8,662			-			-			17,044
	Intangible assets			286			11,939			-			-			12,225
	Other non-current assets			162			5,561			4			-			5,727
	Non-current intercompany loan receivable			-			3,725			19,113			(22,838	)		-
	Investment in subsidiaries			32,379			-			27,039			(59,418	)		-
	Total Non-Current Assets			47,709			39,033			46,156			(82,256	)		50,642
	Total Assets		$	69,435		$	77,604		$	66,887		$	(142,569	)	$	71,357
	Liabilities & Equity
	Current Liabilities:
	Short-term borrowings		$	757		$	304		$	-		$	-		$	1,061
	Trade accounts payable			4,355			5,938			-			-			10,293
	Current intercompany loan payable			12,258			24,604			23,216			(60,078	)		-
	Accrued expenses and other liabilities			2,508			2,153			479			-			5,140
	Income taxes			-			225			206			(235	)		196
	Total Current Liabilities			19,878			33,224			23,901			(60,313	)		16,690
	Non-Current Liabilities:
	Long-term debt			3,737			128			12,136			-			16,001
	Deferred income taxes			283			3,406			-			-			3,689
	Non-current intercompany loan payable			15,983			6,855			-			(22,838	)		-
	Other non-current liabilities			2,515			1,400			36			-			3,951
	Total Non-Current Liabilities			22,518			11,789			12,172			(22,838	)		23,641
	Equity:
	Total Walgreens Boots Alliance, Inc. Shareholders' Equity			27,039			32,379			30,814			(59,418	)		30,814
	Noncontrolling interests			-			212			-			-			212
	Total Equity			27,039			32,591			30,814			(59,418	)		31,026
	Total Liabilities & Equity		$	69,435		$	77,604		$	66,887		$	(142,569	)	$	71,357
	CONSOLIDATED CONDENSED BALANCE SHEETS
	(UNAUDITED)
	(In millions)
			31-Aug-14
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Assets
	Current Assets:
	Cash and cash equivalents		$	2,224		$	422		$	-		$	-		$	2,646
	Accounts receivable, net			1,860			1,358			-			-			3,218
	Inventories			4,301			1,755			-			-			6,076
	Current intercompany loan receivable			6,755			8,277			-			(15,032	)		-
	Other current assets			176			141			-			(15	)		302
	Total Current Assets			15,316			11,973			-			(15,047	)		12,242
	Non-Current Assets:
	Property, plant and equipment, at cost, less accumulated depreciation and amortization			6,932			5,325			-			-			12,257
	Equity investment in Alliance Boots			-			7,336			-			-			7,336
	Goodwill			343			2,016			-			-			2,359
	Intangible assets			417			763			-			-			1,180
Other non-current assets			252			1,644			-			-			1,896
Non-current intercompany loan receivable			-			3,560			-			(3,560	)		-
Investment in subsidiaries			23,250			-			-			(23,250	)		-
Total Non-Current Assets			31,194			20,644			-			(26,810	)		25,028
Total Assets		$	46,510		$	32,617		$	-		$	(41,857	)	$	37,270
Liabilities & Equity
Current Liabilities:
Short-term borrowings		$	766		$	8		$	-		$	-		$	774
Trade accounts payable			3,850			465			-			-			4,315
Current intercompany loan payable			8,277			6,755			-			(15,032	)		-
Accrued expenses and other liabilities			3,044			657			-			-			3,701
Income taxes			-			120			-			(15	)		105
Total Current Liabilities		$	15,937			8,005			-			(15,047	)		8,895
Non-Current Liabilities:
Long-term debt			3,726			10			-			-			3,736
Deferred income taxes			404			676			-			-			1,080
Non-current intercompany loan payable			3,560			-			-			(3,560	)		-
Other non-current liabilities			2,370			572			-			-			2,942
Total Non-Current Liabilities			10,060			1,258			-			(3,560	)		7,758
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity			20,513			23,250			-			(23,250	)		20,513
Noncontrolling interests			-			104			-			-			104
Total Equity			20,513			23,354			-			(23,250	)		20,617
Total Liabilities & Equity		$	46,510		$	32,617		$	-		$	(41,857	)	$	37,270
Consolidated Condensed Statements of Cash Flows	CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
	(UNAUDITED)
	(In millions)
			Six Months Ended February 28, 2015
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Cash Flows from Operating Activities		$	1,011		$	1,254		$	72		$	-		$	2,337
	Cash Flows from Investing Activities:
	Additions to property, plant and equipment			(302	)		(341	)		-			-			(643	)
	Proceeds from sale of assets			121			458			-			-			579
	Return of restricted cash			-			74			-			-			74
	Alliance Boots acquisition, net of cash received			-			-			(4,461	)		-			(4,461	)
	Other business and intangible asset acquisitions, net of cash received			(27	)		(65	)		-			-			(92	)
	Purchases of short-term investments held to maturity			-			(29	)		-			-			(29	)
	Proceeds from short-term investments held to maturity			-			29			-			-			29
	Investment in AmerisourceBergen			-			-			-			-			-
	Other			(165	)		-			-			-			(165	)
	Net cash used for investing activities			(373	)		126			(4,461	)		-			(4,708	)
	Cash Flows from Financing Activities:
	Payments of short-term borrowings			-			(324	)		(6	)		-			(330	)
	Proceeds from issuance of long-term debt			-			-			12,279			-			12,279
	Payments of long-term debt			-			(7,817	)		-			-			(7,817	)
	Stock purchases			(500	)		-			(94	)		-			(594	)
	Proceeds related to employee stock plans			154			-			139			-			293
	Cash dividends paid			(642	)		-			-			-			(642	)
	Intra-company financing activities, net			-36			7,817			(7,781	)		-			-
	Other			2			(286	)		(76	)		-			(360	)
	Net cash (used for) provided by financing activities			(1,022	)		(610	)		4,461			-			2,829
	Effect of exchange rate changes on cash and cash equivalents			-			(27	)		(72	)		-			(99	)
	Changes in Cash and Cash Equivalents:
	Net (decrease) increase in cash and cash equivalents			(384	)		743			-			-			359
	Cash and cash equivalents at beginning of period			2,224			422			-			-			2,646
	Cash and cash equivalents at end of period		$	1,840		$	1,165		$	-		$	-		$	3,005
	CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
	(UNAUDITED)
	(In millions)
			Six Months Ended February 28, 2014
			Guarantor/			Non-guarantor			Parent			Consolidating			Consolidated
			Issuer			Subsidiaries			Company			Adjustments
			Subsidiary
	Cash Flows from Operating Activities		$	471		$	766		$	-		$	-		$	1,237
	Cash Flows from Investing Activities:
	Additions to property, plant and equipment			(342	)		(301	)		-			52			(591	)
	Proceeds from sale of assets			201			60			-			(52	)		209
	Proceeds from sale of business									-						-
	Business and intangible asset acquisitions, net of cash received			(254	)		(43	)		-			-			(297	)
	Purchases of short-term investments held to maturity			-			(34	)		-			-			(34	)
	Proceeds from short-term investments held to maturity			-			34			-			-			34
	Investment in AmerisourceBergen			-			(430	)		-			-			(430	)
	Other			-			(59	)		-			-			(59	)
	Net cash used for investing activities			(395	)		(773	)		-			-			(1,168	)
	Cash Flows from Financing Activities:
	Stock purchases			(205	)		-			-			-			(205	)
	Proceeds related to employee stock plans			416			-			-			-			416
	Cash dividends paid			(597	)		-			-			-			(597	)
	Other			(12	)		-			-			-			(12	)
	Net cash (used for) provided by financing activities			(398	)		-			-			-			(398	)
	Changes in Cash and Cash Equivalents:
	Net (decrease) increase in cash and cash equivalents			(322	)		(7	)		-			-			(329	)
	Cash and cash equivalents at beginning of period			1,771			335			-			-			2,106
	Cash and cash equivalents at end of period		$	1,449		$	328		$	-		$	-		$	1,777

Organization_Details

Organization (Details)	0 Months Ended		6 Months Ended			0 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Feb. 28, 2015	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2014	Feb. 28, 2015	Dec. 31, 2014
	USD ($)	GBP (£)	USD ($)	USD ($)	USD ($)	Walgreens Boots Alliance [Member]	Walgreens Boots Alliance [Member]	Walgreens Boots Alliance [Member]
			Segment			GBP (£)	USD ($)
Schedule of Equity Method Investments [Line Items]
Number of reportable segment			3
Common stock, par value (in dollars per share)			$0.01	$0.08	$0.08		$0.01
Increased ownership percentage of Alliance Boots (in hundredths)								55.00%
Total purchase price cash consideration	$4,900	£ 3,133				£ 3,133
Number of shares exchanged in acquisition (in shares)						144,333,468

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	3 Months Ended	6 Months Ended		0 Months Ended
	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Aug. 31, 2014	Dec. 31, 2014	Jun. 18, 2012	Jan. 01, 2015	Mar. 18, 2013
Schedule of Equity Method Investments [Line Items]
Ownership percentage (in hundredths)		45.00%
Common shares transfer (in shares)		1,172,513,618		1,028,180,150
Restricted Cash [Abstract]
Restricted cash		$206,000,000		$0
Financial Instruments [Abstract]
Minimum highly effective hedging percentage (in hundredths)		80.00%
Maximum highly effective hedging percentage (in hundredths)		125.00%
Income Taxes [Abstract]
Unrecognized tax benefits		115,000,000
Unrecognized tax benefits will decrease in the next 12 months		115,000,000
Non controlling Interest [Abstract]
Threshold percentage to consolidated subsidiaries accounts (in hundredths)		100.00%
Currency [Abstract]
Net gain (loss) from foreign currency transactions	0	0	0
Retail Pharmacy USA [Member]
Inventory [Abstract]
Inventory increase in carrying amount if valued on LIFO basis		2,400,000,000		2,300,000,000
Alliance Boots [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage (in hundredths)		100.00%		45.00%	45.00%	45.00%
Walgreens Boots Alliance Development GmbH [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage (in hundredths)		72.50%
Additional ownership interest, direct (in hundredths)		50.00%
Additional ownership interest, indirect (in hundredths)		27.50%
Equity method ownership option to repurchase shares, amount		$100,000
Alliance Healthcare Italia Distribuzione S.p.A. [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage (in hundredths)							5.00%
Common shares transfer (in shares)		320
AmerisourceBergen Corporation [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Common shares transfer (in shares)								19,859,795

Basis_of_Presentation_Class_of

Basis of Presentation, Class of Warrant or Right (Details) (USD $)	Feb. 28, 2015	Aug. 31, 2014	Mar. 18, 2013
Class of Warrant or Right [Line Items]
Right to purchase minority equity position (in shares)	1,172,513,618	1,028,180,150
Warrants Exercisable in March 2016 [Member]
Class of Warrant or Right [Line Items]
Warrant issued to purchase common stock (in shares)	22,696,912
Warrant exercise price (in dollars per share)	51.5
Warrants Exercisable in March 2017 [Member]
Class of Warrant or Right [Line Items]
Warrant issued to purchase common stock (in shares)	22,696,912
Warrant exercise price (in dollars per share)	52.5
AmerisourceBergen Corporation [Member]
Class of Warrant or Right [Line Items]
Percentge of fully diluted equity (in hundredths)			7.00%
Maximum [Member] | AmerisourceBergen Corporation [Member]
Class of Warrant or Right [Line Items]
Right to purchase minority equity position (in shares)			19,859,795

Change_in_Accounting_Policy_De

Change in Accounting Policy (Details) (USD $)	3 Months Ended				6 Months Ended				12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Feb. 28, 2015		Feb. 28, 2014		Feb. 28, 2015		Feb. 28, 2014		Aug. 31, 2014	Nov. 30, 2014	Nov. 30, 2013	Aug. 31, 2013	Aug. 31, 2012
Consolidated Condensed Statements of Earnings [Abstract]
Equity earnings in Alliance Boots	$109	[1]	$136	[1]	$323	[1]	$330	[1]
Operating Income	1,377		1,217		2,431		2,184
Earnings Before Income Tax Provision	2,443		1,121		3,641		2,272
Income tax provision	391		391		712		810
Net Earnings (loss)	2,060		730		2,937		1,462
Net Earnings Attributable to Walgreens Boots Alliance, Inc.	2,042		716		2,892		1,439
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share)	$1.96		$0.75		$2.91		$1.51
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share)	$1.93		$0.74		$2.88		$1.49
Consolidated Condensed Statements of Comprehensive Income [Abstract]
Net earnings	2,060		730		2,937		1,462
Share of other comprehensive income (loss) of Alliance Boots	92		-19		113		-56
Cumulative translation adjustments	-301		116		-490		281
Total Other Comprehensive Income	-127		46		-209		266
Total Comprehensive Income (loss)	1,933		776		2,728		1,728
Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.	1,920		762		2,688		1,705
Non-Current Assets [Abstract]
Equity investment in Alliance Boots	0				0				7,336
Total Non-Current Assets	50,642				50,642				25,028
Total Assets	71,357				71,357				37,270
Non-Current Liabilities [Abstract]
Deferred income taxes	3,689				3,689				1,080
Total Non-Current Liabilities	23,641				23,641				7,758
Equity [Abstract]
Retained earnings	24,526				24,526				22,327
Accumulated other comprehensive income	-68		174		-68		174		136	54	128	-92
Total Walgreens Boots Alliance Inc. Shareholders' Equity	30,814				30,814				20,513
Total Equity	31,026				31,026				20,617
Total Liabilities and Equity	71,357				71,357				37,270
Cash Flows from Operating Activities [Abstract]
Net earnings	2,060		730		2,937		1,462
Deferred income taxes					181		29
Equity earnings in Alliance Boots	-109	[1]	-136	[1]	-323	[1]	-330	[1]
Increase in retained earnings, net of tax									98
Alliance Boots [Member]
Non-Current Assets [Abstract]
Equity investment in Alliance Boots									7,336
Cash Flows from Operating Activities [Abstract]
Percentage of initial interest													45.00%
As Reported [Member]
Consolidated Condensed Statements of Earnings [Abstract]
Equity earnings in Alliance Boots			194				345
Operating Income			1,275				2,199
Earnings Before Income Tax Provision			1,179				2,287
Income tax provision			411				815
Net Earnings (loss)			768				1,472
Net Earnings Attributable to Walgreens Boots Alliance, Inc.			754				1,449
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share)			$0.79				$1.52
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share)			$0.78				$1.51
Consolidated Condensed Statements of Comprehensive Income [Abstract]
Net earnings			768				1,472
Share of other comprehensive income (loss) of Alliance Boots			-36				-70
Cumulative translation adjustments			191				253
Total Other Comprehensive Income			104				224
Total Comprehensive Income (loss)			872				1,696
Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.			858				1,673
Non-Current Assets [Abstract]
Equity investment in Alliance Boots									7,248
Total Non-Current Assets									24,940
Total Assets									37,182
Non-Current Liabilities [Abstract]
Deferred income taxes									1,048
Total Non-Current Liabilities									7,726
Equity [Abstract]
Retained earnings									22,229
Accumulated other comprehensive income									178
Total Walgreens Boots Alliance Inc. Shareholders' Equity									20,457
Total Equity									20,561
Total Liabilities and Equity									37,182
Cash Flows from Operating Activities [Abstract]
Net earnings			768				1,472
Deferred income taxes							34
Equity earnings in Alliance Boots			-194				-345
Adjustments [Member]
Consolidated Condensed Statements of Earnings [Abstract]
Equity earnings in Alliance Boots			-58				-15
Operating Income			-58				-15
Earnings Before Income Tax Provision			-58				-15
Income tax provision			-20				-5
Net Earnings (loss)			-38				-10
Net Earnings Attributable to Walgreens Boots Alliance, Inc.			-38				-10
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - basic (in dollars per share)			($0.04)				($0.01)
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. - diluted (in dollars per share)			($0.04)				($0.02)
Consolidated Condensed Statements of Comprehensive Income [Abstract]
Net earnings			-38				-10
Share of other comprehensive income (loss) of Alliance Boots			17				14
Cumulative translation adjustments			-75				28
Total Other Comprehensive Income			-58				42
Total Comprehensive Income (loss)			-96				32
Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.			-96				32
Non-Current Assets [Abstract]
Equity investment in Alliance Boots									88
Total Non-Current Assets									88
Total Assets									88
Non-Current Liabilities [Abstract]
Deferred income taxes									32
Total Non-Current Liabilities									32
Equity [Abstract]
Retained earnings									98
Accumulated other comprehensive income									-42
Total Walgreens Boots Alliance Inc. Shareholders' Equity									56
Total Equity									56
Total Liabilities and Equity									88
Cash Flows from Operating Activities [Abstract]
Net earnings			-38				-10
Deferred income taxes							-5
Equity earnings in Alliance Boots			$58				$15
[1]	Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method upon completion of the Second Step Transaction on December 31, 2014. Earnings for the quarter and six month periods ended February 28, 2015 reflect incremental acquisition-related amortization expense of $4 million ($3 million net of tax) and $14 million ($8 million net of tax), respectively. Incremental acquisition-related amortization for the three and six month periods ended February 28, 2014 were $10 million ($8 million net of tax) and $20 million ($16 million net of tax), respectively. Earnings in foreign equity method investments and joint ventures are translated at the average exchange rates of $1.56 and $1.58 to one British Pound Sterling for the quarter and six month periods ended February 28, 2015, respectively. Prior year's earnings in foreign equity method investments and joint ventures were translated at the average exchange rate of $1.64 and $1.62 to one British Pound Sterling for the quarter and six month periods ended February 28, 2014, respectively.

Leases_and_Store_Closures_Deta

Leases and Store Closures (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Aug. 31, 2014
	Lease		Lease
Leases and Store Closures [Abstract]
Initial term of operating lease, lower range			15 years
Initial term of operating lease, upper range			25 years
Financing Obligation [Abstract]
2015	$19		$19
2016	18		18
2017	18		18
2018	18		18
2019	18		18
Later	1,153		1,153
Total minimum lease payments	1,244		1,244
Capital Lease [Abstract]
2015	68		68
2016	66		66
2017	62		62
2018	59		59
2019	59		59
Later	901		901
Total minimum lease payments	1,215		1,215
Operating Lease [Abstract]
2015	3,071		3,071
2016	3,006		3,006
2017	2,886		2,886
2018	2,814		2,814
2019	2,561		2,561
Later	23,102		23,102
Total minimum lease payments	37,440		37,440
Executory costs and imputed interest	1,600		1,600
Minimum sublease rentals	211		211
Pre-tax charges	0	0	17	0
Charges related to facilities that were closed or relocated	0	6	26	33
Changes in reserve for facility closings and related lease termination charges [Roll Forward]
Balance - beginning of period			257	123	123
Provision for present value of non-cancellable lease payments on closed facilities			11		171
Assumptions about future sublease income, terminations and changes in interest rates			2		-8
Interest accretion			13		14
Liability assumed through acquisition of Alliance Boots			13		0
Cash payments, net of sublease income			-36		-43
Balance - end of period	260		260		257
Number of leases	72		72
Maximum potential undiscounted future payments	360		360
Rent Expense [Abstract]
Minimum rentals	809	673	1,486	1,333
Contingent rentals	1	1	3	4
Less: Sublease rental income	-6	-7	-11	-12
Total rental expense	$804	$667	$1,478	$1,325

Equity_Method_Investments_Equi

Equity Method Investments, Equity Method Investments (Details) (USD $)	Feb. 28, 2015	Dec. 31, 2014	Aug. 31, 2014	Jun. 18, 2012
In Millions, unless otherwise specified
Schedule of Equity Method Investments [Line Items]
Carrying Value	0		$7,336
Equity method investment ownership interest percentage (in hundredths)	45.00%
Alliance Boots [Member]
Schedule of Equity Method Investments [Line Items]
Carrying Value			7,336
Equity method investment ownership interest percentage (in hundredths)	100.00%	45.00%	45.00%	45.00%
Other [Member]
Schedule of Equity Method Investments [Line Items]
Carrying Value	762		74
Other [Member] | Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership interest percentage (in hundredths)	12.00%		30.00%
Other [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership interest percentage (in hundredths)	50.00%		50.00%
Total [Member]
Schedule of Equity Method Investments [Line Items]
Carrying Value	762		$7,410

Equity_Method_Investments_Deta

Equity Method Investments (Details)

0 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2014

Aug. 31, 2014

Dec. 31, 2014

Jun. 18, 2012

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Dec. 31, 2014

Aug. 31, 2014

Feb. 28, 2015

Feb. 28, 2015

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Alliance Boots [Member]

Other Equity Method Investments [Member]

Other Equity Method Investments [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

GBP (£)

USD ($)

USD ($)

Schedule of Equity Method Investments [Line Items]

Equity interest in Alliance Boots (in hundredths)

45.00%

45.00%

45.00%

100.00%

100.00%

45.00%

45.00%

Cash paid to acquire investment

$4,025

Shares issued for Investment in Alliance Boots (in shares)

83.4

Remaining ownership subject to call option (in hundredths)

55.00%

55.00%

Cash price to exercise call option

3,100

Shares issued upon exercise of call option (in shares)

144.3

144.3

Equity method investments investment amount

2,400

Non-controlling interests

151

151

283

Incremental acquisition related amortization

4

10

14

20

Incremental acquisition related amortization, net of tax

3

8

8

16

Non-cash gain resulting from the remeasurement of previously held equity interest

706

Foreign currency translation gains and losses recycled from cumulative other comprehensive income

80

80

Equity earnings

$109

[1]

$136

[1]

$323

[1]

$330

[1]

$8

$8

[1]

Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method upon completion of the Second Step Transaction on December 31, 2014. Earnings for the quarter and six month periods ended February 28, 2015 reflect incremental acquisition-related amortization expense of $4 million ($3 million net of tax) and $14 million ($8 million net of tax), respectively. Incremental acquisition-related amortization for the three and six month periods ended February 28, 2014 were $10 million ($8 million net of tax) and $20 million ($16 million net of tax), respectively. Earnings in foreign equity method investments and joint ventures are translated at the average exchange rates of $1.56 and $1.58 to one British Pound Sterling for the quarter and six month periods ended February 28, 2015, respectively. Prior year's earnings in foreign equity method investments and joint ventures were translated at the average exchange rate of $1.64 and $1.62 to one British Pound Sterling for the quarter and six month periods ended February 28, 2014, respectively.

Equity_Method_Investments_Summ

Equity Method Investments, Summarized Financial Information of Equity Method Investees (Details) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015		Feb. 28, 2014		Feb. 28, 2015		Feb. 28, 2014		Aug. 31, 2014
Balance Sheet [Abstract]
Current assets	$4,674	[1]			$4,674	[1]			$9,074	[1]
Noncurrent assets	625	[1]			625	[1]			22,363	[1]
Current liabilities	4,067	[1]			4,067	[1]			9,372	[1]
Noncurrent liabilities	253	[1]			253	[1]			10,608	[1]
Shareholders' equity	979	[1],[2]			979	[1],[2]			11,457	[1],[2]
Income Statement [Abstract]
Net sales	5,317	[3]	9,688	[3]	14,978	[3]	19,100	[3]
Gross Profit	979	[3]	2,083	[3]	3,168	[3]	4,055	[3]
Net Income	246	[3]	324	[3]	743	[3]	771	[3]
Share of income from equity method investments	$109	[3]	$136	[3]	$323	[3]	$330	[3]
[1]	Net assets in foreign equity method investments are translated at their respective February 28, 2015 and August 31, 2014 spot rates.
[2]	Shareholders' equity at February 28, 2015 and August 31, 2014 includes $151 million and $283 million respectively, related to noncontrolling interests.
[3]	Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method upon completion of the Second Step Transaction on December 31, 2014. Earnings for the quarter and six month periods ended February 28, 2015 reflect incremental acquisition-related amortization expense of $4 million ($3 million net of tax) and $14 million ($8 million net of tax), respectively. Incremental acquisition-related amortization for the three and six month periods ended February 28, 2014 were $10 million ($8 million net of tax) and $20 million ($16 million net of tax), respectively. Earnings in foreign equity method investments and joint ventures are translated at the average exchange rates of $1.56 and $1.58 to one British Pound Sterling for the quarter and six month periods ended February 28, 2015, respectively. Prior year's earnings in foreign equity method investments and joint ventures were translated at the average exchange rate of $1.64 and $1.62 to one British Pound Sterling for the quarter and six month periods ended February 28, 2014, respectively.

AvailableforSale_Investments_D

Available-for-Sale Investments (Details) (USD $)	3 Months Ended	6 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Aug. 31, 2014
Summary of cost and fair value of available-for-sale securities [Abstract]
Cost		$792		$717
Unrealized gains		467		170
Foreign Exchange losses		-4		0
Unrealized losses		0		0
Fair value		1,255		887
Available for sale securities, current		77
AmerisourceBergen Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Maximum number of shares in minority equity position		19,859,795
Percentage of rights to acquire common share (in hundredths)		7.00%
Percentage of outstanding common stock held (in hundredths)		5.20%
Price of shares acquired through open market transactions	140		430
Number of shares held		11,500,000
Summary of cost and fair value of available-for-sale securities [Abstract]
Cost		717		717
Unrealized gains		461		170
Foreign Exchange losses		0		0
Unrealized losses		0		0
Fair value		1,178		887
Other Investments [Member]
Summary of cost and fair value of available-for-sale securities [Abstract]
Cost		75
Unrealized gains		6
Foreign Exchange losses		-4
Unrealized losses		0
Fair value		$77

Acquisitions_Details

Acquisitions (Details)	0 Months Ended		3 Months Ended		6 Months Ended					3 Months Ended	6 Months Ended			0 Months Ended	6 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Dec. 31, 2014	Dec. 30, 2014	Aug. 31, 2014	Feb. 28, 2015	Feb. 28, 2015	Dec. 31, 2014	Feb. 28, 2014	Jan. 01, 2015	Feb. 28, 2015	Feb. 28, 2015	Feb. 28, 2015	Feb. 28, 2015	Feb. 28, 2015
	USD ($)	GBP (£)	USD ($)	USD ($)	USD ($)	USD ($)		USD ($)	USD ($)	Alliance Boots [Member]	Alliance Boots [Member]	Alliance Boots [Member]	Alliance Boots [Member]	Walgreens Boots Alliance Development GmbH [Member]	Walgreens Boots Alliance Development GmbH [Member]	Other Acquisition [Member]	Retail Pharmacy International [Member]	Retail Pharmacy USA [Member]	Pharmaceutical Wholesale [Member]
										USD ($)	USD ($)				USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Business Acquisition [Line Items]
Business Acquisition, Percentage of issued and outstanding capital acquired (in hundredths)												55.00%
Equity method investment ownership interest percentage (in hundredths)			45.00%		45.00%					100.00%	100.00%	45.00%	45.00%		100.00%
Ownership interest percentage prior to Second Step Transaction															50.00%
Ownership interest percentage indirectly owned (in hundredths)															27.50%
Common shares sold (in shares)														320
Common shares transferred percentage (in hundredths)														5.00%
Equity method ownership option to repurchase shares, amount															$100,000
Noncontrolling interest (in hundredths)															27.50%
Noncontrolling interest acquired			212,000,000		212,000,000				104,000,000						2,600,000,000
Total purchase price	15,900,000,000				13,300,000,000						15,851,000,000
Total purchase price cash consideration	4,900,000,000	3,133,000,000									4,874,000,000
Spot rate							1.56
Purchase price consideration, common shares (in shares)	144,300,000	144,300,000
Purchase price consideration common shares fair value	11,000,000,000										8,290,000,000
Closing market price per share (in dollars per share)								$76.05
Gain on previously held equity interest	706,000,000		706,000,000	0	706,000,000	0
Fair value of previously held equity interest											8,300,000,000
Fair value of the assets acquired					3,700,000,000
Estimated manufacturing profit in acquired finished goods inventory capitalized			106,000,000		106,000,000					106,000,000	106,000,000
Aggregate purchase price					4,461,000,000	0										92,000,000
Intangible assets										11,461,000,000	11,461,000,000					64,000,000
Goodwill					15,579,000,000						15,556,000,000					23,000,000	3,747,000,000	8,311,000,000	3,521,000,000
Goodwill arising from synergies																		4,700,000,000
Goodwill based on a with and without analysis																		3,600,000,000
Selling, general and administrative expenses			$5,606,000,000	$4,569,000,000	$10,062,000,000	$8,948,000,000				$59,000,000	$83,000,000

Acquisitions_Impact_of_equity_

Acquisitions, Impact of equity transaction (Details) (Alliance Boots [Member], USD $)	6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015
Alliance Boots [Member]
Business Acquisition [Line Items]
Consideration attributable to WBAD	$2,569
Less: Carrying value of the Company's pre-existing noncontrolling interest	130
Impact to additional paid in capital	$2,439

Acquisitions_Consideration_pai

Acquisitions, Consideration paid (Details)	0 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Feb. 28, 2015	Feb. 28, 2015
	USD ($)	GBP (£)	USD ($)	Alliance Boots [Member]
				USD ($)
Consideration paid [Abstract]
Cash	$4,900	£ 3,133		$4,874
Common stock				10,977
Total consideration transferred	15,900		13,300	15,851
Less: consideration attributed to WBAD				-2,569
Total consideration after attributed amount to WBAD				13,282
Fair value of the investment in Alliance Boots held before the Second Step Transaction	11,000			8,290
Total consideration				$21,572

Acquisitions_Identifiable_asse

Acquisitions, Identifiable assets acquired and liabilities assumed including noncontrolling interests (Details) (USD $)	Feb. 28, 2015	Aug. 31, 2014
In Millions, unless otherwise specified
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill	$17,044	$2,359
Alliance Boots [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and cash equivalents	413
Accounts receivable	3,805
Inventories	3,713
Other current assets	902
Property, plant and equipment	3,774
Intangible assets	11,461
Other non-current assets	1,760
Trade accounts payable, accrued expenses and other liabilities	-7,722
Borrowings	-8,999
Deferred income taxes	-2,437
Other non-current liabilities	-456
Noncontrolling interests	-198
Total identifiable net assets and noncontrolling interests	6,016
Goodwill	$15,556

Acquisitions_The_preliminary_i

Acquisitions, The preliminary identified definite and indefinite lived intangible assets (Details) (Alliance Boots [Member], USD $)	6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015
Definite-Lived Intangible Assets [Roll Forward]
Amount	$2,998
Indefinite-Lived Intangible Assets [Roll Forward]
Amount	8,463
Trade Names and Trademarks [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Amount	6,192
Pharmacy Licenses [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Amount	2,271
Customer Relationships [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life (in years)	12 years
Amount	1,676
Loyalty Card Holders [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life (in years)	12 years
Amount	723
Trade Names and Trademarks [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life (in years)	15 years
Amount	544
Favorable Lease Interests [Member]
Definite-Lived Intangible Assets [Roll Forward]
Weighted-Average Useful Life (in years)	3 years
Amount	$55

Acquisitions_Unaudited_pro_for

Acquisitions, Unaudited pro forma results prepared for comparative purposes (Details) (Alliance Boots [Member], USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Alliance Boots [Member]
Business Acquisition [Line Items]
Net sales	$30,202	$29,276	$59,173	$56,999
Net earnings	$1,253	$966	$2,621	$1,973
Net earnings per common share [Abstract]
Basic (in dollars per share)	$1.20	$0.88	$2.51	$1.80
Diluted (in dollars per share)	$1.19	$0.87	$2.49	$1.78

Acquisitions_Actual_results_fr

Acquisitions, Actual results from Alliance Boots operations included in the Consolidated Condensed Statements of Earnings (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Earnings Per Share [Abstract]
Basic (in dollars per share)	$1.96	$0.75	$2.91	$1.51
Diluted (in dollars per share)	$1.93	$0.74	$2.88	$1.49
Alliance Boots [Member]
Business Acquisition [Line Items]
Net sales	$5,525		$5,525
Net earnings	$330		$330
Earnings Per Share [Abstract]
Basic (in dollars per share)	$0.32		$0.33
Diluted (in dollars per share)	$0.31		$0.33

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, Schedule of Goodwill (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015
Goodwill [Roll Forward]
Net book value - Beginning Period	$2,359
Acquisitions	15,579
Sale of business	-706	[1]
Other	-3	[2]
Currency translation adjustments	-185
Net book value - Ending Period	17,044
Retail Pharmacy USA [Member]
Goodwill [Roll Forward]
Net book value - Beginning Period	2,359
Acquisitions	8,311
Sale of business	-706	[1]
Other	-3	[2]
Currency translation adjustments	0
Net book value - Ending Period	9,961
Retail Pharmacy International [Member]
Goodwill [Roll Forward]
Net book value - Beginning Period	0
Acquisitions	3,747
Sale of business	0	[1]
Other	0	[2]
Currency translation adjustments	-99
Net book value - Ending Period	3,648
Pharmaceutical Wholesale [Member]
Goodwill [Roll Forward]
Net book value - Beginning Period	0
Acquisitions	3,521
Sale of business	0	[1]
Other	0	[2]
Currency translation adjustments	-86
Net book value - Ending Period	$3,435
[1]	Represents Walgreens Infusion and Respiratory Services goodwill that has been reclassified as an asset held for sale. See Note 22, Subsequent Events for further details.
[2]	Other primarily represents immaterial purchase accounting adjustments for the Company's acquisitions.

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Aug. 31, 2014
Business Acquisition [Line Items]
Amortization expense for intangible assets	$209	$73	$276	$143
Foreign currency adjustments related to carrying amount			-129
Currency translation adjustments related to accumulated amortization			46
Goodwill	17,044		17,044		2,359
Indefinite-lived Intangible Assets, Translation Adjustments			-76
Alliance Boots [Member]
Business Acquisition [Line Items]
Goodwill	15,556		15,556
Intangible assets	$11,461		$11,461

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets by Major Class (Details) (USD $)	Feb. 28, 2015	Aug. 31, 2014	Feb. 28, 2014
In Millions, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	$4,780	$2,108
Accumulated amortization	942	936
Total amortizable intangible assets, net	3,838	1,172
Total indefinite lived intangible assets	8,387	8
Total intangible assets, net	12,225	1,180
Purchased Prescription File [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	925	1,079
Accumulated amortization	471	474
Favorable lease interests [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	427	382
Accumulated amortization	187	174
Purchasing and Payer Contract [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	95	301
Accumulated amortization	61	145
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	154	151
Accumulated amortization	82	70
Trade names and trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	735	191
Accumulated amortization	84	69
Total indefinite lived intangible assets	6,136	8
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	1,724	0
Accumulated amortization	46	0
Loyalty Card Holders [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	716	0
Accumulated amortization	10	0
Other Amortizable Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amortizable Intangible Assets	4	4
Accumulated amortization	1	4
Pharmacy Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Total indefinite lived intangible assets	$2,251	$0

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets, Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) (USD $)	Feb. 28, 2015
In Millions, unless otherwise specified
Estimated annual intangible assets amortization expense [Abstract]
2015	$426
2016	465
2017	424
2018	388
2019	$366

ShortTerm_Borrowings_and_LongT2

Short-Term Borrowings and Long-Term Debt (Details)

Feb. 28, 2015

Dec. 31, 2014

Aug. 31, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Aug. 31, 2014

Feb. 28, 2015

Aug. 31, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

USD ($)

USD ($)

Commercial Paper [Member]

Commercial Paper [Member]

Term Loan [Member]

Term Loan [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Letter of Credit [Member]

Letter of Credit [Member]

Term loan and revolving credit agreement [Member]

Alliance Boots [Member]

United Kingdom, Pounds

Euro Member Countries, Euro

Total $8.0 billion debt issuance [Member]

Total $4.0 billion debt issuance [Member]

Total $4.0 billion debt issuance [Member]

Total $1.0 billion debt issuance [Member]

Total $1.0 billion debt issuance [Member]

Euro and Pound Sterling Notes [Member]

Unsecured Variable Rate Notes Due 2016 [Member]

1.750% unsecured notes due 2017 [Member]

2.700% unsecured notes due 2019 [Member]

3.300% unsecured notes due 2021 [Member]

3.800% unsecured notes due 2024 [Member]

4.500% unsecured notes due 2034 [Member]

4.800% unsecured notes due 2044 [Member]

Notes Due 2014 [Member]

1.000% Unsecured Notes Due 2015 [Member]

1.800% Unsecured Notes Due 2017 [Member]

3.100% Unsecured Notes Due 2022 [Member]

4.400% Unsecured Notes Due 2042 [Member]

Variable Rate Borrowings [Member]

USD ($)

USD ($)

USD ($)

GBP (£)

USD ($)

Upon the affirmative vote [Member]

USD ($)

Upon the affirmative vote [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Long-Term Debt [Abstract]

Other short-term borrowings

$1,061,000,000

$774,000,000

$29,000,000

Spot rate

1.56

1.54

1.12

Repayment of debt

9,000,000,000

550,000,000

750,000,000

Debt instrument, description of variable rate basis

Three-month U.S. Dollar LIBOR

Basis spread on variable rate (in hundredths)

0.45%

Net proceeds from notes payable

7,900,000,000

4,000,000,000

1,000,000,000

Total issuance costs

44,000,000

26,000,000

8,000,000

11,000,000

Fair value of the notes

8,300,000,000

3,500,000,000

3,400,000,000

1,100,000,000

1,100,000,000

2,000,000,000

Maximum aggregate outstanding amount of indebtedness

2,000,000,000

2,000,000,000

Stated interest rate (in hundredths)

5.25%

Interest payment frequency

semiannually in arrears on January 15 and July 15

Percentage of principal amount of fixed rate notes can be redeemed (in hundredths)

100.00%

100.00%

100.00%

Redemption of notes description

Redemption price equal to the greater of : (1) 100% of the principal amount of the fixed rate notes being redeemed; and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044.

Redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 20 basis points for the notes due 2017, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042.

Redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption.

Redemption price equal to rge greater of: (1) 100% of the principal amount of the notes to be redeemed; and (2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate, (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025.

At any time in whole or from time to time in part

At any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part

At any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part

At any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part

At any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part

At any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part

Basis points added to treasury rate to calculate redemption rate (in hundredths)

45

20

15

15

20

20

20

25

12

20

22

25

Percentage of redemption price (in hundredths)

100.00%

100.00%

100.00%

Percentage of principal amount required on triggering event to repurchase notes (in hundredths)

101.00%

101.00%

101.00%

101.00%

Line of Credit Facility [Line Items]

Balance outstanding at fiscal year-end

0

0

Average daily short-term borrowings

4,000,000

14,000,000

Weighted-average interest rate (in hundredths)

0.02%

0.23%

Maximum borrowing capacity

2,200,000,000

1,450,000,000

2,250,000,000

3,000,000,000

375,000,000

500,000,000

Amount borrowed

1,450,000,000

Term of facility

5 years

Fees related to borrowings

$14,000,000

ShortTerm_Borrowings_and_LongT3

Short-Term Borrowings and Long-Term Debt, Short-Term Borrowings (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015		Feb. 28, 2015		Aug. 31, 2014		Feb. 28, 2014
Short-Term Borrowings [Abstract]
Current maturities of loans assumed through the purchase of land and buildings	($2)	[1]	($2)	[1]	($8)	[1]
Other	1,061		1,061		774
Minimum interest rate (in hundredths)	5.00%	[1]
Maximum interest rate (in hundredths)	8.75%	[1]
Maturity year start	2015	[1]
Maturity year end	2035	[1]
Other Short-Term Debt [Member]
Short-Term Borrowings [Abstract]
Other	309	[1],[2]	309	[1],[2]	16	[1],[2]		[1],[2]
Total short-term borrowings	1,061	[1]	1,061	[1]	774	[1]		[1]
Notes Due 2015 [Member]
Short-Term Borrowings [Abstract]
1.000% unsecured notes due 2015	750	[1]	750	[1]	750	[1]
Stated interest rate (in hundredths)	1.00%	[1]	1.00%	[1]
Maturity year			2015	[1]	2015	[1]
Assumed Loans [Member]
Short-Term Borrowings [Abstract]
Current maturities of loans assumed through the purchase of land and buildings	$2	[1]	$2	[1]	$8	[1]
[1]	All notes are presented net of unamortized discount, where applicable.
[2]	Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including $29 million of U.S. dollar equivalent bank overdrafts.

ShortTerm_Borrowings_and_LongT4

Short-Term Borrowings and Long-Term Debt, Long-Term Debt (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015		Feb. 28, 2015		Aug. 31, 2014
Long-Term Debt [Abstract]
Loans assumed through the purchase of land and buildings	$41	[1]	$41	[1]	$40	[1]
Other	117	[1],[2]	117	[1],[2]	0	[1]
Total long-term debt including current maturities	16,003	[1]	16,003	[1]	3,744	[1]
Less: current maturities	2	[1]	2	[1]	8	[1]
Total long term debt	16,001	[1]	16,001	[1]	3,736	[1]
Notes Due 2015 [Member]
Long-Term Debt [Abstract]
Stated interest rate (in hundredths)	1.00%		1.00%
Notes Due 2016 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	750	[1]	750	[1]	0	[1]
Maturity year	2016	[1]
Notes Due 2019 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	2,235	[1]	2,235	[1]	0	[1]
Maturity year	2019	[1]
Notes Due 2017 One [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	999	[1]	999	[1]	999	[1]
Stated interest rate (in hundredths)	1.80%	[1]	1.80%	[1]
Maturity year	2017	[1]
Notes Due 2017 Two [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	749	[1]	749	[1]	0	[1]
Stated interest rate (in hundredths)	1.75%	[1]	1.75%	[1]
Maturity year	2017	[1]
Notes Due 2019 One [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	1,016	[1],[3]	1,016	[1],[3]	1,010	[1],[3]
Stated interest rate (in hundredths)	5.25%	[1],[3]	5.25%	[1],[3]
Maturity year	2019	[1],[3]
Notes Due 2019 Two [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	1,248	[1]	1,248	[1]	0	[1]
Stated interest rate (in hundredths)	2.70%	[1]	2.70%	[1]
Maturity year	2019	[1]
Notes Due 2020 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	615	[1],[4]	615	[1],[4]	0	[1],[4]
Stated interest rate (in hundredths)	2.88%	[1],[4]	2.88%	[1],[4]
Maturity year	2020	[1],[4]
Spot rate	1.54	[1],[4]	1.54	[1],[4]
Notes Due 2021 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	1,247	[1]	1,247	[1]	0	[1]
Stated interest rate (in hundredths)	3.30%	[1]	3.30%	[1]
Maturity year	2021	[1]
Notes Due 2022 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	1,199	[1]	1,199	[1]	1,199	[1]
Stated interest rate (in hundredths)	3.10%	[1]	3.10%	[1]
Maturity year	2022	[1]
Notes Due 2024 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	1,995	[1]	1,995	[1]	0	[1]
Stated interest rate (in hundredths)	3.80%	[1]	3.80%	[1]
Maturity year	2024	[1]	2024
Notes Due 2025 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	462	[1],[4]	462	[1],[4]	0	[1],[4]
Stated interest rate (in hundredths)	3.60%	[1],[4]	3.60%	[1],[4]
Maturity year	2025	[1],[4]
Spot rate	1.54	[1],[4]	1.54	[1],[4]
Notes Due 2026 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	837	[1],[5]	837	[1],[5]	0	[1],[5]
Stated interest rate (in hundredths)	2.13%	[1],[5]	2.13%	[1],[5]
Maturity year	2026	[1],[5]
Spot rate	1.12	[1],[5]	1.12	[1],[5]
Notes Due 2034 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	497	[1]	497	[1]	0	[1]
Stated interest rate (in hundredths)	4.50%	[1]	4.50%	[1]
Maturity year	2034	[1]
Notes Due 2042 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	496	[1]	496	[1]	496	[1]
Stated interest rate (in hundredths)	4.40%	[1]	4.40%	[1]
Maturity year	2042	[1]
Notes Due 2044 [Member]
Long-Term Debt [Abstract]
Carrying value of notes, net of unamortized discount and interest rate swap FMV adjustment	$1,500	[1]	$1,500	[1]	$0	[1]
Stated interest rate (in hundredths)	4.80%	[1]	4.80%	[1]
Maturity year	2044	[1]	2044
[1]	All notes are presented net of unamortized discount, where applicable.
[2]	Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
[3]	Also includes interest rate swap fair market value adjustments, see Note 11, Fair Value Measurements for additional fair value disclosures.
[4]	Pound Sterling denominated notes are translated at the February 28, 2015 spot rate of $1.54 to one British Pound Sterling.
[5]	Euro denominated notes are translated at the February 28, 2015 spot rate of $1.12 to one Euro.

ShortTerm_Borrowings_and_LongT5

Short-Term Borrowings and Long-Term Debt, Debt Issuance (Details)

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

In Millions, unless otherwise specified

Notes Due 2015 [Member]

Notes Due 2017 One [Member]

Notes Due 2017 Two [Member]

Notes Due 2019 [Member]

Unsecured Pound Sterling Notes Due 2020 [Member]

Notes Due 2021 [Member]

Notes Due 2022 [Member]

Notes Due 2024 [Member]

Unsecured Pound Sterling Notes Due 2025 [Member]

Unsecured Euro Notes Due 2026 [Member]

Notes Due 2034 [Member]

Notes Due 2042 [Member]

Notes Due 2044 [Member]

Pound Sterling Notes [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

Unsecured Debt [Member]

GBP (£)

GBP (£)

EUR (€)

GBP (£)

USD ($)

USD ($)

Notes Due 2015 [Member]

Notes Due 2015 [Member]

Notes Due 2016 [Member]

Notes Due 2017 One [Member]

Notes Due 2017 One [Member]

Notes Due 2017 Two [Member]

Notes Due 2019 [Member]

Notes Due 2021 [Member]

Notes Due 2022 [Member]

Notes Due 2022 [Member]

Notes Due 2024 [Member]

Notes Due 2034 [Member]

Notes Due 2042 [Member]

Notes Due 2042 [Member]

Notes Due 2044 [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Debt Instrument [Line Items]

Face amount of notes issued

£ 400

£ 300

€ 750

£ 700

$8,000

$3,450

$750

$750

$1,000

$750

$1,250

$1,250

$1,200

$2,000

$500

$500

$1,500

Maturity date of note

20-Nov-20

20-Nov-25

20-Nov-26

13-Mar-15

18-May-16

15-Sep-17

17-Nov-17

18-Nov-19

18-Nov-21

15-Sep-22

18-Nov-24

18-Nov-34

15-Sep-42

18-Nov-44

Interest payment frequency

March 13 and September 13; commencing on March 13, 2013

February 18, May 18, August 18, and November 18; commencing on February 18, 2015

March 15 and September 15; commencing on March 15, 2013

May 17 and November 17; commencing on May 17, 2015

May 18 and November 18; commencing on May 18, 2015

May 18 and November 18; commencing on May 18, 2015

March 15 and September 15; commencing on March 15, 2013

May 18 and November 18; commencing on May 18, 2015

May 18 and November 18; commencing on May 18, 2015

March 15 and September 15; commencing on March 15, 2013

May 18 and November 18; commencing on May 18, 2015

Stated interest rate (in hundredths)

1.00%

1.80%

[1]

1.75%

[1]

2.70%

2.88%

3.30%

[1]

3.10%

[1]

3.80%

[1]

3.60%

2.13%

4.50%

[1]

4.40%

[1]

4.80%

[1]

[1]

All notes are presented net of unamortized discount, where applicable.

Financial_Instruments_Details

Financial Instruments (Details)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Aug. 31, 2014

Feb. 28, 2015

Aug. 31, 2014

Aug. 31, 2014

Feb. 28, 2015

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Notes [Member]

Interest Rate Cap [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Warrants [Member]

Foreign Currency Forwards [Member]

Foreign Currency Forwards [Member]

Foreign Currency Forwards [Member]

Foreign Currency Forwards [Member]

Other current assets [Member]

Other current assets [Member]

Other current assets [Member]

Other current assets [Member]

Other non-currents assets [Member]

Other non-currents assets [Member]

Other non-currents assets [Member]

Other non-currents assets [Member]

Other Noncurrent Liabilities [Member]

Other current liabilities [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

EUR (€)

Other income/(expenses) [Member]

Other income/(expenses) [Member]

Other income/(expenses) [Member]

Other income/(expenses) [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Interest Rate Swap [Member]

Interest Rate Cap [Member]

Foreign Currency Forwards [Member]

Cash Flow Hedging [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Warrants [Member]

Warrants [Member]

Cash Flow Hedging [Member]

Foreign Currency Forwards [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Other income/(expenses) [Member]

Other income/(expenses) [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Basis Swaps [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

USD ($)

USD ($)

Forward Interest Rate Swaps [Member]

Not Designated as Hedging Instrument [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Designated as Hedging Instrument [Member]

USD ($)

USD ($)

Derivatives, Fair Value [Line Items]

Derivatives aseets, Notional Amount

€ 2,000

$1,542

[1]

$3,879

[1]

$2,037

[1]

$71

[1]

$1,000

[1]

$1,000

$104

[1]

Derivative liability, Notional Amount

1,500

Derivatives assets, Fair Value

0

0

60

6

22

16

7

Derivative liability, fair value

44

Effect of Fair Value Hedges on Results of Operations [Abstract]

Gains and losses due to changes in fair value of derivative instruments

4

-6

-6

-17

-1

-1

-4

6

6

18

559

-64

849

156

-28

-28

-70

-166

Warrants [Abstract]

Derivative asset

2,231

553

Gains and losses due to changes in fair value of derivative instruments

$4

($6)

($6)

($17)

($1)

($1)

($4)

$6

$6

$18

$559

($64)

$849

$156

($28)

($28)

($70)

($166)

[1]

Amounts in U.S. dollar equivalents, where appropriate.

Financial_Instruments_Textual_

Financial Instruments, Textual Information (Details)

Feb. 28, 2015

Jan. 31, 2015

Aug. 31, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Aug. 31, 2014

Feb. 28, 2015

Feb. 28, 2015

Aug. 31, 2014

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Jan. 31, 2015

In Millions, except Share data, unless otherwise specified

USD ($)

GBP (£)

USD ($)

Warrants Exercisable in March 2016 [Member]

Warrants Exercisable in March 2017 [Member]

Alliance Boots [Member]

Notes Due 2024 [Member]

Notes Due 2024 [Member]

Notes Due 2024 [Member]

Notes Due 2044 [Member]

Notes Due 2044 [Member]

Notes Due 2044 [Member]

Three-month LIBOR [Member]

Three-month LIBOR [Member]

Three-month LIBOR [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Cap [Member]

Interest Rate Cap [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Contract One [Member]

Contract Two [Member]

one-month LIBOR [Member]

six-month LIBOR [Member]

EUR (€)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

Derivative [Line Items]

Derivative instrument fair value hedge

$250

$750

Fixed interest rate percentage (in hundredths)

5.25%

5.25%

Cumulative fair value adjustments resulted in increase in long-term debt

18

12

Debt instrument, maturity period

10 years

30 years

Debt issuance

1,995

[1]

1,995

[1]

0

[1]

1,500

[1]

1,500

[1]

0

[1]

Maturity year

2024

[1]

2024

2044

[1]

2044

Cash paid to settle swap

45

18

Outstanding debt

16,003

[1]

3,744

[1]

9,000

Value of Interest rate swap terminated

1,000

Derivative maturity date

31-Jul-15

Derivative notional principal amount

1,500

2,000

Derivative notional amount terminated

€ 600

Class of Warrant or Right [Line Items]

Warrant issued to purchase common stock (in share)

22,696,912

22,696,912

Warrant exercise price (in dollars per share)

$51.50

$52.50

[1]

All notes are presented net of unamortized discount, where applicable.

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Recurring [Member], USD $)	Feb. 28, 2015		Aug. 31, 2014
In Millions, unless otherwise specified
Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	$206	[1]
Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	1,881	[2]	1,879	[2]
Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	1,255	[3]	887	[3]
Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	22	[4]	16	[4]
Basis Swap [Member]
Assets [Abstract]
Fair value of assets	6
Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	60	[5]
Liabilities [Abstract]
Fair value of liabilities	7	[5]
Warrants [Member]
Assets [Abstract]
Fair value of assets	2,231	[6]	553	[5]
Forward Interest Rate Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities			44	[7]
Level 1 [Member] | Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	206	[1]
Level 1 [Member] | Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	1,881	[2]	1,879	[2]
Level 1 [Member] | Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	1,255	[3]	887	[3]
Level 1 [Member] | Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	0	[4]	0	[4]
Level 1 [Member] | Basis Swap [Member]
Assets [Abstract]
Fair value of assets	0
Level 1 [Member] | Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	0	[5]
Liabilities [Abstract]
Fair value of liabilities	0	[5]
Level 1 [Member] | Warrants [Member]
Assets [Abstract]
Fair value of assets	0	[6]	0	[5]
Level 1 [Member] | Forward Interest Rate Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities			0	[7]
Level 2 [Member] | Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	0	[1]
Level 2 [Member] | Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	0	[2]	0	[2]
Level 2 [Member] | Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	0	[3]	0	[3]
Level 2 [Member] | Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	22	[4]	16	[4]
Level 2 [Member] | Basis Swap [Member]
Assets [Abstract]
Fair value of assets	6
Level 2 [Member] | Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	60	[5]
Liabilities [Abstract]
Fair value of liabilities	7	[5]
Level 2 [Member] | Warrants [Member]
Assets [Abstract]
Fair value of assets	2,231	[6]	553	[5]
Level 2 [Member] | Forward Interest Rate Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities			44	[7]
Level 3 [Member] | Restricted Cash [Member]
Assets [Abstract]
Fair value of assets	0	[1]
Level 3 [Member] | Money Market Funds [Member]
Assets [Abstract]
Fair value of assets	0	[2]	0	[2]
Level 3 [Member] | Available-for-sale Investments [Member]
Assets [Abstract]
Fair value of assets	0	[3]	0	[3]
Level 3 [Member] | Interest Rate Swaps [Member]
Assets [Abstract]
Fair value of assets	0	[4]	0	[4]
Level 3 [Member] | Basis Swap [Member]
Assets [Abstract]
Fair value of assets	0
Level 3 [Member] | Foreign Currency Forwards [Member]
Assets [Abstract]
Fair value of assets	0	[5]
Liabilities [Abstract]
Fair value of liabilities	0	[5]
Level 3 [Member] | Warrants [Member]
Assets [Abstract]
Fair value of assets	0	[6]	0	[5]
Level 3 [Member] | Forward Interest Rate Swaps [Member]
Liabilities [Abstract]
Fair value of liabilities			$0	[7]
[1]	Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
[2]	Money market funds are valued at the closing price reported by the fund sponsor.
[3]	Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional disclosures.
[4]	The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional disclosures.
[5]	The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
[6]	Warrants were valued using a Monte Carlo simulation. Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen's common stock; AmerisourceBergen's common stock price at the valuation date; AmerisourceBergen's equity volatility; the number of shares of AmerisourceBergen's common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.
[7]	Forward interest rate swaps were valued using three-month LIBOR rates. See Note 10, Financial Instruments for additional disclosures.

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015
	Store
DEA Settlement [Member]
Loss Contingencies [Line Items]
Reserve for litigation settlements	$80
Number of DEA pharmacy registrations surrendered	6
Derivative Settlement [Member]
Loss Contingencies [Line Items]
Reserve for litigation settlements	$3.50

Stock_Compensation_Plans_Detai

Stock Compensation Plans (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense for the period			$65	$52
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value for options exercised	153		226
Fair value of options vested	1		51
Cash received from the exercise of options	132		226
Tax benefit from exercise of stock options	58		85
Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares authorized under Omnibus Plan (in shares)			60,400,000
Omnibus Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted in period (in shares)	15,458	149,684	4,117,968	6,534,762
Total stock based compensation expense for the period	34	31	65	52
Fully recognized retiree eligible expense	3	5	2	8
Grant date fair value (in dollars per share)			$14.64
Weighted average volatility rate (in hundredths)			25.51%
Weighted average dividend yield (in hundredths)			1.79%
Expected term			6 years 8 months 5 days
Omnibus Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted in period (in shares)	227,220	30,122	1,132,171	641,009
Restricted stock dividend (in shares)	16,886	19,159	37,421	40,457
Total stock based compensation expense for the period	$28	$16	$47	$26
Vesting period			3 years
Grant date fair value (in dollars per share)			$74.61
Omnibus Plan [Member] | Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted in period (in shares)	3,688	5,807	484,011	702,939
Vesting period			3 years
Grant date fair value restricted and performance shares (in dollars per share)			$66.82

Retirement_Benefits_Details

Retirement Benefits (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit pension plans			3
Employer cash contributions to defined benefit pension plans			$85
Employee expected additional contribution in current fiscal year			65
Walgreen Profit Sharing Retirement Trust [Member]
Defined Contribution Plan Disclosure [Line Items]
Profit sharing provision (benefit) expense	21	85	54	165
Alliance Boots Retirement Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Cost recognized in the consolidated condensed statements of earnings			22
Boots Pension Plan [Member]
Components of net periodic benefit costs [Abstract]
Service cost	0		0
Interest cost	52		52
Expected return on plan assets	-43		-43
Settlements	0		0
Total postretirement benefit cost	9		9
Other Pension Plan [Member]
Components of net periodic benefit costs [Abstract]
Service cost	1		1
Interest cost	1		1
Expected return on plan assets	0		0
Settlements	1		1
Total postretirement benefit cost	3		3
Postretirement Health Benefit Plan[Member]
Components of net periodic benefit costs [Abstract]
Service cost	2	2	5	4
Interest cost	4	4	8	8
Amortization of actuarial loss	5	3	10	6
Amortization of prior service cost	-6	-6	-12	-11
Total postretirement benefit cost	$5	$3	$11	$7

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended		6 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Earnings Per Share [Abstract]
Antidilutive securities excluded from EPS calculations (in shares)	3,437,516	6,347,469	4,957,390	4,343,079

Depreciation_and_Amortization_1

Depreciation and Amortization (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Dec. 31, 2014
Depreciation and Amortization [Abstract]
Depreciation expense	$311	$258	$567	$520
Intangible asset and other amortization	196	73	259	143
Total depreciation and amortization expense	507	331	826	663
Business Acquisition [Line Items]
Ownership percentage (in hundredths)	45.00%		45.00%
Depreciation and amortization expense included in inventory step-up amortization	106		106
Alliance Boots [Member]
Business Acquisition [Line Items]
Remaining ownership percentage (in hundredths)					55.00%
Ownership percentage (in hundredths)	100.00%	45.00%	100.00%	45.00%	45.00%
Depreciation and amortization expense included in inventory step-up amortization	$106		$106

Supplemental_Cash_Flow_Disclos1

Supplemental Cash Flow Disclosures (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Aug. 31, 2014
Supplemental Cash Flow Disclosures [Abstract]
Non-cash transactions for debt assumed	$9,000
Non-cash transaction for common stock issued in relation to the second step transaction	11,000
Business Acquisition [Line Items]
Consideration received	212		104
Purchase consideration transferred	8,300
Ownership percentage (in hundredths)	45.00%
Fair value of assets acquired	25,800
Liabilities assumed	19,800
Capital lease obligations	282
Cash paid for interest	90	67
Cash paid for income taxes	553	674
Walgreens Boots Alliance Development GmbH [Member]
Business Acquisition [Line Items]
Consideration received	$2,600

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$54	$128	$136	($92)
Other comprehensive income (loss) before reclassification adjustments	-313	96	-436	387
Amounts reclassified from accumulated OCI	309		309
Tax benefit (provision)	-118	-50	-77	-121
Net other comprehensive income (loss)	-122	46	-204	266
Balance	-68	174	-68	174
Post-retirement Liability [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	14	71	15	63
Other comprehensive income (loss) before reclassification adjustments	-8	-3	-10	9
Amounts reclassified from accumulated OCI	0		0
Tax benefit (provision)	0	1	1	-3
Net other comprehensive income (loss)	-8	-2	-9	6
Balance	6	69	6	69
Unrecognized Gains on Available-for-Sale Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	206	85	107	1
Other comprehensive income (loss) before reclassification adjustments	140	-27	297	57
Amounts reclassified from accumulated OCI	0		0
Tax benefit (provision)	-50	-22	-108	-22
Net other comprehensive income (loss)	90	-49	189	35
Balance	296	36	296	36
Unrealized Loss on Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	-39	0	-27	0
Other comprehensive income (loss) before reclassification adjustments	2	0	-18	0
Amounts reclassified from accumulated OCI	-1		-1
Tax benefit (provision)	-1	0	7	0
Net other comprehensive income (loss)	0	0	-12	0
Balance	-39	0	-39	0
Share of Alliance Boots OCI [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	-92	-132	-113	-95
Other comprehensive income (loss) before reclassification adjustments	-89	-30	-57	-86
Amounts reclassified from accumulated OCI	230		230
Tax benefit (provision)	-49	11	-60	30
Net other comprehensive income (loss)	92	-19	113	-56
Balance	0	-151	0	-151
Cumulative Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	-35	104	154	-61
Other comprehensive income (loss) before reclassification adjustments	-358	156	-648	407
Amounts reclassified from accumulated OCI	80		80
Tax benefit (provision)	-18	-40	83	-126
Net other comprehensive income (loss)	-296	116	-485	281
Balance	($331)	$220	($331)	$220

Segment_Reporting_Details

Segment Reporting (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	Aug. 31, 2014
				Segment
Segment Reporting [Abstract]
Number of reportable segments				3
Equity interest in Alliance Boots (in hundredths)		45.00%		45.00%
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		$26,573	$19,605	$46,127	$37,934
Cost of sales		19,691	13,955	33,949	27,132
Gross Profit		6,882	5,650	12,178	10,802
Selling, general and administrative expenses		5,606	4,569	10,062	8,948
Equity earnings in Alliance Boots		101	136	315	330
Operating Income (loss)		1,377	1,217	2,431	2,184
Total assets		71,357		71,357		37,270
Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]
Operating Income		1,377	1,217	2,431	2,184
Gain on previously held equity interest	706	706	0	706	0
Other (expense) income		504	-59	703	166
Earnings (loss) before Interest and Tax Provision		2,587	1,158	3,840	2,350
Retail Pharmacy USA [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		21,048	19,605	40,602	37,934
Retail Pharmacy International [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		2,047	0	2,047	0
Pharmaceutical Wholesale [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		3,865	0	3,865	0
Eliminations and Unallocated Items [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		-387	0	-387	0
Reportable Segments [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		26,573	19,605	46,127	37,934
Cost of sales		19,691	13,995	33,949	27,132
Gross Profit		6,882	5,650	12,178	10,802
Selling, general and administrative expenses		5,606	4,569	10,062	8,948
Equity earnings in Alliance Boots		101	136	315	330
Operating Income (loss)		1,377	1,217	2,431	2,184
Total assets		71,357		71,357		37,270
Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]
Operating Income		1,377	1,217	2,431	2,184
Gain on previously held equity interest		706	0	706	0
Other (expense) income		504	-59	703	166
Earnings (loss) before Interest and Tax Provision		2,587	1,158	3,840	2,350
Reportable Segments [Member] | Retail Pharmacy USA [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		21,048	19,605	40,602	37,934
Cost of sales		15,302	13,955	29,560	27,132
Gross Profit		5,746	5,650	11,042	10,802
Selling, general and administrative expenses		4,555	4,569	9,011	8,948
Equity earnings in Alliance Boots		101	136	315	330
Operating Income (loss)		1,292	1,217	2,346	2,184
Total assets		77,466		77,466		44,275
Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]
Operating Income		1,292	1,217	2,346	2,184
Reportable Segments [Member] | Retail Pharmacy International [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		2,017	0	2,017	0
Cost of sales		1,294	0	1,294	0
Gross Profit		753	0	753	0
Selling, general and administrative expenses		745	0	745	0
Equity earnings in Alliance Boots		0	0	0	0
Operating Income (loss)		8	0	8	0
Total assets		22,131		22,131		0
Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]
Operating Income		8	0	8	0
Reportable Segments [Member] | Pharmaceutical Wholesale [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		3,508	0	3,508	0
Cost of sales		3,478	0	3,478	0
Gross Profit		387	0	387	0
Selling, general and administrative expenses		306	0	306	0
Equity earnings in Alliance Boots		0	0	0	0
Operating Income (loss)		81	0	81	0
Total assets		13,706		13,706		0
Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]
Operating Income		81	0	81	0
Reportable Segments [Member] | Eliminations and Unallocated Items [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		0	0	0	0
Cost of sales		-383	0	-383	0
Gross Profit		-4	0	-4	0
Selling, general and administrative expenses		0	0	0	0
Equity earnings in Alliance Boots		0	0	0	0
Operating Income (loss)		-4	0	-4	0
Total assets		-41,946		-41,946		-7,005
Segment Reporting Information, Income (Loss) before Income Taxes [Abstract]
Operating Income		-4	0	-4	0
Intersegment Eliminations [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		0	0	0	0
Intersegment Eliminations [Member] | Retail Pharmacy USA [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		0	0	0	0
Intersegment Eliminations [Member] | Retail Pharmacy International [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		30	0	30	0
Intersegment Eliminations [Member] | Pharmaceutical Wholesale [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		357	0	357	0
Intersegment Eliminations [Member] | Eliminations and Unallocated Items [Member]
Segment Reporting Information, Operating Income (Loss) [Abstract]
Sales		($387)	$0	($387)	$0

Supplemental_Guarantor_Condens2

Supplemental Guarantor Condensed Consolidating Financial Information (Details)

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

Feb. 28, 2015

In Millions, unless otherwise specified

Notes Due 2019 [Member]

Notes Due 2021 [Member]

Notes Due 2024 [Member]

Notes Due 2034 [Member]

Notes Due 2044 [Member]

Notes Due 2026 [Member]

Notes Due 2020 [Member]

Notes Due 2025 [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

Walgreens Boots Alliance [Member]

USD ($)

GBP (£)

Notes Due 2016 [Member]

Notes Due 2017 [Member]

Notes Due 2019 [Member]

Notes Due 2021 [Member]

Notes Due 2024 [Member]

Notes Due 2034 [Member]

Notes Due 2044 [Member]

Notes Due 2026 [Member]

Notes Due 2020 [Member]

Notes Due 2025 [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

GBP (£)

GBP (£)

Debt Instrument [Line Items]

Increased ownership percentage of Alliance Boots (in hundredths)

100.00%

100.00%

Maximum aggregate outstanding amount of indebtedness

$2,000

Face amount of notes issued

$36,739

£ 700

$750

$750

$1,250

$1,250

$2,000

$500

$1,500

€ 750

£ 400

£ 300

Maturity date of note

18-May-16

17-Nov-17

18-Nov-19

18-Nov-21

18-Nov-24

18-Nov-34

18-Nov-44

20-Nov-26

20-Nov-20

20-Nov-25

Basis spread on variable rate (in hundredths)

0.05%

Debt instrument, description of variable rate basis

three-month U.S. dollar LIBOR, reset quarterly

Stated interest rate (in hundredths)

2.70%

3.30%

[1]

3.80%

[1]

4.50%

[1]

4.80%

[1]

2.13%

[1],[2]

2.88%

[1],[3]

3.60%

[1],[3]

1.75%

2.70%

3.30%

3.80%

4.50%

4.80%

2.13%

2.88%

3.60%

[1]

All notes are presented net of unamortized discount, where applicable.

[2]

Euro denominated notes are translated at the February 28, 2015 spot rate of $1.12 to one Euro.

[3]

Pound Sterling denominated notes are translated at the February 28, 2015 spot rate of $1.54 to one British Pound Sterling.

Supplemental_Guarantor_Condens3

Supplemental Guarantor Condensed Consolidating Financial Information, Statements of Earnings (Details) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Consolidated Condensed Statements of Earnings [Abstract]
Net sales		$26,573	$19,605	$46,127	$37,934
Cost of sales		19,691	13,955	33,949	27,132
Gross Profit		6,882	5,650	12,178	10,802
Selling, general and administrative expenses		5,606	4,569	10,062	8,948
Equity earnings in Alliance Boots		101	136	315	330
Operating Income (loss)		1,377	1,217	2,431	2,184
Gain on previously held equity interest	706	706	0	706	0
Other income (expense)		504	-59	703	166
Earnings (loss) before Interest and Tax Provision		2,587	1,158	3,840	2,350
Interest expense, net		144	37	199	78
Earnings (loss) Before Income Tax Provision		2,443	1,121	3,641	2,272
Income tax provision		391	391	712	810
Post tax earnings from equity method investments		8	0	8	0
Equity in income of subsidiaries		0	0	0	0
Net Earnings (loss)		2,060	730	2,937	1,462
Net earnings attributable to noncontrolling interests		18	14	45	23
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		2,042	716	2,892	1,439
Guarantor/Issuer Subsidiary [Member]
Consolidated Condensed Statements of Earnings [Abstract]
Net sales		14,379	13,364	27,702	25,872
Cost of sales		9,949	9,027	19,160	17,599
Gross Profit		4,430	4,336	8,542	8,273
Selling, general and administrative expenses		4,596	4,095	8,608	7,753
Equity earnings in Alliance Boots		0	0	0	0
Operating Income (loss)		-166	242	-66	520
Gain on previously held equity interest		0	0	0	0
Other income (expense)		-69	0	-166	0
Earnings (loss) before Interest and Tax Provision		-235	242	-232	520
Interest expense, net		106	45	153	90
Earnings (loss) Before Income Tax Provision		-341	197	-385	430
Income tax provision		-171	69	-190	163
Post tax earnings from equity method investments		0		0
Equity in income of subsidiaries		2,222	602	3,133	1,195
Net Earnings (loss)		2,052	730	2,938	1,462
Net earnings attributable to noncontrolling interests		0	0	0	0
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		2,052	730	2,938	1,462
Non-guarantor Subsidiaries [Member]
Consolidated Condensed Statements of Earnings [Abstract]
Net sales		12,545	6,363	19,168	12,278
Cost of sales		10,033	4,985	15,416	9,632
Gross Profit		2,512	1,378	3,752	2,646
Selling, general and administrative expenses		1,117	539	1,617	1,312
Equity earnings in Alliance Boots		101	136	315	330
Operating Income (loss)		1,496	975	2,450	1,664
Gain on previously held equity interest		706	0	706	0
Other income (expense)		575	-59	871	166
Earnings (loss) before Interest and Tax Provision		2,777	916	4,027	1,830
Interest expense, net		6	-8	0	-12
Earnings (loss) Before Income Tax Provision		2,771	924	4,027	1,842
Income tax provision		557	322	902	647
Post tax earnings from equity method investments		8		8
Equity in income of subsidiaries		0	0	0	0
Net Earnings (loss)		2,222	602	3,133	1,195
Net earnings attributable to noncontrolling interests		18	14	45	23
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		2,204	588	3,088	1,172
Parent Company [Member]
Consolidated Condensed Statements of Earnings [Abstract]
Net sales		0	0	0	0
Cost of sales		0	0	0	0
Gross Profit		0	0	0	0
Selling, general and administrative expenses		-47	0	-47	0
Equity earnings in Alliance Boots		0	0	0	0
Operating Income (loss)		47	0	47	0
Gain on previously held equity interest		0	0	0	0
Other income (expense)		-2	0	-2	0
Earnings (loss) before Interest and Tax Provision		45	0	45	0
Interest expense, net		32	0	46	0
Earnings (loss) Before Income Tax Provision		13	0	-1	0
Income tax provision		5	0	0	0
Post tax earnings from equity method investments		0		0
Equity in income of subsidiaries		2,052	0	2,938	0
Net Earnings (loss)		2,060	0	2,937	0
Net earnings attributable to noncontrolling interests		0	0	0	0
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		2,060	0	2,937	0
Consolidating Adjustments [Member]
Consolidated Condensed Statements of Earnings [Abstract]
Net sales		-351	-122	-743	-216
Cost of sales		-291	-57	-627	-99
Gross Profit		-60	-65	-116	-117
Selling, general and administrative expenses		-60	-65	-116	-117
Equity earnings in Alliance Boots		0	0	0	0
Operating Income (loss)		0	0	0	0
Gain on previously held equity interest		0	0	0	0
Other income (expense)		0	0	0	0
Earnings (loss) before Interest and Tax Provision		0	0	0	0
Interest expense, net		0	0	0	0
Earnings (loss) Before Income Tax Provision		0	0	0	0
Income tax provision		0	0	0	0
Post tax earnings from equity method investments		0		0
Equity in income of subsidiaries		-4,274	-602	-6,071	-1,195
Net Earnings (loss)		-4,274	-602	-6,071	-1,195
Net earnings attributable to noncontrolling interests		0	0	0	0
Net Earnings (loss) Attributable to Walgreens Boots Alliance, Inc.		($4,274)	($602)	($6,071)	($1,195)

Supplemental_Guarantor_Condens4

Supplemental Guarantor Condensed Consolidating Financial Information, Statements of Comprehensive Income (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Statement of Comprehensive Income [Abstract]
Net Earnings (loss)	$2,060	$730	$2,937	$1,462
Other comprehensive income (loss), net of tax:
Postretirement liability	-8	-2	-9	6
Unrealized gain (loss) on cash flow hedges	0	0	-12	0
Changes in unrecognized gain (loss) on available-for-sale investments	90	-49	189	35
Share of other comprehensive income (loss) of Alliance Boots	92	-19	113	-56
Currency translation adjustments	-301	116	-490	281
Other Comprehensive Income (loss) of subsidiaries	0	0	0	0
Total Other Comprehensive Income (loss)	-127	46	-209	266
Total Comprehensive Income (loss)	1,933	776	2,728	1,728
Comprehensive income attributable to noncontrolling interests	13	14	40	23
Comprehensive income attributable to Walgreens Boots Alliance, Inc.	1,920	762	2,688	1,705
Guarantor/Issuer Subsidiary [Member]
Statement of Comprehensive Income [Abstract]
Net Earnings (loss)	2,052	730	2,938	1,462
Other comprehensive income (loss), net of tax:
Postretirement liability	-1	-2	-2	6
Unrealized gain (loss) on cash flow hedges	0	0	27	0
Changes in unrecognized gain (loss) on available-for-sale investments	0	0	0	0
Share of other comprehensive income (loss) of Alliance Boots	0	0	0	0
Currency translation adjustments	0	0	0	0
Other Comprehensive Income (loss) of subsidiaries	-127	48	-196	260
Total Other Comprehensive Income (loss)	-128	46	-171	266
Total Comprehensive Income (loss)	1,924	776	2,767	1,728
Comprehensive income attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Walgreens Boots Alliance, Inc.	1,924	776	2,767	1,728
Non-guarantor Subsidiaries [Member]
Statement of Comprehensive Income [Abstract]
Net Earnings (loss)	2,222	602	3,133	1,195
Other comprehensive income (loss), net of tax:
Postretirement liability	-7	0	-7	0
Unrealized gain (loss) on cash flow hedges	-1	0	-1	0
Changes in unrecognized gain (loss) on available-for-sale investments	90	-49	189	35
Share of other comprehensive income (loss) of Alliance Boots	92	-19	113	-56
Currency translation adjustments	-301	116	-490	281
Other Comprehensive Income (loss) of subsidiaries	0	0	0	0
Total Other Comprehensive Income (loss)	-127	48	-196	260
Total Comprehensive Income (loss)	2,095	650	2,937	1,455
Comprehensive income attributable to noncontrolling interests	13	14	40	23
Comprehensive income attributable to Walgreens Boots Alliance, Inc.	2,082	636	2,897	1,432
Parent Company [Member]
Statement of Comprehensive Income [Abstract]
Net Earnings (loss)	2,060	0	2,937	0
Other comprehensive income (loss), net of tax:
Postretirement liability	0	0	0	0
Unrealized gain (loss) on cash flow hedges	1	0	-38	0
Changes in unrecognized gain (loss) on available-for-sale investments	0	0	0	0
Share of other comprehensive income (loss) of Alliance Boots	0	0	0	0
Currency translation adjustments	0	0	0	0
Other Comprehensive Income (loss) of subsidiaries	-128	0	-171	0
Total Other Comprehensive Income (loss)	-127	0	-209	0
Total Comprehensive Income (loss)	1,933	0	2,728	0
Comprehensive income attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Walgreens Boots Alliance, Inc.	1,933	0	2,728	0
Consolidating Adjustments [Member]
Statement of Comprehensive Income [Abstract]
Net Earnings (loss)	-4,274	-602	-6,071	-1,195
Other comprehensive income (loss), net of tax:
Postretirement liability	0	0	0	0
Unrealized gain (loss) on cash flow hedges	0	0	0	0
Changes in unrecognized gain (loss) on available-for-sale investments	0	0	0	0
Share of other comprehensive income (loss) of Alliance Boots	0	0	0	0
Currency translation adjustments	0	0	0	0
Other Comprehensive Income (loss) of subsidiaries	255	-48	367	-260
Total Other Comprehensive Income (loss)	255	-48	367	-260
Total Comprehensive Income (loss)	-4,019	-650	-5,704	-1,455
Comprehensive income attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Walgreens Boots Alliance, Inc.	($4,019)	($650)	($5,704)	($1,455)

Supplemental_Guarantor_Condens5

Supplemental Guarantor Condensed Consolidating Financial Information, Balance Sheets (Unaudited) (Details) (USD $)	Feb. 28, 2015		Aug. 31, 2014		Feb. 28, 2014	Aug. 31, 2013
In Millions, unless otherwise specified
Current Assets:
Cash and cash equivalents	$3,005		$2,646		$1,777	$2,106
Accounts receivable, net	7,017		3,218
Inventories	9,379		6,076
Current intercompany loan receivable	0		0
Other current assets	1,314		302
Total Current Assets	20,715		12,242
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization	15,646		12,257
Equity investment in Alliance Boots	0		7,336
Goodwill	17,044		2,359
Intangible assets	12,225		1,180
Other non-current assets	5,727		1,896
Non-current intercompany loan receivable	0		0
Investment in subsidiaries	0		0
Total Non-Current Assets	50,642		25,028
Total Assets	71,357		37,270
Current Liabilities:
Short-term borrowings	1,061		774
Trade accounts payable	10,293		4,315
Current intercompany loan payable	0		0
Accrued expenses and other liabilities	5,140		3,701
Income taxes	196		105
Total Current Liabilities	16,690		8,895
Non-Current Liabilities:
Long-term debt	16,001	[1]	3,736	[1]
Deferred income taxes	3,689		1,080
Non-current intercompany loan payable	0		0
Other non-current liabilities	3,951		2,942
Total Non-Current Liabilities	23,641		7,758
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity	30,814		20,513
Noncontrolling interests	212		104
Total Equity	31,026		20,617
Total Liabilities and Equity	71,357		37,270
Guarantor/Issuer Subsidiary [Member]
Current Assets:
Cash and cash equivalents	1,840		2,224		1,449	1,771
Accounts receivable, net	2,027		1,860
Inventories	4,396		4,301
Current intercompany loan receivable	12,930		6,755
Other current assets	533		176
Total Current Assets	21,726		15,316
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization	6,500		6,932
Equity investment in Alliance Boots	0		0
Goodwill	8,382		343
Intangible assets	286		417
Other non-current assets	162		252
Non-current intercompany loan receivable	0		0
Investment in subsidiaries	32,379		23,250
Total Non-Current Assets	47,709		31,194
Total Assets	69,435		46,510
Current Liabilities:
Short-term borrowings	757		766
Trade accounts payable	4,355		3,850
Current intercompany loan payable	12,258		8,277
Accrued expenses and other liabilities	2,508		3,044
Income taxes	0		0
Total Current Liabilities	19,878		15,937
Non-Current Liabilities:
Long-term debt	3,737		3,726
Deferred income taxes	283		404
Non-current intercompany loan payable	15,983		3,560
Other non-current liabilities	2,515		2,370
Total Non-Current Liabilities	22,518		10,060
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity	27,039		20,513
Noncontrolling interests	0		0
Total Equity	27,039		20,513
Total Liabilities and Equity	69,435		46,510
Non-guarantor Subsidiaries [Member]
Current Assets:
Cash and cash equivalents	1,165		422		328	335
Accounts receivable, net	4,990		1,358
Inventories	4,983		1,755
Current intercompany loan receivable	26,428		8,277
Other current assets	1,005		141
Total Current Assets	38,571		11,973
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization	9,146		5,325
Equity investment in Alliance Boots	0		7,336
Goodwill	8,662		2,016
Intangible assets	11,939		763
Other non-current assets	5,561		1,644
Non-current intercompany loan receivable	3,725		3,560
Investment in subsidiaries	0		0
Total Non-Current Assets	39,033		20,644
Total Assets	77,604		32,617
Current Liabilities:
Short-term borrowings	304		8
Trade accounts payable	5,938		465
Current intercompany loan payable	24,604		6,755
Accrued expenses and other liabilities	2,153		657
Income taxes	225		120
Total Current Liabilities	33,224		8,005
Non-Current Liabilities:
Long-term debt	128		10
Deferred income taxes	3,406		676
Non-current intercompany loan payable	6,855		0
Other non-current liabilities	1,400		572
Total Non-Current Liabilities	11,789		1,258
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity	32,379		23,250
Noncontrolling interests	212		104
Total Equity	32,591		23,354
Total Liabilities and Equity	77,604		32,617
Parent Company [Member]
Current Assets:
Cash and cash equivalents	0		0		0	0
Accounts receivable, net	0		0
Inventories	0		0
Current intercompany loan receivable	20,720		0
Other current assets	11		0
Total Current Assets	20,731		0
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization	0		0
Equity investment in Alliance Boots	0		0
Goodwill	0		0
Intangible assets	0		0
Other non-current assets	4		0
Non-current intercompany loan receivable	19,113		0
Investment in subsidiaries	27,039		0
Total Non-Current Assets	46,156		0
Total Assets	66,887		0
Current Liabilities:
Short-term borrowings	0		0
Trade accounts payable	0		0
Current intercompany loan payable	23,216		0
Accrued expenses and other liabilities	479		0
Income taxes	206		0
Total Current Liabilities	23,901		0
Non-Current Liabilities:
Long-term debt	12,136		0
Deferred income taxes	0		0
Non-current intercompany loan payable	0		0
Other non-current liabilities	36		0
Total Non-Current Liabilities	12,172		0
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity	30,814		0
Noncontrolling interests	0		0
Total Equity	30,814		0
Total Liabilities and Equity	66,887		0
Consolidating Adjustments [Member]
Current Assets:
Cash and cash equivalents	0		0		0	0
Accounts receivable, net	0		0
Inventories	0		0
Current intercompany loan receivable	-60,078		-15,032
Other current assets	-235		-15
Total Current Assets	-60,313		-15,047
Non-Current Assets:
Property, plant and equipment, at cost, less accumulated depreciation and amortization	0		0
Equity investment in Alliance Boots	0		0
Goodwill	0		0
Intangible assets	0		0
Other non-current assets	0		0
Non-current intercompany loan receivable	-22,838		-3,560
Investment in subsidiaries	-59,418		-23,250
Total Non-Current Assets	-82,256		-26,810
Total Assets	-142,569		-41,857
Current Liabilities:
Short-term borrowings	0		0
Trade accounts payable	0		0
Current intercompany loan payable	-60,078		-15,032
Accrued expenses and other liabilities	0		0
Income taxes	-235		-15
Total Current Liabilities	-60,313		-15,047
Non-Current Liabilities:
Long-term debt	0		0
Deferred income taxes	0		0
Non-current intercompany loan payable	-22,838		-3,560
Other non-current liabilities	0		0
Total Non-Current Liabilities	-22,838		-3,560
Equity:
Total Walgreens Boots Alliance, Inc. Shareholders' Equity	-59,418		-23,250
Noncontrolling interests	0		0
Total Equity	-59,418		-23,250
Total Liabilities and Equity	($142,569)		($41,857)
[1]	All notes are presented net of unamortized discount, where applicable.

Supplemental_Guarantor_Condens6

Supplemental Guarantor Condensed Consolidating Financial Information, Statements of Cash Flows (Unaudited) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014
Net cash provided by operating activities [Abstract]
Net cash provided by operating activities	$2,337	$1,237
Cash Flows from Investing Activities
Additions to property, plant and equipment	-643	-591
Proceeds from sale of assets	579	209
Return of restricted cash	74	0
Proceeds from sale of business		0
Alliance Boots acquisition, net of cash received	-4,461	0
Other business and intangible asset acquisitions, net of cash received	-92	-297
Purchases of short-term investments held to maturity	-29	-34
Proceeds from short-term investments held to maturity	29	34
Investment in AmerisourceBergen	0	-430
Other	-165	-59
Net cash used for investing activities	-4,708	-1,168
Cash Flows from Financing Activities
Payments of short-term borrowings	-330	0
Proceeds from issuance of long-term debt	12,279	0
Payments of long-term debt	-7,817
Stock purchases	-594	-205
Proceeds related to employee stock plans	293	416
Cash dividends paid	-642	-597
Intra-company financing activities, net	0
Other	-360	-12
Net cash (used for) provided by financing activities	2,829	-398
Effect of exchange rate changes on cash and cash equivalents	-99	0
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents	359	-329
Cash and cash equivalents at beginning of period	2,646	2,106
Cash and cash equivalents at end of period	3,005	1,777
Guarantor/Issuer Subsidiary [Member]
Net cash provided by operating activities [Abstract]
Net cash provided by operating activities	1,011	471
Cash Flows from Investing Activities
Additions to property, plant and equipment	-302	-342
Proceeds from sale of assets	121	201
Return of restricted cash	0
Alliance Boots acquisition, net of cash received	0
Other business and intangible asset acquisitions, net of cash received	-27	-254
Purchases of short-term investments held to maturity	0	0
Proceeds from short-term investments held to maturity	0	0
Investment in AmerisourceBergen	0	0
Other	-165	0
Net cash used for investing activities	-373	-395
Cash Flows from Financing Activities
Payments of short-term borrowings	0
Proceeds from issuance of long-term debt	0
Payments of long-term debt	0
Stock purchases	-500	-205
Proceeds related to employee stock plans	154	416
Cash dividends paid	-642	-597
Intra-company financing activities, net	-36
Other	2	-12
Net cash (used for) provided by financing activities	-1,022	-398
Effect of exchange rate changes on cash and cash equivalents	0
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents	-384	-322
Cash and cash equivalents at beginning of period	2,224	1,771
Cash and cash equivalents at end of period	1,840	1,449
Non-guarantor Subsidiaries [Member]
Net cash provided by operating activities [Abstract]
Net cash provided by operating activities	1,254	766
Cash Flows from Investing Activities
Additions to property, plant and equipment	-341	-301
Proceeds from sale of assets	458	60
Return of restricted cash	74
Alliance Boots acquisition, net of cash received	0
Other business and intangible asset acquisitions, net of cash received	-65	-43
Purchases of short-term investments held to maturity	-29	-34
Proceeds from short-term investments held to maturity	29	34
Investment in AmerisourceBergen	0	-430
Other	0	-59
Net cash used for investing activities	126	-773
Cash Flows from Financing Activities
Payments of short-term borrowings	-324
Proceeds from issuance of long-term debt	0
Payments of long-term debt	-7,817
Stock purchases	0	0
Proceeds related to employee stock plans	0	0
Cash dividends paid	0	0
Intra-company financing activities, net	7,817
Other	-286	0
Net cash (used for) provided by financing activities	-610	0
Effect of exchange rate changes on cash and cash equivalents	-27
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents	743	-7
Cash and cash equivalents at beginning of period	422	335
Cash and cash equivalents at end of period	1,165	328
Parent Company [Member]
Net cash provided by operating activities [Abstract]
Net cash provided by operating activities	72	0
Cash Flows from Investing Activities
Additions to property, plant and equipment	0	0
Proceeds from sale of assets	0	0
Return of restricted cash	0
Proceeds from sale of business		0
Alliance Boots acquisition, net of cash received	-4,461
Other business and intangible asset acquisitions, net of cash received	0	0
Purchases of short-term investments held to maturity	0	0
Proceeds from short-term investments held to maturity	0	0
Investment in AmerisourceBergen	0	0
Other	0	0
Net cash used for investing activities	-4,461	0
Cash Flows from Financing Activities
Payments of short-term borrowings	-6
Proceeds from issuance of long-term debt	12,279
Payments of long-term debt	0
Stock purchases	-94	0
Proceeds related to employee stock plans	139	0
Cash dividends paid	0	0
Intra-company financing activities, net	-7,781
Other	-76	0
Net cash (used for) provided by financing activities	4,461	0
Effect of exchange rate changes on cash and cash equivalents	-72
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments [Member]
Net cash provided by operating activities [Abstract]
Net cash provided by operating activities	0	0
Cash Flows from Investing Activities
Additions to property, plant and equipment	0	52
Proceeds from sale of assets	0	52
Return of restricted cash	0
Alliance Boots acquisition, net of cash received	0
Other business and intangible asset acquisitions, net of cash received	0	0
Purchases of short-term investments held to maturity	0	0
Proceeds from short-term investments held to maturity	0	0
Investment in AmerisourceBergen	0	0
Other	0	0
Net cash used for investing activities	0	0
Cash Flows from Financing Activities
Payments of short-term borrowings	0
Proceeds from issuance of long-term debt	0
Payments of long-term debt	0
Stock purchases	0	0
Proceeds related to employee stock plans	0	0
Cash dividends paid	0	0
Intra-company financing activities, net	0
Other	0	0
Net cash (used for) provided by financing activities	0	0
Effect of exchange rate changes on cash and cash equivalents	0
Changes in Cash and Cash Equivalents:
Net (decrease) increase in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	$0	$0

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event [Member], USD $)	0 Months Ended
	Apr. 08, 2015	Feb. 28, 2015
	Store
Subsequent Event [Line Items]
Disposal group, including discontinued operation, current asssets held for sale		$300,000,000
Disposal group, including discontinued operation, long-term assets available for sale		900,000,000
Disposal group, including discontinued operation, current liabilities held for sale		100,000,000
Restructuring Plan [Member]
Subsequent Event [Line Items]
Term of cost reduction initiative	3 years
Cost reduction initiative	1,000,000,000
Approximate number of store closings	200
Restructuring Plan [Member] | Maximum [Member]
Subsequent Event [Line Items]
Estimated restructuring costs	2,000,000,000
Real estate costs	600,000,000
Write-offs	800,000,000
Employee severance costs	600,000,000
Estimated restructuring charges related to the program	750,000,000
Estimated restructuring charges related to the program in fiscal 2016	700,000,000
Restructuring Plan [Member] | Minimum [Member]
Subsequent Event [Line Items]
Estimated restructuring costs	1,500,000,000
Real estate costs	450,000,000
Write-offs	600,000,000
Employee severance costs	450,000,000
Estimated restructuring charges related to the program	500,000,000
Estimated restructuring charges related to the program in fiscal 2016	$400,000,000